

CITATION REPORT

List of articles citing

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

DOI: 10.1038/367645a0
Nature, 1994, 367, 645-8.

Source: <https://exaly.com/paper-pdf/25190249/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2308	Targeting acute myelogenous leukemia stem cells. 93-108		
2307	In vitro growth behaviour of acute myeloid leukaemic cells. 1994 , 30A, 1407-8		
2306	Future prospects for animal models created by transplanting human haematopoietic cells into immune-deficient mice. 1994 , 145, 380-4		15
2305	Autocrine factors sustain glioblastoma stem cell self-renewal. 1994 , 21, 419		2
2304	Establishment of human acute myelogenous leukemia lines secreting interleukin-1 beta in SCID mice. 1995 , 61, 280-5		13
2303	Flow cytometric determination of glutathione in clinical samples. 1995 , 21, 68-71		17
2302	The biology of hematopoietic stem cells. 1995 , 11, 35-71		615
2301	Significance of the SCID Mouse Models for the Study of Normal and Leukemic Human Hemopoiesis and Gene Therapy. 1995 , 18, 434-438		3
2300	Differentiation in vitro of hybrid eosinophil/basophil granulocytes: autocrine function of an eosinophil developmental intermediate. 1995 , 182, 49-57		84
2299	Human stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy-induced apoptosis. 1995 , 31A, 1883-4		3
2298	Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. 1995 , 18, 1-16		93
2297	Purification and expansion of human hematopoietic stem/progenitor cells. 1995 , 770, 91-8		13
2296	Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. 1995 , 4, 163-72		79
2295	Normal and leukemic human stem cells assayed in SCID mice. 1996 , 8, 197-206		134
2294	Hematopoietic growth factors in leukemia. 1996 , 192, 734-42		4
2293	The use of SCID mice in biotechnology and as a model for human disease. 1996 , 16, 95-118		12
2292	Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model. 1996 , 20, 581-9		3

2291	Therapy of childhood acute myelogenous leukemias. 1996 , 73, 11-24	22
2290	Establishment of human granulocyte-macrophage colony stimulating factor producing transgenic SCID mice. 1996 , 95, 437-42	12
2289	Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. 1996 , 93, 754-61	78
2288	Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. 1996 , 2, 1329-37	709
2287	The role of the bone marrow in allergy and asthma. 1996 , 51, 141-8	31
2286	DNA triplex formation selectively inhibits granulocyte-macrophage colony-stimulating factor gene expression in human T cells. 1996 , 271, 14438-44	37
2285	Human-mouse xenografts in stem cell research. 1996 , 5, 379-90	16
2284	Myeloma stem cells in autografting in multiple myeloma. 1996 , 5, 557-9	
2283	Differential expression of receptors for hemopoietic growth factors on subsets of CD34+ hemopoietic cells. 1996 , 24, 11-25	25
2282	High-dose therapy in acute leukemia. 1997 , 26 Suppl 1, 61-7	
2281	Cloning, expression, and chromosomal localization to 11p12-13 of a human LIM/HOMEBOX gene, hLim-1. 1997 , 16, 671-8	19
2280	Hematopoietic Growth Factors and Blast Progenitors in Acute Leukemia. 1997 , 2, 435-58	1
2279	Biology of acute leukaemia. 1997 , 349, 118-22	26
2278	Detection of Trisomy 12 and Rb-Deletion in CD34+ Cells of Patients With B-Cell Chronic Lymphocytic Leukemia. 1997 , 89, 4275-4281	39
2277	Lack of Expression of Thy-1 (CD90) on Acute Myeloid Leukemia Cells With Long-Term Proliferative Ability In Vitro and In Vivo. 1997 , 89, 3104-3112	289
2276	A Model for Human B-Chronic Lymphocytic Leukemia in Human/Mouse Radiation Chimera: Evidence for Tumor-Mediated Suppression of Antibody Production in Low-Stage Disease. 1997 , 89, 2210-2218 ³⁰	
2275	Engraftment and Development of Human CD34+-Enriched Cells From Umbilical Cord Blood in NOD/LtSz-scid/scid Mice. 1997 , 90, 85-96	191
2274	Functional Expression of Fas (CD95) in Acute Myeloid Leukemia Cells in the Context of CD34 and CD38 Expression: Possible Correlation With Sensitivity to Chemotherapy. 1997 , 90, 4901-4909	49

2273	Long-Term Malignant Hematopoiesis in Human Acute Leukemia Bone Marrow Biopsies Implanted in Severe Combined Immunodeficiency Mice. 1997 , 90, 2001-2009	5
2272	Detection and Characterization of Primitive Malignant and Normal Progenitors in Patients With Acute Myelogenous Leukemia Using Long-Term Coculture With Supportive Feeder Layers and Cytokines. 1997 , 90, 2555-2564	81
2271	Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Eliminates Acute Myeloid Leukemia Cells With the Potential to Initiate Leukemia in Immunodeficient Mice, But Spares Normal Hemopoietic Stem Cells. 1997 , 90, 3735-3742	26
2270	Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. 1997 , 4, 691-9	46
2269	Cytogenetic analysis of CD34+ subpopulations in AML and MDS characterized by the expression of CD38 and CD117. 1997 , 11, 674-9	43
2268	Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. 1997 , 3, 730-7	5283
2267	Contribution of oncogenes and tumor suppressor genes to myeloid leukemia. 1997 , 1332, F67-104	9
2266	Cytokines, molecular biological abnormalities, and acute myelogenous leukemia. 1997 , 21, 299-312	9
2265	A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice. 1997 , 21, 1107-14	14
2264	[Sensitive detection of disseminated tumor cells--prognostic significance and therapeutic approaches]. 1997 , 38, 1083-91	2
2263	Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. 1997 , 75, 664-73	60
2262	The SCID mouse mutant: definition and potential use as a model for immune and hematological disorders. 1997 , 39, 213-21	13
2261	Mechanisms of the graft-versus-leukemia reaction. 1997 , 15, 248-58	80
2260	Stem cell manipulation: why and how performing peripheral blood progenitor cell purging. 1997 , 26, 101-15	7
2259	Sensitivity of human acute myeloid leukaemia to diphtheria toxin-GM-CSF fusion protein. 1997 , 98, 952-9	6
2258	Reduction of heat-induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP. 1997 , 99, 692-8	5
2257	Haemopoietic stem cells: their heterogeneity and regulation. 1997 , 78, 197-218	37
2256	Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. 1998 , 17, 3714-25	499

2255	A newly discovered class of human hematopoietic cells with SCID-repopulating activity. 1998 , 4, 1038-45	556
2254	GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF. 1998 , 12, 1962-70	8
2253	Establishment of a retinoic acid-resistant human acute promyelocytic leukaemia (APL) model in human granulocyte-macrophage colony-stimulating factor (hGM-CSF) transgenic severe combined immunodeficiency (SCID) mice. 1998 , 78, 878-84	10
2252	Overgrowth of a leukemic culture by a minor CD34+ population. 1998 , 22, 549-56	1
2251	Possible association between adult T-cell leukemia/lymphoma and acute myeloid leukemia. 1998 , 82, 488-94	16
2250	Engraftment of chronic myeloid leukemia in SCID mice. 1998 , 16, 87-100	6
2249	The potential for antitumor vaccination in acute myelogenous leukemia. 1998 , 76, 80-93	11
2248	SCID mouse models of human stem cell engraftment. 1998 , 16, 166-77	255
2247	Flow cytometric identification of candidate normal stem cell populations in CD45-negative B-cell precursor acute lymphoblastic leukaemia. 1998 , 100, 501-8	12
2246	Haemopoietic defect and decreased expansion potential of bone marrow autografts from patients with acute myeloid leukaemia in first remission. 1998 , 101, 571-81	9
2245	Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia. 1998 , 29, 339-50	3
2244	Gene transfer and the treatment of childhood cancer. 1998 , 16, 269-78	2
2243	Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. 1998 , 95, 8239-44	69
2242	Biology of CD34+CD38- cells in lymphohematopoiesis. 1998 , 31, 285-93	32
2241	Purification and Characterization of a Cell Initiating Human Acute Leukemia after Transplantation into NOD-SCID Mice. 1998 , 30, 47-48	
2240	Cytotoxic T-Lymphocyte Defined Human Minor Histocompatibility Antigens With a Restricted Tissue Distribution. 1998 , 91, 2197-2207	195
2239	Establishment of a Reproducible Model of Chronic-Phase Chronic Myeloid Leukemia in NOD/SCID Mice Using Blood-Derived Mononuclear or CD34+ Cells. 1998 , 91, 630-640	60
2238	Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow. 1998 , 92, 3780-3792	648

2237	Most Acute Myeloid Leukemia Progenitor Cells With Long-Term Proliferative Ability In Vitro and In Vivo Have the Phenotype CD34+/CD71 ^{hi} HLA-DR ^{hi} 1998 , 92, 4325-4335	196
2236	Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia. 1998 , 92, 1073-1090	104
2235	Autologous Stem Cell Transplantation. 1999 , 99-126	1
2234	Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. 1999 , 94, 1761-1772	138
2233	CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. 1999 , 96, 8639-44	189
2232	Expression of AC133 and CD117 on candidate normal stem cell populations in childhood B-cell precursor acute lymphoblastic leukaemia. 1999 , 107, 572-80	24
2231	Absence of CD34 on some human SCID-repopulating cells. 1999 , 872, 211-7; discussion 217-9	11
2230	Clonal chromosomal abnormalities in the stem cell compartment of patients with acute myeloid leukemia in morphological complete remission. 1999 , 13, 386-92	19
2229	Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. 1999 , 13, 618-28	16
2228	The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38 ⁻ leukemic progenitors. 1999 , 13, 1513-8	34
2227	Leukemogenesis by CBF oncoproteins. 1999 , 13, 1932-42	90
2226	Cytokine treatment or accessory cells are required to initiate engraftment of purified primitive human hematopoietic cells transplanted at limiting doses into NOD/SCID mice. 1999 , 23, 203-9	105
2225	Peripheral Stem Cells in Bone Marrow Transplantation. Future prospects. 1999 , 12, 307-18	3
2224	Chromatin remodeling gene SMARCA5 is dysregulated in primitive hematopoietic cells of acute leukemia. 2000 , 14, 1247-52	38
2223	Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. 2000 , 14, 1711-7	37
2222	Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). 2000 , 28, 660-71	140
2221	A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. 2000 , 95, 1007-1013	212
2220	CD38 in hematopoietic malignancies. 2000 , 75, 189-206	16

2219	SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. 2000 , 12, 699-707	26
2218	Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice. 2000 , 36, 221-8	6
2217	New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients. 2000 , 18, 343-51	99
2216	CD133 (AC133) expression on AML cells and progenitors. 2001 , 3, 449-59	32
2215	Non-myeloablative transplants for malignant disease. 2001 , 2001, 375-91	80
2214	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. 2001 , 97, 2177-9	47
2213	A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. 2001 , 98, 1166-73	289
2212	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. 2001 , 98, 2301-7	631
2211	Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. 2001 , 114, 296-306	18
2210	Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. 2001 , 15, 814-8	25
2209	Minimal residual disease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. 2001 , 15, 1408-14	19
2208	The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective. 2001 , 15, 1489-94	12
2207	Introduction. 2001 , 15, 1677-1680	4
2206	Haematopoietic cell transplantation as immunotherapy. <i>Nature</i> , 2001 , 411, 385-9	50.4 341
2205	High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. 2001 , 25, 875-81	31
2204	Normal and leukemic CD34-negative human hematopoietic stem cells. 2001 , 5, 42-61	15
2203	Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice. 2001 , 49, 332-41	29
2202	Acute myeloid leukemia. 2001 , 2001, 62-86	90

2201	Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging. 2001 , 10, 777-85	2
2200	Preferential induction of apoptosis for primary human leukemic stem cells. 2002 , 99, 16220-5	368
2199	Unique molecular and cellular features of acute myelogenous leukemia stem cells. 2002 , 16, 559-62	97
2198	Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. 2002 , 62, 304-12	32
2197	Progress and controversies in the treatment of pediatric acute myelogenous leukemia. 2002 , 9, 353-60	30
2196	The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. 2002 , 99, 15-23	173
2195	Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal. 2002 , 100, 640-6	63
2194	Effect of rhGM-CSF on the kinetics of hematopoiesis in long-term marrow cultures from patients with acute myelogenous leukemia. 2002 , 43, 2383-90	6
2193	Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. 2002 , 30, 481-7	50
2192	Minor histocompatibility antigens--targets of graft versus leukemia responses. 2002 , 76 Suppl 2, 155-61	28
2191	HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. 2002 , 16, 1791-8	159
2190	Human AML cells in NOD/SCID mice: engraftment potential and gene expression. 2002 , 16, 1818-26	52
2189	The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. 2002 , 16, 1992-2003	361
2188	Signaling revisited in acute promyelocytic leukemia. 2002 , 16, 1933-9	11
2187	The biology of chronic myelogenous leukemia: mouse models and cell adhesion. 2002 , 21, 8612-28	34
2186	Differences in heat sensitivity between normal and acute myeloid leukemic stem cells: feasibility of hyperthermic purging of leukemic cells from autologous stem cell grafts. 2003 , 31, 421-7	21
2185	Human acute myeloid leukemia stem cells. 2003 , 34, 507-14	82
2184	CS-1, a novel c-kithi+ acute myeloid leukemia cell line with dendritic cell differentiation capacity and absent immunogenicity. 2003 , 105, 232-40	2

2183	The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. 2003 , 17, 153-62	63
2182	Leukaemic stem cells. 2003 , 13, 363-75	4
2181	Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. <i>Nature</i> , 2003 , 423, 255-60.4	1249
2180	A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis. 2003 , 10, 745-54	6
2179	Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells. 2003 , 17, 2130-9	35
2178	Telomerase is limiting the growth of acute myeloid leukemia cells. 2003 , 17, 2410-7	40
2177	Stem cells: Self-renewal writ in blood. <i>Nature</i> , 2003 , 423, 231-3	50.4 91
2176	Genomics: Yeast rises again. <i>Nature</i> , 2003 , 423, 233-4	50.4 13
2175	Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. 2003 , 9, 1158-65	440
2174	Applying the principles of stem-cell biology to cancer. 2003 , 3, 895-902	1329
2173	Receptor induction and targeted drug delivery: a new antileukaemia strategy. 2003 , 3, 563-74	28
2172	Prospective identification of tumorigenic breast cancer cells. 2003 , 100, 3983-8	8089
2171	Introducing the concept of breast cancer stem cells. 2004 , 6, 53-4	17
2170	Breast cancer stem cells revealed. 2003 , 100, 3547-9	270
2169	Stem cell gene therapy: breakthrough culminating in combination of ex vivo protocols with transient topical gene therapy. 2003 , 2, 91-102	1
2168	Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation. 2003 , 44, 691-8	14
2167	Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). 2003 , 101, 3142-9	228
2166	Survival of acute myeloid leukemia cells requires PI3 kinase activation. 2003 , 102, 972-80	402

2165	The effect of anti-CD44 monoclonal antibodies on differentiation and proliferation of human acute myeloid leukemia cells. 2004 , 45, 1501-10	48
2164	The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. 2004 , 279, 24218-25	501
2163	Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation. 2004 , 200, 623-35	111
2162	Cancer stem cells: are we missing the target?. 2004 , 96, 583-5	140
2161	Zinc finger nuclease-boosted gene targeting and synergistic transient regenerative gene therapy for long-term stem cell gene therapy. 2004 , 18, 503-538	3
2160	CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. 2004 , 64, 2817-24	287
2159	Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. 2004 , 172, 3462-8	24
2158	Hematopoietic cell fate and the initiation of leukemic properties in primitive primary human cells are influenced by Ras activity and farnesyltransferase inhibition. 2004 , 24, 6993-7002	34
2157	Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia. 2004 , 127, 264-79	25
2156	Cancer stem cells refined. 2004 , 5, 701-3	40
2155	Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. 2004 , 5, 738-43	742
2154	Acute promyelocytic leukemia: where does it stem from?. 2004 , 18, 375-84	73
2153	Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell. 2004 , 18, 1169-75	66
2152	Epigenetic gene silencing by Runx proteins. 2004 , 23, 4341-5	56
2151	Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. 2004 , 23, 4275-83	127
2150	Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. 2004 , 23, 4249-54	48
2149	Concepts of human leukemic development. 2004 , 23, 7164-77	178
2148	Mechanisms controlling pathogenesis and survival of leukemic stem cells. 2004 , 23, 7178-87	105

2147	Identification of hematopoietic stem/progenitor cells: strength and drawbacks of functional assays. 2004 , 23, 7210-22	96
2146	Self-renewal and solid tumor stem cells. 2004 , 23, 7274-82	725
2145	Stem cells, aging, and cancer: inevitabilities and outcomes. 2004 , 23, 7290-6	83
2144	Isolation of cancer stem cells from adult glioblastoma multiforme. 2004 , 23, 9392-400	656
2143	Tissue repair and stem cell renewal in carcinogenesis. <i>Nature</i> , 2004 , 432, 324-31	50.4 995
2142	Identification of human brain tumour initiating cells. <i>Nature</i> , 2004 , 432, 396-401	50.4 5869
2141	Neurobiology: at the root of brain cancer. <i>Nature</i> , 2004 , 432, 281-2	50.4 51
2140	MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. 2004 , 6, 587-96	575
2139	Cancer stem cell biology: from leukemia to solid tumors. 2004 , 16, 708-12	96
2138	Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. 2004 , 64, 4434-41	111
2137	Stem cells and cancer; the polycomb connection. 2004 , 118, 409-18	614
2136	Hedgehog--Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. 2004 , 204, 145-57	95
2135	Characterization of clonogenic multiple myeloma cells. 2004 , 103, 2332-6	653
2134	Blood and Runx1: got to have it, really need it. 2004 , 104, 3420-3421	
2133	Considerations for targeting malignant stem cells in leukemia. 2004 , 11, 97-104	68
2132	Telomerase and cancer stem cells. 2005 , 70, 205-8	61
2131	Cancer stem cells: AMLs show the way. 2005 , 33, 1531-1533	10
2130	Cancer stem cells: AMLs show the way. 2005 , 33, 1531-3	11

2129	Punish the parent not the progeny. 2005 , 105, 1862-6	131
2128	Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. 2005 , 106, 2498-505	112
2127	Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. 2005 , 106, 2120-7	29
2126	Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. 2005 , 106, 3932-9	167
2125	Therapeutically targeting leukemia stem cells. 2005 , 106, 4021-4022	4
2124	VPS33B: let there be Egranules. 2005 , 106, 4022-4023	
2123	Transplantation of human acute myeloid leukemia (AML) cells in immunodeficient mice reveals altered cell surface phenotypes and expression of human endothelial markers. 2005 , 29, 1191-9	10
2122	Neosis—a paradigm of self-renewal in cancer. 2005 , 29, 1084-97	64
2121	Hunting the mechanisms of self-renewal of immortal cell populations by means of real-time imaging of living cells. 2005 , 29, 1019-24	
2120	Acute myeloid leukemia stem cells. 2005 , 1044, 1-5	121
2119	Leukemia: stem cells, maturation arrest, and differentiation therapy. 2005 , 1, 197-205	76
2118	Biology of normal and acute myeloid leukemia stem cells. 2005 , 82, 389-96	83
2117	Normal and leukaemic stem cells. 2005 , 130, 469-79	42
2116	Cancer stem cells: lessons from leukaemia. 2005 , 38, 357-61	17
2115	Tumour stem cells and drug resistance. 2005 , 5, 275-84	2947
2114	Leukaemia stem cells and the evolution of cancer-stem-cell research. 2005 , 5, 311-21	481
2113	Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. 2005 , 5, 744-9	1132
2112	Opinion: the origin of the cancer stem cell: current controversies and new insights. 2005 , 5, 899-904	446

2111	Animal models of acute myelogenous leukaemia - development, application and future perspectives. 2005 , 19, 687-706	60
2110	Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells. 2005 , 19, 1794-805	92
2109	MicroRNA expression profiles classify human cancers. <i>Nature</i> , 2005 , 435, 834-8	50.4 7870
2108	Radial glia cells are candidate stem cells of ependymoma. 2005 , 8, 323-35	670
2107	Cancer stem cells: lessons from leukemia. 2005 , 15, 494-501	484
2106	Brain as a paradigm of organ growth: Hedgehog-Gli signaling in neural stem cells and brain tumors. 2005 , 64, 476-90	68
2105	The molecular biology of esophageal adenocarcinoma. 2005 , 92, 169-90	99
2104	Use of preclinical models to improve treatment of retinoblastoma. 2005 , 2, e332	44
2103	The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. 2005 , 105, 4163-9	544
2102	Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. 2005 , 106, 4086-92	280
2101	Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue. 2005 , 102, 7180-5	220
2100	Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. 2005 , 65, 1442-9	84
2099	Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. 2005 , 11, 2436-44	83
2098	Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage. 2005 , 202, 85-96	89
2097	The potential of targeting malignant stem cells as a treatment for leukemia. 2005 , 1, 205-7	2
2096	Natural killer cells in breast cancer cell growth and metastasis in SCID mice. 2005 , 59 Suppl 2, S375-9	36
2095	Abstraction, Reformulation and Approximation. 2005 ,	
2094	Epidermal stem cells. 2005 , 21, 335-55	

2093	MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice. 2005 , 106, 4278-86	24
2092	How do stem cells find their way home?. 2005 , 106, 1901-10	800
2091	The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. 2005 , 102, 6942-7	375
2090	Interference with HH-Gli signaling inhibits prostate cancer. 2005 , 11, 199-203	46
2089	Complexity of the human acute myeloid leukemia stem cell compartment: implications for therapy. 2005 , 11, 9-11	7
2088	Homeobox gene expression in cancer: insights from developmental regulation and deregulation. 2005 , 41, 2428-37	142
2087	Neural stem cells and the origin of gliomas. 2005 , 353, 811-22	801
2086	Feverfew: weeding out the root of leukaemia. 2005 , 5, 1147-52	25
2085	[Cancer stem cells: new insights]. 2005 , 25, 64-6	1
2084	Stem Cells. 2006 ,	
2083	Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies. 2006 , 47, 207-22	123
2082	Deficient proliferation and expansion in vitro of two bone marrow cell populations from patients with acute myeloid leukemia in response to hematopoietic cytokines. 2006 , 47, 1379-86	9
2081	First among equals: the cancer cell hierarchy. 2006 , 47, 2017-27	32
2080	Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. 2006 , 66, 7445-52	540
2079	The molecular biology of pulmonary metastasis. 2006 , 16, 115-24	23
2078	Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. 2006 , 24, 1095-103	439
2077	Implications of cancer stem cells in the treatment of cancer. 2006 , 2, 723-31	26
2076	Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?. 2006 , 15 Spec No 2, R210-9	89

2075	Genetics and biology of pancreatic ductal adenocarcinoma. 2006 , 20, 1218-49	818
2074	Stem cells and cancer: two faces of eve. 2006 , 124, 1111-5	753
2073	Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. 2006 , 351, 820-4	493
2072	Stem cells in the etiology and treatment of cancer. 2006 , 16, 60-4	113
2071	Tumor development: haploinsufficiency and local network assembly. 2006 , 240, 17-28	28
2070	Telomeres and telomerase in cancer stem cells. 2006 , 42, 1197-203	82
2069	Profiling cancer stem cells using protein array technology. 2006 , 42, 1273-82	20
2068	Strategies to eliminate cancer stem cells: clinical implications. 2006 , 42, 1293-7	49
2067	Hematopoietic stem-cell transplantation. 2006 , 354, 1813-26	1602
2066	Oncogenes, self-renewal and cancer. 2006 , 54, 109-11	9
2065	Cancer Stem Cells. 2006 ,	11
2064	The paradox of response and survival in cancer therapeutics. 2006 , 107, 431-4	126
2063	Characterization of stem cell-like cancer cells in immune-competent mice. 2006 , 108, 3906-12	82
2062	The stem cell niche and bone metastasis. 2006 , 3, 19-29	2
2061	Stem cells, senescence, neosis and self-renewal in cancer. 2006 , 6, 25	85
2060	Origin of hepatocellular carcinoma: role of stem cells. 2006 , 21, 1093-8	56
2059	Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. 2006 , 22, 801-10	50
2058	Cancer stem cells in human gastrointestinal cancers. 2006 , 19, 24-9	99

2057	Lack of expression of the chondroitin sulphate proteoglycan neuron-gial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11). 2006 , 133, 337-44		13
2056	Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. 2006 , 97, 1381-7		16
2055	Leukaemia: niche retreats for stem cells. <i>Nature</i> , 2006 , 444, 827-8	50.4	32
2054	Semiconductor electronics: organic crystals at large. <i>Nature</i> , 2006 , 444, 828-31	50.4	9
2053	Roots and stems: stem cells in cancer. 2006 , 12, 296-300		308
2052	Targeting of CD44 eradicates human acute myeloid leukemic stem cells. 2006 , 12, 1167-74		984
2051	Invasive growth: a MET-driven genetic programme for cancer and stem cells. 2006 , 6, 637-45		440
2050	The cancer stem cell hypothesis: a work in progress. 2006 , 86, 1203-7		237
2049	Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. <i>Nature</i> , 2006 , 441, 475-82	50.4	1104
2048	The stem-cell niche as an entity of action. <i>Nature</i> , 2006 , 441, 1075-9	50.4	1453
2047	Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. <i>Nature</i> , 2006 , 442, 818-22	50.4	1130
2046	Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. <i>Nature</i> , 2006 , 444, 761-5	50.4	966
2045	Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. 2006 , 20, 2147-54		131
2044	mTOR and cancer therapy. 2006 , 25, 6436-46		398
2043	Hypothesis: myeloid-restricted hematopoietic stem cells with self-renewal capacity may be the transformation site in acute myeloid leukemia. 2006 , 30, 491-5		12
2042	AML: many new tools for discovery, not enough answers (yet). 2006 , 30, 1073-5		2
2041	Characterization of a side population of cancer cells from human gastrointestinal system. 2006 , 24, 506-13		489
2040	Normal stem cells and cancer stem cells: the niche matters. 2006 , 66, 4553-7		577

2039	Cancer stem cells. 2006 , 355, 1253-61	1256
2038	Future perspectives for cancer metastasis and the lymphovascular system. 2006 , 25, 293-4	3
2037	Satellite Symposia and Meet-the-Professor Sessions. 2006 , 85, 28-126	2
2036	Aneuploidy in the normal and diseased brain. 2006 , 63, 2626-41	79
2035	Somatic stem cells and the origin of cancer. 2006 , 8, 647-63	42
2034	Repair and regeneration: opportunities for carcinogenesis from tissue stem cells. 2006 , 10, 292-308	25
2033	Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. 2006 , 34, 967-75	281
2032	Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. 2006 , 10, 257-68	432
2031	Searching for leukemia stem cells--not yet the end of the road?. 2006 , 10, 253-4	26
2030	Neoplastic stem cells: a novel therapeutic target in clinical oncology. 2006 , 107, 2512-20	65
2029	Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. 2006 , 44, 240-51	574
2028	Cancer dormancy: from mice to man. 2006 , 5, 1772-8	53
2027	Brain tumors provide new clues to the source of cancer stem cells: does oncology recapitulate ontogeny?. 2006 , 5, 135-7	16
2026	Meeting report: Barossa 2005--Signaling Networks. 2006 , 2006, pe9	5
2025	Hedgehog-Gli Signaling in Human Disease. 2006 ,	10
2024	Eradication of leukemia stem cells as a new goal of therapy in leukemia. 2006 , 12, 340-4	49
2023	Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. 2006 , 103, 8959-64	43
2022	Rb is dispensable for self-renewal and multilineage differentiation of adult hematopoietic stem cells. 2006 , 103, 9057-62	59

2021	Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. 2006 , 103, 3304-9	202
2020	Role of stem cells in melanoma progression: hopes for a better treatment. 2007 , 2, 191-201	
2019	MicroRNAs and regenerative medicine. 2007 , 26, 257-64	22
2018	Molecular pathogenesis of pancreatic cancer: advances and challenges. 2007 , 7, 504-21	52
2017	Local radiotherapy induces homing of hematopoietic stem cells to the irradiated bone marrow. 2007 , 67, 10112-6	26
2016	Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia. 2007 , 92, 542-5	42
2015	A translational view of the molecular pathogenesis of lung cancer. 2007 , 2, 327-43	237
2014	Tumor cell dormancy: an NCI workshop report. 2007 , 6, 1496-504	70
2013	Lymphoid progenitors as candidate cancer stem cells in AML: new perspectives. 2007 , 6, 543-5	8
2012	Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. 2007 , 6, 2554-62	68
2011	Adenoviruses 16 and CV23 efficiently transduce human low-passage brain tumor and cancer stem cells. 2007 , 15, 2140-5	28
2010	Defining leukemia stem cells in MLL-translocated leukemias: implications for novel therapeutic strategies. 2007 , 219, 306-11	4
2009	LEUKEMIA STEM CELLS: STUDYING THE ROOT OF LEUKEMIA. 2007 , 03, 65-90	
2008	Characterization of side-population cells in human normal endometrium. 2007 , 22, 1214-23	189
2007	Breast tumor heterogeneity: cancer stem cells or clonal evolution?. 2007 , 6, 2332-8	313
2006	New insights into thyroid stem cells. 2007 , 17, 1019-23	14
2005	Bone marrow niche and leukemia. 2006 , 125-39	3
2004	Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. 2007 , 104, 16158-63	550

2003	Xenograft models for the preclinical evaluation of new therapies in acute leukemia. 2007 , 48, 659-68	17
2002	Comment on "Tumor growth need not be driven by rare cancer stem cells". 2007 , 318, 1722; author reply 1722	83
2001	CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. 2007 , 104, 11008-13	278
2000	Therapeutic implications of leukemia stem cell development. 2007 , 13, 3439-42	17
1999	Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. 2007 , 13, 5675-9	30
1998	The neural crest: understanding stem cell function in development and disease. 2007 , 4, 6-12	14
1997	Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. 2006 , 59-81	41
1996	Cancer Stem Cells. 2007 ,	2
1995	Mixed lineage leukemia translocations and a leukemia stem cell program. 2007 , 67, 8425-8	10
1994	Stem cells, cancer, liver, and liver cancer stem cells: finding a way out of the labyrinth. 2007 , 7, 582-90	10
1993	Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. 2007 , 34, 429-35	99
1992	Markers in normal and cancer stem cells. 2007 , 3, 211-31	25
1991	Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. 2007 , 92, 323-31	74
1990	Donor cell leukemia: insight into cancer stem cells and the stem cell niche. 2007 , 109, 2688-92	118
1989	STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. 2007 , 110, 2880-8	86
1988	Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia. 2007 , 110, 1831-9	60
1987	Leukemia stem cells in a genetically defined murine model of blast-crisis CML. 2007 , 110, 2578-85	117
1986	The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. 2007 , 110, 2659-66	303

1985	Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). 2007 , 110, 4436-44	94
1984	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. 2007 , 110, 4427-35	319
1983	In vivo models of childhood leukemia for preclinical drug testing. 2007 , 8, 773-83	4
1982	Drosophila brain tumor metastases express both neuronal and glial cell type markers. 2007 , 301, 287-97	39
1981	Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. 2007 , 1, 635-45	395
1980	The endosteum region keeps human leukemic stem cells alive. 2007 , 1, 483-4	7
1979	Location, location, location: the cancer stem cell niche. 2007 , 1, 607-11	156
1978	Analytical methods for cancer stem cells. 2007 , 407, 83-95	6
1977	Cancer Stem Cells: From Bench to Bedside. 2007 , 13, 47-52	15
1976	Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?. 2007 , 355, 855-9	161
1975	A rapid assay for drug sensitivity of glioblastoma stem cells. 2007 , 358, 908-13	25
1974	Most MCF7 and SK-OV3 cells were deprived of their stem nature by Hoechst 33342. 2007 , 364, 338-43	19
1973	Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. 2007 , 364, 778-82	85
1972	Cancer stem cells: at the headwaters of tumor development. 2007 , 2, 175-89	118
1971	Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. 2007 , 42, 2040-5	53
1970	Bone marrow cells: the source of hepatocellular carcinoma?. 2007 , 69, 36-42	13
1969	Right on target: eradicating leukemic stem cells. 2007 , 13, 470-81	104
1968	Developmental biology, self-renewal, and cancer. 2007 , 8, 456-7	6

1967	Cancer stem cells and human malignant melanoma. 2008 , 21, 39-55	154
1966	Modeling the initiation and progression of human acute leukemia in mice. 2007 , 316, 600-4	279
1965	Prostate (Cancer) Stem Cells. 2007 , 63-72	1
1964	Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?. 2007 , 9, 303	110
1963	Stem Cell Assays. 2007 ,	1
1962	Identification of pancreatic cancer stem cells. 2007 , 67, 1030-7	2659
1961	Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. 2007 , 67, 8671-81	135
1960	Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively. 2007 , 148, 1797-803	210
1959	Acute Myelogenous Leukemia. 2007 ,	
1958	Deregulation of apoptosis in acute myeloid leukemia. 2007 , 92, 81-94	93
1957	Targeting cancer stem cells. 2007 , 11, 915-27	51
1956	Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. 2007 , 104, 973-8	1732
1955	The prognostic role of a gene signature from tumorigenic breast-cancer cells. 2007 , 356, 217-26	826
1954	Primitive AML progenitors from most CD34(+) patients lack CD33 expression but progenitors from many CD34(-) AML patients express CD33. 2007 , 9, 194-204	8
1953	In search of the medulloblast: neural stem cells and embryonal brain tumors. 2007 , 18, 59-69, viii-ix	41
1952	Modeling notch signaling in normal and neoplastic hematopoiesis: global gene expression profiling in response to activated notch expression. 2007 , 25, 1872-80	7
1951	Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. 2007 , 25, 2903-9	70
1950	The biology of cancer stem cells. 2007 , 23, 675-99	829

1949	Identification and characterization of tumorigenic liver cancer stem/progenitor cells. 2007 , 132, 2542-56	991
1948	Cancer stem cells. 2007 , 4, 47-52	
1947	Stem cell-like cancer cells in cancer cell lines. 2007 , 27, 506-511	1
1946	Stem cells of the melanocyte lineage. 2007 , 3, 203-9	19
1945	Targeting treatment in AML. 2007 , 429-34	9
1944	Models for Human Leukaemias. 2007 ,	1
1943	Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis. 2007 , 29, 842-5	37
1942	CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. 2007 , 120, 1444-50	448
1941	The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. 2007 , 101, 908-17	51
1940	Old disease, new culprit: tumor stem cells in cancer. 2007 , 213, 603-9	33
1939	A challenge for regenerative medicine: proper genetic programming, not cellular mimicry. 2007 , 236, 3199-207	34
1938	Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. 2007 , 26, 1357-60	187
1937	Aberrant cytokine signaling in leukemia. 2007 , 26, 6738-49	69
1936	Stem cells and breast cancer. 2008 , 52, 99-107	23
1935	Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. 2007 , 25, 1315-21	722
1934	PTEN-deficient intestinal stem cells initiate intestinal polyposis. 2007 , 39, 189-98	357
1933	Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. 2007 , 13, 78-83	164
1932	Myelodysplastic syndromes: the complexity of stem-cell diseases. 2007 , 7, 118-29	271

1931	Reprogramming metastatic tumour cells with embryonic microenvironments. 2007 , 7, 246-55	377
1930	Making a tumour's bed: glioblastoma stem cells and the vascular niche. 2007 , 7, 733-6	558
1929	Spindle orientation, asymmetric division and tumour suppression in <i>Drosophila</i> stem cells. 2007 , 8, 462-72	156
1928	Symmetric division of cancer stem cells--a key mechanism in tumor growth that should be targeted in future therapeutic approaches. 2007 , 81, 893-8	83
1927	Unraveling the complex regulation of stem cells: implications for aging and cancer. 2007 , 21, 612-21	31
1926	Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. 2007 , 21, 1423-30	193
1925	The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. 2007 , 21, 1638-47	92
1924	The hunt for cancer-initiating cells: a history stemming from leukemia. 2007 , 21, 1619-27	34
1923	Induction of folate receptor type beta in a bone marrow engraftment model of acute myelogenous leukemia. 2007 , 21, 2233-5	7
1922	ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia. 2007 , 21, 2094-102	77
1921	Stem cells of ependymoma. 2007 , 96, 6-10	67
1920	Telomere and telomerase in stem cells. 2007 , 96, 1020-4	355
1919	Increased expression of stem cell markers in malignant melanoma. 2007 , 20, 102-7	268
1918	A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. <i>Nature</i> , 2007 , 445, 106-10	504 3323
1917	Cancer stem cells in 2007. 2007 , 77, 409	
1916	Is cancer a stem cell disease? Theory, evidence and implications. 2007 , 5, 76-89	12
1915	Cancer initiation and progression: involvement of stem cells and the microenvironment. 2007 , 1775, 283-97	59
1914	A perivascular niche for brain tumor stem cells. 2007 , 11, 69-82	1742

1913	Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. 2007 , 12, 328-41	241
1912	Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells. 2007 , 35, 1538-49	69
1911	Systems biology and cancer stem cells. 2008 , 12, 97-110	21
1910	Cancer stem cells: the lessons from pre-cancerous stem cells. 2008 , 12, 67-96	71
1909	Genomic mechanisms and measurement of structural and numerical instability in cancer cells. 2007 , 17, 5-18	101
1908	Malignant transformation of multipotent muscle-derived cells by concurrent differentiation signals. 2007 , 25, 2302-11	10
1907	Cancer stem cells: models and concepts. 2007 , 58, 267-84	1047
1906	Malignant astrocytic glioma: genetics, biology, and paths to treatment. 2007 , 21, 2683-710	1682
1905	Leukemogenesis of the EVI1/MEL1 gene family. 2007 , 85, 279-86	32
1904	Brain tumor stem cells: identification and concepts. 2007 , 18, 31-8, viii	47
1903	[Pathobiology of acute myeloid leukemia]. 2007 , 102, 290-5	4
1902	Metastasis and stem cell pathways. 2007 , 26, 261-71	49
1901	Exploiting the convergence of embryonic and tumorigenic signaling pathways to develop new therapeutic targets. 2007 , 3, 68-78	14
1900	Prospective isolation and functional analysis of stem and differentiated cells from the mouse mammary gland. 2007 , 3, 124-36	19
1899	Stem cells: A dormant volcano within our body?. 2007 , 12, 27-34	
1898	Expression and significance of Oct4 in bladder cancer. 2007 , 27, 675-7	18
1897	ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. 2007 , 62, 214-26	73
1896	Apoptosis in normal and cancer stem cells. 2008 , 66, 42-51	69

1895	Brain tumor stem cells. 2008 , 32, 124-42	20
1894	NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. 2008 , 111, 419-27	173
1893	Limitations of the cancer stem cell theory. 2008 , 58, 3-9	10
1892	CD133 identifies perivascular niches in grade II-IV astrocytomas. 2008 , 90, 157-70	87
1891	An overview of cancer multidrug resistance: a still unsolved problem. 2008 , 65, 3145-67	335
1890	Stochastic model of the formation of cancer metastases via cancer stem cells. 2008 , 37, 1329-34	9
1889	ACUTE LEUKEMIAS XII. 2008 , 87, 21-98	1
1888	A novel strategy for cancer treatment: Targeting cancer stem cells. 2008 , 53, 1777-1783	1
1887	Tumorstammzellen: Grundlagen, klinische Implikationen und Kontroversen. 2008 , 1, 91-100	1
1886	In search of liver cancer stem cells. 2008 , 4, 179-92	21
1885	Targeting cancer stem cells in cancer prevention and therapy. 2008 , 4, 211-6	11
1884	The role of cancer stem cells in neoplasia of the lung: past, present and future. 2008 , 10, 719-25	11
1883	Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review. 2008 , 88, 111-115	14
1882	Ovarian cancer: emerging concept on cancer stem cells. 2008 , 1, 4	53
1881	Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. 2008 , 1, 8	27
1880	Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. 2008 , 215, 369-76	58
1879	Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia. 2008 , 51, 741-6	7
1878	Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype. 2008 , 73, 940-8	35

1877	Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. 2008 , 74, 163-8	55
1876	CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. 2008 , 122, 761-8	464
1875	The stem cell hypothesis in head and neck cancer. 2008 , 103, 408-12	36
1874	Identification of genes with abnormal expression changes in acute myeloid leukemia. 2008 , 47, 8-20	130
1873	Molecular mechanisms of hepatocellular carcinoma. 2008 , 48, 2047-63	495
1872	Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia. 2008 , 32, 1374-81	2
1871	Cancer stem cells and impaired apoptosis. 2008 , 615, 331-44	11
1870	Biological and genetic characteristics of tumor-initiating cells in colon cancer. 2008 , 15, 638-48	119
1869	CD133+CD44+ population efficiently enriches colon cancer initiating cells. 2008 , 15, 2927-33	171
1868	Chronic myeloid leukemia stem cells. 2008 , 26, 2911-5	82
1867	Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. 2008 , 26, 364-71	244
1866	Melanoma stem cells: targets for successful therapy?. 2008 , 6, 541-6	8
1865	Melanomstammzellen: die Zielzellen einer erfolgreichen Therapie?. 2008 , 6, no	
1864	Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. 2008 , 62, 1212-8	173
1863	Melanoma, neovogenesis, and stem cell biology. 2008 , 128, 2365-80	87
1862	The cancer stem cell hypothesis: in search of definitions, markers, and relevance. 2008 , 88, 459-63	185
1861	Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. 2008 , 22, 1576-86	102
1860	Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. 2008 , 22, 1395-401	32

1859	Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia. 2008 , 22, 2029-40		27
1858	The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. 2008 , 22, 2151-5158		87
1857	Miscreant myeloproliferative disorder stem cells. 2008 , 22, 2011-9		20
1856	CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. 2008 , 22, 1207-13		135
1855	Identification of cells initiating human melanomas. <i>Nature</i> , 2008 , 451, 345-9	50.4	1143
1854	Melanoma in mice casts doubt on scarcity of cancer stem cells. <i>Nature</i> , 2008 , 456, 553	50.4	10
1853	Cancer stem cells--old concepts, new insights. 2008 , 15, 947-58		277
1852	CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. 2008 , 27, 1749-58		635
1851	Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. 2008 , 27, 2542-51		98
1850	Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. 2008 , 8, 755-68		2715
1849	Insertional mutagenesis and clonal dominance: biological and statistical considerations. 2008 , 15, 143-53		41
1848	MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. 2008 , 22, 66-77		88
1847	Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells. 2008 , 22, 1466-9		17
1846	Large-scale expansion of mammary epithelial stem cell aggregates in suspension bioreactors. 2005 , 21, 984-93		31
1845	Cancer stem cells and chemoradiation resistance. 2008 , 99, 1871-7		97
1844	Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. 2008 , 142, 695-708		64
1843	Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. 2008 , 314, 2110-22		65
1842	Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. 2008 , 9, 15		53

1841	MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. 2008 , 36, 433-42	76
1840	Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. 2008 , 13, 299-310	196
1839	In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. 2008 , 14, 47-58	223
1838	Leukemia stem cells in acute myeloid leukemia. 2008 , 35, 326-35	50
1837	Cancer stem cells: implications for the progression and treatment of metastatic disease. 2008 , 12, 374-90	216
1836	Etoposide-initiated MLL rearrangements detected at high frequency in human primitive hematopoietic stem cells with in vitro and in vivo long-term repopulating potential. 2008 , 81, 185-95	19
1835	New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells. 2008 , 119, 74-82	33
1834	The search for cancer stem cells in hepatocellular carcinoma. 2008 , 144, 119-24	39
1833	From viruses to cancer stem cells: dissecting the pathways to malignancy. 2008 , 177, 311-23	13
1832	Mechanisms of Disease: cancer stem cells--targeting the evil twin. 2008 , 5, 337-47	160
1831	Successful Cancer Treatment: Eradication of Cancer Stem Cells. 2008 , 179-191	
1830	Pancreatic cancer. 2008 , 3, 157-88	541
1829	Cancer stem cells and glioma. 2008 , 4, 427-35	97
1828	Current status and issues in cancer stem cell study. 2008 , 26, 741-55	53
1827	Cancer Stem Cells in Hematopoietic Malignancies. 2008 , 14, 12-16	15
1826	Can we finally target the leukemic stem cells?. 2008 , 21, 615-20	10
1825	Current Perspectives in microRNAs (miRNA). 2008 ,	2
1824	Breast cancer stem cells: implications for therapy of breast cancer. 2008 , 10, 210	91

1823	Mouse Models of Human Blood Cancers. 2008,	1
1822	Pathways to tumorigenesis--modeling mutation acquisition in stem cells and their progeny. 2008, 10, 1170-82	67
1821	Cell polarity and cancer--cell and tissue polarity as a non-canonical tumor suppressor. 2008, 121, 1141-50	202
1820	Targeted Radionuclide Tumor Therapy. 2008,	9
1819	Tumor Angiogenesis and the Cancer Stem Cell Model. 2008, 249-258	1
1818	Stem Cells. 2008,	9
1817	Gliomagenesis and neural stem cells: Key role of hypoxia and concept of tumor "neo-niche". 2008, 70, 96-104	23
1816	Cancer stem cells, CD200 and immunoevasion. 2008, 29, 464-8	83
1815	Glioma stem cells: a midterm exam. 2008, 58, 832-46	257
1814	The systematic production of cells for cell therapies. 2008, 3, 369-81	240
1813	Tumor angiogenesis. 2008, 358, 2039-49	1788
1812	Side population cells in human cancers. 2008, 268, 1-9	280
1811	Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. 2008, 14, 556-67	30
1810	The E. Donnall Thomas lecture: normal and neoplastic stem cells. 2008, 14, 849-58	7
1809	The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. 2008, 41, 73-6	24
1808	Recent advances in cancer stem cells. 2008, 18, 48-53	186
1807	DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?. 2008, 34, 558-67	107
1806	Colonic and colorectal cancer stem cells: progress in the search for putative biomarkers. 2008, 213, 59-65	27

1805	Tumor Stem Cells: How to Define Them and How to Find Them?. 2008 , 165-185	2
1804	Acute myeloid leukemia. 2008 , 55, 21-51, ix	45
1803	Profil diagnostyczny wznowy ostrej białczki limfoblastycznej. 2008 , 83, 128-135	
1802	Gastric cancer stem cells. 2008 , 26, 2876-82	152
1801	Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. 2008 , 26, 725-33	92
1800	Cancer, stem cells, and oncolytic viruses. 2008 , 40, 496-505	35
1799	Stem cell concepts renew cancer research. 2008 , 112, 4793-807	791
1798	Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. 2008 , 68, 8094-103	141
1797	The origins of medulloblastoma subtypes. 2008 , 3, 341-65	222
1796	Mathematical models of cancer stem cells. 2008 , 26, 2854-61	95
1795	The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. 2008 , 31, 809-19	87
1794	Prowling wolves in sheep's clothing: the search for tumor stem cells. 2008 , 389, 799-811	9
1793	Establishment of a normal hematopoietic and leukemia stem cell hierarchy. 2008 , 73, 439-49	105
1792	Cancer Stem Cells: On the Verge of Clinical Translation. 2008 , 39, 679-686	1
1791	Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. 2008 , 68, 190-7	433
1790	Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. 2008 , 14, 4891-7	16
1789	Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. 2008 , 6, 1146-53	383
1788	Of germ cells, trophoblasts, and cancer stem cells. 2008 , 7, 276-81	12

1787	Aldehyde dehydrogenase as a marker for stem cells. 2008 , 3, 237-46	190
1786	Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling. 2008 , 7, 3314-9	24
1785	MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?. 2008 , 43-51	43
1784	Chronic myeloid leukemia stem cells. 2008 , 436-42	44
1783	Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. 2008 , 29, 161-80	51
1782	Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis. 2008 , 23, 74-81	20
1781	Cancer stem cells and survival pathways. 2008 , 7, 1371-8	94
1780	Mechanisms of Disease: the role of stem cells in the biology and treatment of gliomas. 2008 , 5, 393-404	39
1779	Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. 2008 , 98, 1670-4	63
1778	Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia. 2008 , 4, 31-49	1
1777	Notch signaling in leukemias and lymphomas. 2008 , 8, 51-9	45
1776	CD44 and EpCAM: cancer-initiating cell markers. 2008 , 8, 784-804	153
1775	Prostate cancer stem cell therapy: hype or hope?. 2008 , 11, 316-9	10
1774	Ultrastructural studies of glioma stem cells/progenitor cells. 2008 , 32, 241-5	10
1773	Multiple myeloma cancer stem cells. 2008 , 26, 2895-900	88
1772	Molecular predictors in glioblastoma: toward personalized therapy. 2008 , 65, 877-83	57
1771	Melanoma. 2008 ,	1
1770	Generation of breast cancer stem cells through epithelial-mesenchymal transition. 2008 , 3, e2888	1183

1769	MicroRNAs and Regenerative Medicine. 2008 , 145-166	
1768	Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. 2008 , 11, 32-9	52
1767	CD44 is of functional importance for colorectal cancer stem cells. 2008 , 14, 6751-60	459
1766	Cancer stem cell patents. 2008 , 18, 1405-1416	
1765	Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. 2008 , 363, 139-52	56
1764	Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. 2008 , 68, 4674-82	283
1763	Brain tumor stem cells and the tumor microenvironment. 2008 , 24, E27	9
1762	Drug delivery in acute myeloid leukemia. 2008 , 5, 653-63	13
1761	New strategy for the analysis of phenotypic marker antigens in brain tumor-derived neurospheres in mice and humans. 2008 , 24, E28	19
1760	Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell. 2008 , 105, 14088-93	33
1759	Cancer stem cells: how can we target them?. 2008 , 15, 3171-84	92
1758	The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology. 2008 , 3, 265-273	5
1757	Cancer stem cells: Models, mechanisms and implications for improved treatment. 2008 , 7, 1360-70	77
1756	Cancer stem cells: a step toward the cure. 2008 , 26, 2795-9	217
1755	Label-retaining cells in the rat submandibular gland. 2008 , 56, 15-24	35
1754	Cancer Stem Cells: Similarities and Variations in the Theme of Normal Stem Cells. 1-26	
1753	Leukemic Stem Cells. 27-55	
1752	Adult Stem Cells. 27-58	

1751	Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. 2008 , 111, 5654-62	157
1750	The biologic properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19ARF gene. 2008 , 112, 4184-92	18
1749	Cancer stem cells: the seeds of metastasis?. 2008 , 8, 140-2	22
1748	The Molecular Bases of the Self-Renewal and Differentiation of Leukemic Stem Cells. 2008 , 4, 178-187	
1747	Self-renewal versus differentiation in hematopoietic stem and progenitor cells: a focus on asymmetric cell divisions. 2008 , 3, 9-16	21
1746	Cancer stem cells in brain tumor biology. 2008 , 73, 411-20	61
1745	Transplantation of human hematopoietic repopulating cells: mechanisms of regeneration and differentiation using human-mouse xenografts. 2008 , 13, 44-52	5
1744	Use of human neural tissue for the generation of progenitors. 2008 , 62, 21-37; discussion 27-30	9
1743	. 2008 ,	
1742	Exploring Stem Cell Biology with Small Molecules and Functional Genomics. 187-206	1
1741	. 2008 ,	
1740	Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. 2008 , 8, 1168-76	89
1739	Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. 2008 , 4, 133-42	54
1738	Chemokines and chemokine receptors in stem cell circulation. 2008 , 13, 6820-33	22
1737	Potential of neural stem cells for the treatment of brain tumors. 2008 , 2, 451-4	
1736	Cancer Stem Cells. 2008 , 141-154	1
1735	In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. 2008 , 3, e3544	81
1734	c-Myc is required for maintenance of glioma cancer stem cells. 2008 , 3, e3769	295

1733	Evidence for Cancer Stem Cells in Retinoblastoma. 87-94	
1732	[Melanocyte stem cells in adults]. 2008 , 202, 25-32	1
1731	Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex. 2008 , 13, 3986-4001	30
1730	Immunobiology of Cancer Stem Cells. 233-242	
1729	Prostate Cancer Stem Cells. 111-134	
1728	. 2009 ,	9
1727	Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements. 2009 , 1, 41-7	1
1726	Purification and characterization of cancer stem cells. 1-14	
1725	Cancer Stem Cells. 2009 , 467-483	0
1724	Phenotypic characterization of retinoblastoma for the presence of putative cancer stem-like cell markers by flow cytometry. 2009 , 50, 1506-14	35
1723	Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. 2009 , 15, 2258-64	158
1722	Gene expression in stem cells. 2009 , 19, 289-300	9
1721	The cancer stem cell microenvironment and anti-cancer therapy. 2009 , 85, 955-62	32
1720	The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. 2009 , 8, 3274-84	613
1719	The future of targeted therapy approaches in melanoma. 2009 , 4, 445-56	1
1718	Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. 2009 , 106, 3396-401	219
1717	Identification of cancer stem cells in Ewing's sarcoma. 2009 , 69, 1776-81	257
1716	Preclinical development of cancer stem cell drugs. 2009 , 4, 741-52	7

1715	A progenitor cell origin of myeloid malignancies. 2009 , 106, 16616-21	40
1714	Zebrafish as a model for cancer self-renewal. 2009 , 6, 377-87	18
1713	Possible involvement of brain tumour stem cells in the emergence of a fast-growing malignant meningioma after surgical resection and radiotherapy of high-grade astrocytoma: case report and preliminary laboratory investigation. 2009 , 37, 240-6	10
1712	The Importance of Spatial Distribution of Stemness and Proliferation State in Determining Tumor Radioresponse. 2009 , 4, 117-133	51
1711	Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. 2009 , 15, 3076-83	26
1710	Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. 2009 , 21, 793-801	118
1709	Murine models of human acute myeloid leukemia. 2010 , 145, 183-96	11
1708	Identifying and enumerating neural stem cells: application to aging and cancer. 2009 , 175, 43-51	9
1707	Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. 2009 , 15, 4234-41	454
1706	One renegade cancer stem cell?. 2009 , 8, 803-8	22
1705	Malignant stem cells in childhood acute lymphoblastic leukemia: the stem cell concept revisited. 2009 , 8, 996-9	10
1704	L1 cell adhesion molecules as regulators of tumor cell invasiveness. 2009 , 3, 275-7	33
1703	Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. 2009 , 8, 331-7	31
1702	An interesting fishing expedition. 2009 , 8, 338-9	1
1701	Revisiting calcein AM: alternative tool for identifying dye-effluxing cancer stem cells?. 2009 , 8, 2206-8	2
1700	Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells?. 2009 , 4, 168-77	69
1699	Primary liver tumors: origin and target therapy. 2009 , 13, 957-65	7
1698	Targeting prostate cancer stem cells. 2009 , 9, 1105-13	13

1697	Cancer stem cells: the emerging challenge of drug targeting. 2009 , 16, 394-416	50
1696	Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. 2009 , 5, e1000503	45
1695	Differential destruction of stem cells: implications for targeted cancer stem cell therapy. 2009 , 69, 9481-9	32
1694	Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer. 2009 , 23, 2675-99	284
1693	Evidence for cancer stem cells in human endometrial carcinoma. 2009 , 69, 8241-8	92
1692	Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene. 2009 , 15, 119-30	19
1691	Selective enrichment of hepatocellular cancer stem cells by chemotherapy. 2009 , 37, 1046-56	15
1690	Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. 2009 , 15, 4299-311	138
1689	Characterization of stem cell attributes in human osteosarcoma cell lines. 2009 , 8, 543-52	66
1688	Detection of cancer stem cells from the C6 glioma cell line. 2009 , 37, 503-10	34
1687	The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. 2009 , 106, 268-73	448
1686	Oncolytic adenoviruses targeted to cancer stem cells. 2009 , 8, 2096-102	45
1685	Multilevel targeting of hematopoietic stem cell self-renewal, differentiation and apoptosis for leukemia therapy. 2009 , 122, 264-80	29
1684	Cancer stem cells and angiogenesis. 2009 , 19, 279-84	41
1683	Cancer stem cells in solid tumors: an overview. 2009 , 19, 71-7	142
1682	Therapeutic implications of the cancer stem cell hypothesis. 2009 , 19, 78-86	109
1681	Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization. 2010 , 14, 1453-67	22
1680	Engraftment of human myelodysplastic syndrome derived cell line in transgenic severe combined immunodeficient (TG-SCID) mice expressing human GM-CSF and IL-3. 1998 , 61, 93-9	7

1679	Expression of gastrin precursors by CD133-positive colorectal cancer cells is crucial for tumour growth. 2009 , 1793, 477-88	28
1678	Stem cells of GATA1-related leukemia undergo pernicious changes after 5-fluorouracil treatment. 2009 , 37, 435-445.e1	4
1677	Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. 2009 , 37, 1423-34	83
1676	Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. 2009 , 16, 390-400	121
1675	Cancer Stem Cells. 129-151	3
1674	Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. 2009 , 124, 1245-50	14
1673	Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. 2010 , 126, 2067-78	290
1672	Die hard: are cancer stem cells the Bruce Willises of tumor biology?. 2009 , 75, 67-74	71
1671	Oncoprotein BMI-1 induces the malignant transformation of HaCaT cells. 2009 , 106, 16-24	14
1670	Pancreatic cancer stem cells and relevance to cancer treatments. 2009 , 107, 40-5	29
1669	Future use of mitocans against tumour-initiating cells?. 2009 , 53, 147-53	7
1668	Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells. 2009 , 31, 993-1001	10
1667	Identification and targeting of cancer stem cells. 2009 , 31, 1038-49	123
1666	Biology of glioma cancer stem cells. 2009 , 28, 7-12	106
1665	Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. 2009 , 44, 167-72	53
1664	The Stem Cell Network model: clinical implications in cancer. 2009 , 266, 161-70	14
1663	Origins and clinical implications of the brain tumor stem cell hypothesis. 2009 , 93, 49-60	29
1662	Brain tumor stem cells. 2009 , 34, 2055-66	17

1661	Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. 2009 , 115, 269-77	35
1660	Urothelial carcinoma: stem cells on the edge. 2009 , 28, 291-304	48
1659	Progress on potential strategies to target brain tumor stem cells. 2009 , 29, 141-55	19
1658	Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. 2009 , 29, 845-58	26
1657	The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. 2009 , 14, 29-43	292
1656	Building a framework for embryonic microenvironments and cancer stem cells. 2009 , 5, 319-27	34
1655	Tumor initiating cells in malignant gliomas: biology and implications for therapy. 2009 , 87, 363-74	67
1654	Cancer stem cells: controversies in multiple myeloma. 2009 , 87, 1079-85	28
1653	Cancer stem cells-clinical relevance. 2009 , 87, 1105-10	15
1652	Brain cancer stem cells. 2009 , 87, 1087-95	50
1651	Controversies in cancer stem cells. 2009 , 87, 1077-8	2
1650	Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. 2009 , 27, 3103-11	58
1649	NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. 2010 , 28, 5-16	473
1648	Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. 2010 , 28, 390-8	57
1647	Identification of gastric cancer stem cells using the cell surface marker CD44. 2009 , 27, 1006-20	754
1646	Maturation hierarchy of leukemic stem cells. 1998 , 16 Suppl 1, 85-8; discussion 89	2
1645	Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. 2009 , 27, 1604-15	25
1644	DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation. 2009 , 27, 1473-86	72

1643	Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. 2009 , 69, 401-10	74
1642	Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line. 2009 , 127, 429-41	20
1641	Cancer stem cells and their niche. 2009 , 100, 1166-72	112
1640	Characterization of brain cancer stem cells: a mathematical approach. 2009 , 42, 529-40	25
1639	Roles of TGF-beta family signaling in stem cell renewal and differentiation. 2009 , 19, 103-15	319
1638	Targeting a chronic problem: elimination of cancer stem cells in CML. 2009 , 28, 167-8	2
1637	Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. 2009 , 23, 25-42	161
1636	CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. 2009 , 23, 43-52	376
1635	PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. 2009 , 23, 1462-71	72
1634	Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. <i>Nature</i> , 2009 , 457, 603-7	50.4 536
1633	Cancer stem cells: relevance to SCT. 2009 , 43, 517-23	5
1632	Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. 2009 , 41, 783-92	232
1631	A safer stem cell: inducing pluripotency. 2009 , 15, 1001-2	7
1630	Cancer stem cells: mirage or reality?. 2009 , 15, 1010-2	789
1629	A safer stem cell: on guard against cancer. 2009 , 15, 999-1001	35
1628	The metastatic niche: adapting the foreign soil. 2009 , 9, 285-93	939
1627	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. 2009 , 8, 806-23	667
1626	Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. 2009 , 101, 2030-7	34

1625	Antitumor immunity and cancer stem cells. 2009 , 1176, 154-69	123
1624	Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells. 2009 , 19, 399-408	36
1623	Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation. 2009 , 49, 555-62	16
1622	Reversing the multidrug resistance in acute leukemia: until the leukemia initiating cell?. 2009 , 33, 749	
1621	In vitro biology of human myeloid leukemia. 2009 , 33, 624-37	30
1620	CXCR4 chemokine receptor antagonists: perspectives in SCLC. 2009 , 18, 481-90	54
1619	C/EBPalpha in leukemogenesis: identity and origin of the leukemia-initiating cell. 2009 , 35, 227-31	6
1618	Pediatric ependymoma: biological perspectives. 2009 , 7, 765-86	136
1617	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,	11
1616	How powerful is CD133 as a cancer stem cell marker in brain tumors?. 2009 , 35, 403-8	90
1615	Epigenetic gene regulation in stem cells and correlation to cancer. 2009 , 78, 1-17	63
1614	Cancer stem cells in multiple myeloma. 2009 , 277, 1-7	60
1613	Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. 2009 , 275, 185-93	68
1612	Stem cells in melanoma development. 2009 , 279, 119-25	14
1611	Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. 2009 , 280, 134-44	94
1610	A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. 2009 , 281, 92-9	27
1609	Identification of selective inhibitors of cancer stem cells by high-throughput screening. 2009 , 138, 645-659	1898
1608	Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. 2009 , 138, 592-603	1010

1607	Heterogeneity in cancer: cancer stem cells versus clonal evolution. 2009 , 138, 822-9	892
1606	Cellular immortality in brain tumours: an integration of the cancer stem cell paradigm. 2009 , 1792, 280-8	11
1605	Cancer stem cells: a model in the making. 2009 , 19, 44-50	96
1604	Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. 2009 , 4, 568-80	719
1603	Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. 2009 , 5, 31-42	413
1602	DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. 2009 , 5, 168-77	342
1601	Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. 2009 , 32, 559-65	26
1600	Xenoestrogens may be the cause of high and increasing rates of hormone receptor positive breast cancer in the world. 2009 , 72, 652-6	18
1599	Plasma exchange therapy holds promise in the management of advanced cancer. 2009 , 72, 533-4	1
1598	The increasing complexity of the cancer stem cell paradigm. 2009 , 324, 1670-3	562
1597	Brain Tumor Stem Cell Markers. 2009 , 713-728	
1596	Leadership and innovation. How consensus management blocks genuine innovation. 2009 , 2, 277-281	4
1595	Endocytosis, asymmetric cell division, stem cells and cancer: unus pro omnibus, omnes pro uno. 2009 , 3, 339-53	22
1594	Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. 2009 , 11, 99-133	99
1593	Cancer stem cell-directed therapies: recent data from the laboratory and clinic. 2009 , 17, 219-30	138
1592	Cancer, Stem Cells and the Neoplastic Niche. 2009 , 63-78	
1591	Stem cells and somatic cells: reprogramming and plasticity. 2009 , 9 Suppl 3, S319-28	11
1590	Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias. 2009 , 2, 51	10

1589	The Cancer Stem Cell Hypothesis. 2009 , 3-14	4
1588	History of Cancer Stem Cells. 2009 , 495-503	7
1587	Telomeres and Telomerase in Cancer. 2009 ,	9
1586	The leukemic stem cell niche: current concepts and therapeutic opportunities. 2009 , 114, 1150-7	372
1585	Strategies to Overcome Drug Resistance in Acute and Chronic Leukemias. 315-347	
1584	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. 2009 , 18, 1333-49	94
1583	Zebrafish tumor assays: the state of transplantation. 2009 , 6, 339-46	96
1582	Methodologies in assaying prostate cancer stem cells. 2009 , 568, 85-138	27
1581	Acute myeloid leukemia stem cells: seek and destroy. 2009 , 2, 663-72	45
1580	Defining cancer stem cells by xenotransplantation in zebrafish. 2009 , 568, 1-5	12
1579	Cancer Stem Cells. 2009 ,	4
1578	Biology of Stem Cells and the Molecular Basis of the Stem State. 2009 ,	15
1577	Cancer stem cells and the cell cycle: targeting the drive behind breast cancer. 2009 , 9, 275-9	10
1576	Smoothened antagonists: a promising new class of antitumor agents. 2009 , 4, 525-44	9
1575	Bone marrow-derived cells are not the origin of the cancer stem cells in ultraviolet-induced skin cancer. 2009 , 174, 595-601	11
1574	Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. 2009 , 69, 5331-9	513
1573	Leukemia stem cells and human acute lymphoblastic leukemia. 2009 , 46, 33-8	44
1572	Cancer stem cells and the cellular hierarchy in haematological malignancies. 2009 , 45 Suppl 1, 194-201	18

1571	Recent advances and hurdles in melanoma immunotherapy. 2009 , 22, 711-23	38
1570	Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. 2009 , 5, 559-68	8
1569	Cancer stem cells: never Wnt away from the niche. 2009 , 21, 41-6	35
1568	Micro-RNA mediated regulation of proliferation, self-renewal and differentiation of mammalian stem cells. 2009 , 3, 425-32	13
1567	Epigenetic signatures in stem cells and cancer stem cells. 2009 , 1, 261-80	15
1566	Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. 2009 , 113, 66-74	62
1565	Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. 2009 , 114, 4859-70	51
1564	Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. 2009 , 114, 3983-93	63
1563	Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. 2009 ,	8
1562	[Intestinal stem cells: thirty years of a long and exemplary story]. 2009 , 25, 441-4	1
1561	Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients. 2009 , 14, 359-63	10
1560	Tumor initiating cells. 2009 , 10, 192-6	19
1559	Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. 2009 , 16, 1688-703	106
1558	Targeting Cancer Stem Cells: How to Switch Off Immortality. 2009 , 3, 225-232	
1557	Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. 2009 , 94, 1590-4	23
1556	Inhibiting breast cancer progression by exploiting TGFbeta signaling. 2010 , 11, 1089-102	4
1555	Targeting cancer stem cell lines as a new treatment of human cancer. 2010 , 5, 205-18	12
1554	Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. 2010 , 11, 95-110	35

1553	Targeting the perpetrator: breast cancer stem cell therapeutics. 2010 , 11, 1147-56	11
1552	Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease. 2010 , 10, 744-55	18
1551	Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. 2010 , 21, 897-906	19
1550	Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 ex vivo expansion. 2010 , 33, 684-96	50
1549	Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. 2010 , 37, 1121-31	45
1548	The therapeutic promise of the cancer stem cell concept. 2010 , 120, 41-50	483
1547	Chronic myeloid leukemia: mechanisms of blastic transformation. 2010 , 120, 2254-64	277
1546	The Expanding Mi-2/NuRD Complexes: A Schematic Glance. 2010 , 3, PRI.S6329	4
1545	Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. 2010 , 15, 277-86	45
1544	"Microenvironmental contaminations" induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. 2010 , 115, 5347-54	102
1543	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. 2010 , 116, 3907-22	83
1542	The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. 2010 , 116, 1433-42	43
1541	Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. 2010 , 116, 5983-90	66
1540	Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. 2010 , 116, 5268-79	78
1539	Cbfb/Runx1 repression-independent blockage of differentiation and accumulation of Csf2rb-expressing cells by Cbfb-MYH11. 2010 , 115, 1433-43	37
1538	The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. 2010 , 116, 4532-41	200
1537	Relapse after allogeneic stem cell transplantation. 2010 , 3, 429-41	117
1536	Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. 2010 , 2, 201-11	45

1535	Properties and identification of cancer stem cells: a changing insight into intractable cancer. 2010 , 40, 608-13	8
1534	Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. 2010 , 50, 285-307	38
1533	Signal Transduction Pathways Involved in Hepatocarcinogenesis and Metastasis of Hepatoma. 2010 , 265-282	
1532	Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases. 2010 , 89, 861-71	14
1531	[Current knowledge in molecular pathology of urothelial cancer]. 2010 , 31 Suppl 2, 234-8	5
1530	Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. 2010 , 67, 2605-18	81
1529	Tumorstammzellen in Mamma- und weiblichen Genitalkarzinomen. 2010 , 43, 569-573	
1528	Gastric carcinogenesis and the cancer stem cell hypothesis. 2010 , 13, 11-24	50
1527	Étude de la radiosensibilité intrinsèque des cellules souches cancéreuses (ou cellules souches initiatrices de tumeur) isolées à partir de glioblastomes. 2010 , 12, 384-388	
1526	Characteristics of leukemia stem cells of murine myeloproliferative disease involving the liver. 2010 , 149, 293-7	0
1525	[Tumor stem cell research - basis and challenge for diagnosis and therapy]. 2010 , 122, 423-36	4
1524	Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. 2010 , 1, 638-55	167
1523	Emerging strategies for the identification and targeting of cancer stem cells. 2010 , 31, 243-53	64
1522	Glioma stem cells as a target for treatment. 2010 , 5, 211-5	17
1521	Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia. 2010 , 91, 557-68	24
1520	Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?. 2010 , 91, 735-41	29
1519	Molecular pathways to CML stem cells. 2010 , 91, 748-52	30
1518	Acute myeloid leukemia: when to transplant in first complete remission. 2010 , 5, 101-8	9

1517	Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. 2010 , 340, 265-73	99
1516	The role of surgery in cancer prevention. 2010 , 47, 750-830	11
1515	Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. 2010 , 5, 212-25	21
1514	Leukemia stem cells. 2010 , 20, 71-6	41
1513	Cancer stem cells: back to Darwin?. 2010 , 20, 65-70	107
1512	Normal stem cells and cancer stem cells: similar and different. 2010 , 20, 85-92	105
1511	The stem cell niche in health and malignancy. 2010 , 20, 107-15	43
1510	Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?. 2010 , 20, 178-85	44
1509	Pluripotency-associated genes in human nasopharyngeal carcinoma CNE-2 cells are reactivated by a unique epigenetic sub-microenvironment. 2010 , 10, 68	15
1508	Hematopoietic stem cells and retroviral infection. 2010 , 7, 8	21
1507	Stem cell characteristics in prostate cancer cell lines. 2010 , 57, 246-54	88
1506	Tumor heterogeneity: causes and consequences. 2010 , 1805, 105-17	750
1505	Potential therapeutic implications of cancer stem cells in glioblastoma. 2010 , 80, 654-65	159
1504	Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. 2010 , 18, 341-52	74
1503	Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. 2010 , 18, 510-23	481
1502	ECatenin mediates the establishment and drug resistance of MLL leukemic stem cells. 2010 , 18, 606-18	228
1501	Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. 2010 , 316, 3161-71	21
1500	Ewing's sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity. 2010 , 127, 1295-307	19

1499	Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. 2010 , 62, 268-76	76
1498	Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. 2010 , 78, 287-301	51
1497	Understanding the role of asymmetric cell division in cancer using <i>C. elegans</i> . 2010 , 239, 1378-87	6
1496	Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. 2010 , 28, 343-51	73
1495	Early relapse in a rectal cancer patient: possible implication of circulating cancer stem cell. 2010 , 102, 196-7	5
1494	The expression of stem cell-related indicators as a prognostic factor in human lung adenocarcinoma. 2010 , 102, 856-62	17
1493	Tumor suppressors Sav/Scrib and oncogene Ras regulate stem-cell transformation in adult <i>Drosophila</i> malpighian tubules. 2010 , 224, 766-74	28
1492	Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. 2010 , 34, 757-62	42
1491	Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. 2010 , 34, 1358-65	24
1490	Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34+38- compartment. 2010 , 34, 1287-95	15
1489	High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukemia. 2010 , 34, 1139-42	20
1488	Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. 2010 , 402, 57-63	18
1487	Immunity to stemness genes in human cancer. 2010 , 22, 245-50	24
1486	Neoplastic stem cells: current concepts and clinical perspectives. 2010 , 76, 79-98	23
1485	Targeting the osteosarcoma cancer stem cell. 2010 , 5, 78	135
1484	The dietary bioflavonoid quercetin synergizes with epigallocatechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. 2010 , 5, 14	150
1483	Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. 2010 , 28, 639-48	261
1482	Synovial sarcoma is a stem cell malignancy. 2010 , 28, 1119-31	144

1481	Current and emerging concepts in tumour metastasis. 2010 , 222, 1-15	183
1480	Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. 2010 , 54, 361-8	25
1479	Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. 2010 , 34, 1675-86	65
1478	Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors. 2010 , 39, 87-93	20
1477	Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. 2010 , 148, 879-89	60
1476	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. 2010 , 149, 334-51	78
1475	A recombinant trisppecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. 2010 , 150, 574-86	102
1474	Mouse sarcoma L1 cell line holoclones have a stemness signature. 2010 , 43, 229-34	8
1473	Lung cancer stem cells: tools and targets to fight lung cancer. 2010 , 29, 4625-35	112
1472	EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. 2010 , 29, 4741-51	1927
1471	Hypoxia inducible factors in cancer stem cells. 2010 , 102, 789-95	326
1470	Understanding the cancer stem cell. 2010 , 103, 439-45	153
1469	TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. 2010 , 103, 1692-7	67
1468	Induced pluripotent stem cells and senescence: learning the biology to improve the technology. 2010 , 11, 353-9	85
1467	Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor. 2010 , 90, 1594-603	22
1466	Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. 2010 , 24, 1545-54	51
1465	High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. 2010 , 24, 1859-66	45
1464	Immunotherapy prospects for acute myeloid leukaemia. 2010 , 161, 223-32	51

1463	Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett's esophagus and esophageal adenocarcinoma. 2010 , 23, 168-74	64
1462	Progress in stem cell-derived technologies for hepatocellular carcinoma. 2010 , 3, 81-92	2
1461	TLRs, Alcohol, HCV, and Tumorigenesis. 2010 , 2010, 518674	16
1460	Progress on antiangiogenic therapy for patients with malignant glioma. 2010 , 2010, 689018	34
1459	Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. 2010 , 5, e10320	17
1458	26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. 2010 , 5, e13298	55
1457	Perspective beyond cancer genomics: bioenergetics of cancer stem cells. 2010 , 51, 617-21	2
1456	Cancer stem cell and niche. 2010 , 2, 184-93	18
1455	The difficulty of targeting cancer stem cell niches. 2010 , 16, 3121-9	142
1454	Targeting myeloid leukemia stem cells. 2010 , 2, 31ps21	18
1453	Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. 2010 , 2, 17ra9	289
1452	Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. 2010 , 24, 1093-105	88
1451	Modulation of T-cell activation by malignant melanoma initiating cells. 2010 , 70, 697-708	214
1450	Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. 2010 , 70, 8863-73	67
1449	Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. 2010 , 12, 1205-19	68
1448	plenary session 3: Cancer stem cell targets. 2010 , 21, ii11-ii12	
1447	Therapeutic targeting of NF- κ B in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity. 2010 , 14, 1139-42	7
1446	Characterization of melanoma cells capable of propagating tumors from a single cell. 2010 , 70, 388-97	96

1445	Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. 2010 , 2, 84-95	200
1444	Cancer stem cells in pancreatic cancer. 2010 , 2, 1629-41	18
1443	Brain tumor stem cells. 2010 , 391, 607-17	6
1442	p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. 2010 , 31, 1501-8	110
1441	Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery. 2010 , 78, 309-15	24
1440	Controversies in cancer stem cells: targeting embryonic signaling pathways. 2010 , 16, 3106-12	103
1439	miR-200a regulates epithelial-mesenchymal to stem-like transition via ZEB2 and beta-catenin signaling. 2010 , 285, 36995-7004	92
1438	Stem cells in gastrointestinal cancers: a matter of choice in cell fate determination. 2010 , 10, 1621-33	8
1437	Do stem-like cells play a role in drug resistance of sarcomas?. 2010 , 10, 261-70	29
1436	The tumor microenvironment. 2010 , 671, 67-73	5
1435	Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. 2010 , 70, 3005-8	81
1434	Human ovarian cancer stem cells. 2010 , 140, 33-41	82
1433	A cancer stem cell origin for human endometrial carcinoma?. 2010 , 140, 23-32	43
1432	Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. 2010 , 31, 149-58	65
1431	Acute Myelogenous Leukemia. 2010 ,	
1430	microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. 2010 , 207, 475-89	260
1429	Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia. 2010 , 14, 127-33	24
1428	The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia. 2010 , 16, 5618-23	31

1427	Progress and applications of mouse models for human lung cancer. 2010 , 35, 426-43	34
1426	A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. 2010 , 133, 983-95	342
1425	Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. 2010 , 16, 5692-702	98
1424	A quest for initiating cells of head and neck cancer and their treatment. 2010 , 2, 1528-54	2
1423	Prognostic significance of OCT4 expression in adenocarcinoma of the lung. 2010 , 40, 961-6	40
1422	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. 2010 , 207, 2127-40	123
1421	Biologic and experimental variation of measured cancer stem cells. 2010 , 9, 909-12	5
1420	The Potency of Refined Mouse Models: Implications for Clinical Trials. 2010 , 6, 62-80	1
1419	High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. 2010 , 70, 5163-73	296
1418	CD34-Subpopulations and Clonogenic Progenitors in Mobilized Peripheral Blood Cells from Patients with Acute Myeloid Leukemia. 2010 , 31, 269-275	
1417	Targeting the acute myeloid leukemia stem cells. 2010 , 10, 104-10	13
1416	More than markers: biological significance of cancer stem cell-defining molecules. 2010 , 9, 2450-7	166
1415	Lymphoma stem cells: enough evidence to support their existence?. 2010 , 95, 293-302	48
1414	Future advances in melanoma research. 2010 , 37, 169-76	4
1413	Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. 2010 , 6, 1591-601	42
1412	Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. 2010 , 12, 951-60	12
1411	Tumor-initiating and -propagating cells: cells that we would like to identify and control. 2010 , 12, 506-15	68
1410	Glioma stem cell research for the development of immunotherapy. 2010 , 21, 159-66	31

1409	Mouse models of myelodysplastic syndromes. 2010 , 24, 361-75	22
1408	Stem cells in normal development and cancer. 2010 , 95, 113-58	50
1407	Polyploidy, aneuploidy and the evolution of cancer. 2010 , 676, 1-13	22
1406	The cancer stem cell paradigm: a new understanding of tumor development and treatment. 2010 , 14, 621-32	60
1405	Cancer Stem Cells Finding and Capping the Roots of Cancer. 2010 , 25-43	1
1404	Cancer-Initiating Cells in Colorectal Cancer. 2010 , 127-146	1
1403	HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: Outlook and recent implications in nanomedical approaches. 2010 , 62, 150-65	60
1402	Tracing the tumor lineage. 2010 , 4, 267-83	96
1401	Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. 2010 , 4, 385-96	56
1400	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. 2010 , 28, 275-80	302
1399	Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. 2010 , 107, 18115-20	351
1398	Cancer stem cells and self-renewal. 2010 , 16, 3113-20	338
1397	Developmental plasticity of stem cells and diseases. 2010 , 75, 507-10	5
1396	Good cells gone bad: the cellular origins of cancer. 2010 , 16, 145-51	25
1395	Reduction of CD44(+)/CD24(-) breast cancer cells by conventional cytotoxic chemotherapy. 2010 , 41, 574-81	31
1394	Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. 2010 , 41, 1516-29	53
1393	Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. 2010 , 23, 391-401	29
1392	Monoclonal antibodies in the treatment of hematologic malignancy. 2010 , 23, 403-16	6

1391	Apoptosis signaling in cancer stem cells. 2010 , 42, 31-8	60
1390	Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro. 2010 , 82, 308-12	46
1389	Cancer stem cells sustaining the growth of mouse melanoma are not rare. 2010 , 292, 17-23	19
1388	Enrichment of N-Cadherin and Tie2-bearing CD34+/CD38-/CD123+ leukemic stem cells by chemotherapy-resistance. 2010 , 296, 65-73	22
1387	New models for cancer research: human cancer stem cell xenografts. 2010 , 10, 380-4	41
1386	Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. 2010 , 21, 103-17	50
1385	Stem cells. 2010 , 16, S115-8	5
1384	NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease Following Allogeneic HSCT:	91
1383	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. 2010 , 16, 709-28	28
1382	Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. 2010 , 392, 373-9	189
1381	Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. 2010 , 394, 1098-104	175
1380	ALDH high adenoid cystic carcinoma cells display cancer stem cell properties and are responsible for mediating metastasis. 2010 , 396, 843-8	49
1379	A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. 2010 , 6, 603-15	420
1378	Oxygen in stem cell biology: a critical component of the stem cell niche. 2010 , 7, 150-61	1086
1377	Tumor-initiating cells are rare in many human tumors. 2010 , 7, 279-82	182
1376	TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. 2010 , 7, 708-17	293
1375	Replacing Hoechst33342 with rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. 2010 , 24, 538-45	18
1374	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. 2010 , 28, 429-40	160

1373	Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. 2010 , 2, 63ra94	436
1372	Biomechanics of Single Cells and Cell Populations. 2010 , 235-247	3
1371	Cancer stem cells versus phenotype-switching in melanoma. 2010 , 23, 746-59	320
1370	Asymmetric cell division: recent developments and their implications for tumour biology. 2010 , 11, 849-60	418
1369	Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. 2010 , 176, 381-92	64
1368	On the stem cell origin of cancer. 2010 , 176, 2584-494	157
1367	Targeting breast cancer stem cells. 2010 , 4, 404-19	155
1366	Selection of tumorigenic melanoma cells using ALDH. 2010 , 130, 2799-808	90
1365	Origin of Cancers. 2010 ,	1
1364	Molecularly Targeted Therapy for Childhood Cancer. 2010 ,	1
1363	Methods of Cancer Diagnosis, Therapy, and Prognosis. 2010 ,	
1362	Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. 2010 , 3, 246-51	21
1361	Stem Cell Biology in Health and Disease. 2010 ,	
1360	Sequential CD34 cell fractionation by magnetophoresis in a magnetic dipole flow sorter. 2010 , 135, 62-70	35
1359	Cell Cycle Deregulation in Cancer. 2010 ,	2
1358	An embryo-specific expressing TGF- β -family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma. 2010 , 29, 135	15
1357	Acute myeloid leukemia. 2010 , 24, 35-63	99
1356	Polyploidization and Cancer. 2010 ,	4

1355	The versatility of haematopoietic stem cells: implications for leukaemia. 2010 , 47, 171-80	5
1354	Tumor-initiating function of nucleostemin-enriched mammary tumor cells. 2010 , 70, 9444-52	45
1353	Role of cancer stem cells in hepatocarcinogenesis. 2011 , 3, 11	23
1352	Acute myeloid leukemia: leukemia stem cells write a prognostic signature. 2011 , 2, 21	4
1351	Two-photon induced responsive f-f emissive detection of Cyclin A with a europium-chelating peptide. 2011 , 47, 8052-4	19
1350	Arsenic, stem cells, and the developmental basis of adult cancer. 2011 , 120 Suppl 1, S192-203	69
1349	Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. 2011 , 108, 1397-402	511
1348	Cancer stem cells in tumor heterogeneity. 2011 , 112, 255-81	52
1347	Dynamics of epigenetic modifications in leukemia. 2011 , 10, 18-29	18
1346	Ablation of breast cancer stem cells with radiation. 2011 , 4, 227-33	57
1345	Application of Stem Cell Assays for the Characterization of Cancer Stem Cells. 2011 , 259-282	
1344	Molecular biology of lung cancer: clinical implications. 2011 , 32, 703-40	156
1343	Cancer stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers. 2011 , 3, 1232-52	45
1342	Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer. 2011 , 2, 465-470	5
1341	The clinical and therapeutic implications of cancer stem cell biology. 2011 , 11, 1131-43	24
1340	Therapeutic approaches to target cancer stem cells. 2011 , 3, 3331-52	22
1339	Cancer epigenetics: linking basic biology to clinical medicine. 2011 , 21, 502-17	223
1338	Glioma Cell Lines: Role of Cancer Stem Cells. 2011 , 205-212	

1337	The Biology of Acute Lymphoblastic Leukemia. 2011 , 29-61	1
1336	Stem cell gene expression programs influence clinical outcome in human leukemia. 2011 , 17, 1086-93	713
1335	Hurdles toward a cure for CML: the CML stem cell. 2011 , 25, 951-66, v	17
1334	Cancer Stem Cells: Historical Perspectives and Lessons from Leukemia. 2011 , 3-11	
1333	Targeting the Wnt Pathway in Cancer. 2011 ,	5
1332	Cancer Stem Cells in Solid Tumors. 2011 ,	6
1331	Adult Stem Cells. 2011 ,	2
1330	Childhood Leukemia. 2011 ,	6
1329	Hematopathology. 2011 ,	
1328	Serologic laboratory findings in malignancy. 2011 , 37, 507-25	15
1327	Genome and transcriptome profiles of CD133-positive colorectal cancer cells. 2011 , 178, 1478-88	19
1326	Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. 2011 , 146, 53-66	240
1325	Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. 2011 , 146, 633-44	1074
1324	Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. 2011 , 308, 123-33	37
1323	Hypoxia, stem cells and bone tumor. 2011 , 313, 129-36	48
1322	[Cancer stem cells: a new target for lung cancer treatment]. 2011 , 15, 355-64	2
1321	Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24 ^{lo} cancer stem cell phenotype. 2011 , 47, 1527-36	80
1320	Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL. 2011 , 143-166	

1319	Mouse Models for Studying Normal and Cancer Stem Cells. 2011 , 311-325	1
1318	Heterogeneous sensitivity of human acute myeloid leukemia to Eatenin down-modulation. 2011 , 25, 770-780	46
1317	Mechanisms of Radioresistance in Cancer Stem Cells. 2011 , 345-360	
1316	Chemoattractant receptors as pharmacological targets for elimination of glioma stem-like cells. 2011 , 11, 1961-6	8
1315	Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. 2011 , 722, 94-105	98
1314	Extinction models for cancer stem cell therapy. 2011 , 234, 132-46	24
1313	Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. 2011 , 8, 97-106	757
1312	Cancer stem cells, models of study and implications of therapy resistance mechanisms. 2011 , 720, 105-18	41
1311	Targeting HIF1 α eliminates cancer stem cells in hematological malignancies. 2011 , 8, 399-411	310
1310	Blocking HIF1 α activity eliminates hematological cancer stem cells. 2011 , 8, 354-6	7
1309	CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. 2011 , 9, 50-63	463
1308	Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment. 2011 , 10, 428-34	37
1307	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. 2011 , 25, 1739-50	57
1306	A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. 2011 , 25, 890-6	23
1305	The potential role of CD133 in immune surveillance and apoptosis: a mitochondrial connection?. 2011 , 15, 2989-3002	7
1304	Heating cancer stem cells to reduce tumor relapse. 2011 , 13, 305	18
1303	High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. 2011 , 28, 91-9	35
1302	Breast Cancer Stem Cells. 2011 ,	

1301	The Rocky Road from Cancer Stem Cell Discovery to Diagnostic Applicability. 2011,	
1300	Drugs that Kill Cancer Stem-like Cells. 2011,	2
1299	Development and maintenance of cancer stem cells under chronic inflammation. 2011, 78, 138-45	29
1298	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. 2011,	
1297	Floating cells with stem cell properties in gastric cell line SGC-7901. 2011, 97, 393-399	1
1296	Cancer stem cells and angiogenesis. 2011, 55, 477-82	71
1295	The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. 2011, 5, 397-405	52
1294	Glioma Stem Cells. 2011,	
1293	Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. 2011, 81, 263-70	31
1292	Multidrug Resistance Transporters [Roles in maintaining Cancer Stem-Like Cells. 2011,	1
1291	Cancer stem cells in head and neck squamous cell carcinoma. 2011, 2011, 762780	33
1290	Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. 2011, 2011, 941876	152
1289	Lung cancer stem cell: new insights on experimental models and preclinical data. 2011, 2011, 549181	26
1288	Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres. 2011, 2011, 314962	18
1287	Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. 2011, 2011, 352616	41
1286	Glioblastoma Stem Cells: A Neuropathologist's View. 2011, 2011, 397195	20
1285	Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. 2011, 2011, 620523	63
1284	Cancer Stem Cells and Chemoresistance. 2011,	2

1283	Past, present, and future of molecular and cellular oncology. 2011 , 1, 1	16
1282	Animal models to study cancer-initiating cells from glioblastoma. 2011 , 16, 2243-58	17
1281	Metastatic potential of tumor-initiating cells in solid tumors. 2011 , 16, 1927-38	30
1280	Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. 2011 , 16, 368-92	47
1279	Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. 2011 , 6, e16530	230
1278	An off-target nucleostemin RNAi inhibits growth in human glioblastoma-derived cancer stem cells. 2011 , 6, e28753	11
1277	Glioma stem cell maintenance: the role of the microenvironment. 2011 , 17, 2386-401	67
1276	The cancer stem cell hypothesis: failures and pitfalls. 2011 , 68, 531-45; discussion 545	88
1275	An overview of concepts for cancer stem cells. 2011 , 20, 113-20	33
1274	Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. 2011 , 12, 217-25	6
1273	Induction and postremission strategies in acute myeloid leukemia: what is new?. 2011 , 18, 83-8	13
1272	Stem cells in human endometrium and endometrial carcinoma. 2011 , 30, 317-27	23
1271	Vaccines targeting cancer stem cells: are they within reach?. 2011 , 17, 397-402	13
1270	Differentiation potential of human retinoblastoma cells. 2011 , 12, 213-6	5
1269	Mammary development and breast cancer: the role of stem cells. 2011 , 11, 270-85	30
1268	Metastatic cancer stem cells: new molecular targets for cancer therapy. 2011 , 12, 1909-22	13
1267	Cancer stem cells switch on tumor neovascularization. 2011 , 11, 69-75	19
1266	Cancer stem cells and the tumor microenvironment: soloists or choral singers. 2011 , 12, 171-81	17

1265	Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. 2011 , 26, 523-31	44
1264	Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells. 2011 , 26, 593-601	49
1263	RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity. 2011 , 117, e27-38	46
1262	An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. 2011 , 117, 4262-72	91
1261	Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. 2011 , 118, 1579-90	80
1260	Overexpression of IL-3R α on CD34 ⁺ CD38 ⁻ stem cells defines leukemia-initiating cells in Fanconi anemia AML. 2011 , 117, 4243-52	27
1259	KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. 2011 , 117, 3869-80	157
1258	Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. 2011 , 117, 7112-20	17
1257	CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. 2011 , 25, 701-8	32
1256	Induction of metastatic cancer stem cells from the NK/LAK-resistant floating, but not adherent, subset of the UP-LN1 carcinoma cell line by IFN- γ . 2011 , 91, 1502-13	16
1255	Cancer stem cells and markers: new model of tumorigenesis with therapeutic implications. 2010 , 9, 65-99	10
1254	High levels of CD34 ⁺ CD38 ^{low} / ⁻ CD123 ⁺ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. 2011 , 96, 1792-8	125
1253	Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. 2012 , 40, 71-9	55
1252	Phenotypic heterogeneity of breast cancer stem cells. 2011 , 2011, 135039	66
1251	Pathogenesis of early leukemia and lymphoma. 2010 , 9, 341-74	6
1250	Mobilisation strategies for normal and malignant cells. 2011 , 43, 547-65	5
1249	Establishment of a xenograft model of human myelodysplastic syndromes. 2011 , 96, 543-51	29
1248	Biology of hepatic cancer stem cells. 2011 , 26, 1229-37	41

1247	Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity. 2011 , 102, 1164-70	15
1246	Targeting glioma stem cells: a novel framework for brain tumors. 2011 , 102, 1958-66	80
1245	Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study. 2011 , 58, 608-16	40
1244	CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms. 2011 , 58, 739-49	4
1243	The cancer stem cell: premises, promises and challenges. 2011 , 17, 313-9	1415
1242	A close look at cancer. 2011 , 17, 262-5	7
1241	CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. 2011 , 11, 254-67	796
1240	Notch signalling in solid tumours: a little bit of everything but not all the time. 2011 , 11, 338-51	602
1239	Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. 2011 , 30, 1009-19	129
1238	Revisiting the concept of cancer stem cells in prostate cancer. 2011 , 30, 1261-71	83
1237	Melanoma stem cells: not rare, but well done. 2011 , 91, 647-64	66
1236	Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors. 2011 , 91, 1068-78	38
1235	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. 2011 , 104, 1730-8	143
1234	CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. 2011 , 33, 290-8	50
1233	Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. 2011 , 22, 799-806	137
1232	Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment. 2011 , 35, 1449-52	14
1231	Regenerative medicine. 2011 , 48, 148-212	29
1230	Isolation and characterization of a population of stem-like progenitor cells from an atypical meningioma. 2011 , 90, 179-88	34

1229	Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. 2011 , 91, 596-602	100
1228	Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin. 2011 , 121, 390-4	37
1227	Computational analysis of expression of human embryonic stem cell-associated signatures in tumors. 2011 , 4, 471	7
1226	Differential survival of AML subpopulations in NOD/SCID mice. 2011 , 39, 250-263.e4	19
1225	Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. 2011 , 39, 741-50	64
1224	Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. 2011 , 20, 39-52	68
1223	An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. 2011 , 20, 384-99	89
1222	Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. 2011 , 20, 674-88	425
1221	Cell fusion hypothesis of the cancer stem cell. 2011 , 714, 129-40	32
1220	Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. 2011 , 25, 1825-33	64
1219	Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. 2011 , 29, 928-33	295
1218	Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. 2011 , 30, 4609-21	155
1217	In vitro generation of human cells with cancer stem cell properties. 2011 , 13, 1051-61	105
1216	Leukemia stem cells and microenvironment: biology and therapeutic targeting. 2011 , 29, 591-9	308
1215	Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. 2011 , 9, 1608-20	286
1214	YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. 2011 , 71, 5569-78	64
1213	Cancer stem cell hypotheses: impact on modern molecular physiology and pharmacology research. 2011 , 36, 957-61	18
1212	Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. 2011 , 17, 7105-15	206

1211	Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. 2011 , 18, 1166-74	128
1210	Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. 2011 , 71, 7238-49	188
1209	Targeting the cancer initiating cell: the Achilles' heel of cancer. 2011 , 51, 152-62	13
1208	Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. 2011 , 56, 741-50	108
1207	DNA repair: the culprit for tumor-initiating cell survival?. 2011 , 30, 185-97	30
1206	Nanoparticles: a promising modality in the treatment of sarcomas. 2011 , 28, 260-72	12
1205	CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics. 2011 , 355, 241-8	25
1204	The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon β therapy against advanced hepatocellular carcinoma. 2011 , 46, 212-21	13
1203	Gastrointestinal stem cells in self-renewal and cancer. 2011 , 46, 1039-55	37
1202	Pancreatic cancer stem cell biology and its therapeutic implications. 2011 , 46, 1345-52	22
1201	Glioblastoma stem cells. 2011 , 343, 459-65	61
1200	Isolation and identification of cancer stem cells from a side population of a human hepatoblastoma cell line, HuH-6 clone-5. 2011 , 27, 9-16	15
1199	Cancer stem cells: a new framework for the design of tumor therapies. 2011 , 89, 95-107	57
1198	Leukemia stem cells. 2011 , 90, 245-71	39
1197	ACUTE LEUKEMIAS XIII. 2011 , 90, 25-76	
1196	Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. 2011 , 68, 3589-605	104
1195	Glioma stem/progenitor cells contribute to neovascularization via transdifferentiation. 2011 , 7, 141-52	58
1194	The role of human aldehyde dehydrogenase in normal and cancer stem cells. 2011 , 7, 292-306	375

1193	Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation. 2011 , 93, 27-35	14
1192	Polycomb group proteins in hematopoietic stem cell aging and malignancies. 2011 , 94, 11-23	6
1191	Self-renewal related signaling in myeloid leukemia stem cells. 2011 , 94, 109-117	34
1190	Homing of cancer cells to the bone. 2011 , 4, 221-35	54
1189	Molecular marks for epigenetic identification of developmental and cancer stem cells. 2011 , 2, 27-53	29
1188	Cancer stem cells and cancer therapy. 2011 , 32, 425-40	108
1187	Colorectal Cancer Stem Cells: Biology and Therapeutic Implications. 2011 , 7, 128-135	34
1186	Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. 2011 , 11, 396	83
1185	Activation of E-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. 2011 , 11, 49	251
1184	Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells. 2011 , 10, 112	23
1183	Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. 2011 , 10, 12	621
1182	Understanding tumor heterogeneity as functional compartments--superorganisms revisited. 2011 , 9, 79	30
1181	Epithelial-Mesenchymal Transition in tumor microenvironment. 2011 , 1, 29	183
1180	Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. 2011 , 71, 1084-96	35
1179	Concise review: Emerging concepts in clinical targeting of cancer stem cells. 2011 , 29, 883-7	73
1178	Concise review: Contribution of cancer stem cells to neovascularization. 2011 , 29, 888-94	73
1177	Concise review: stem cell effects in radiation risk. 2011 , 29, 1315-21	36
1176	The role of stem and circulating cells in cancer metastasis. 2011 , 103, 555-7	10

1175	Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. 2011 , 23, H217-47	384
1174	Characterization of chronic myeloid leukemia stem cells. 2011 , 86, 31-7	71
1173	Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. 2011 , 59, 1148-54	110
1172	Gankyrin-mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells. 2011 , 54, 1259-72	47
1171	Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. 2011 , 117, 1516-28	100
1170	Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. 2011 , 128, 294-303	95
1169	Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents. 2011 , 128, 2317-25	21
1168	Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. 2011 , 129, 1990-2001	37
1167	Head neck squamous cell carcinoma c-Met+ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. 2011 , 129, 2337-48	101
1166	Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells?. 2011 , 129, 2310-4	164
1165	The cancer stem cell niche--there goes the neighborhood?. 2011 , 129, 2315-27	190
1164	Leukemia stem cells. 2011 , 129, 2328-36	41
1163	Leukemia stem cells in 2010: current understanding and future directions. 2011 , 25, 75-81	55
1162	Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: effect of vascular endothelial growth factor on development of the microenvironment. 2011 , 35, 663-9	3
1161	Evidence for label-retaining tumour-initiating cells in human glioblastoma. 2011 , 134, 1331-43	122
1160	Genes associated with epithelial-mesenchymal transition: possible therapeutic targets in ductal pancreatic adenocarcinoma?. 2011 , 11, 448-54	13
1159	Sphingolipid metabolism and leukemia: a potential for novel therapeutic approaches. 2011 , 11, 863-81	8
1158	SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. 2011 , 91, 1796-804	100

1157	Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. 2011 , 17, 111-21	47
1156	The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. 2011 , 11, 950-8	74
1155	Chronic myeloid leukemia stem cells and developing therapies. 2011 , 52 Suppl 1, 60-80	6
1154	Krebsstammzellen und ihre Nische als Lebensquelle des Todes. 2011 , 43, 112-118	
1153	The power and the promise of liver cancer stem cell markers. 2011 , 20, 2023-30	74
1152	Normal and Malignant Hematopoiesis. 2011 , 1-30	
1151	Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. 2011 , 108, 6468-73	175
1150	Immunotherapy targeting colon cancer stem cells. 2011 , 3, 97-106	17
1149	Gene silencing by the Polycomb group proteins and associations with cancer. 2011 , 29, 187-95	19
1148	Microfluidics-based devices: New tools for studying cancer and cancer stem cell migration. 2011 , 5, 13412	80
1147	Targeted therapies for lung cancer: clinical experience and novel agents. 2011 , 17, 512-27	80
1146	Clinical review: The emerging cell biology of thyroid stem cells. 2011 , 96, 2692-702	40
1145	Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?. 2011 , 3, 716-29	257
1144	Drug treatment of cancer cell lines: a way to select for cancer stem cells?. 2011 , 3, 1111-28	13
1143	Cancer stem cells in head and neck cancer. 2011 , 3, 415-27	13
1142	Wnt/Ectenin: a new therapeutic approach to acute myeloid leukemia. 2011 , 2011, 428960	9
1141	Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. 2011 , 5, 265-314	27
1140	The Role of MicroRNAs in Hematopoietic Stem Cell and Leukemic Stem Cell Function. 2011 , 2, 317-34	27

1139	Pleural mesothelioma side populations have a precursor phenotype. 2011 , 32, 1324-32	30
1138	Converging histories, reconsidered potentialities: The stem cell and cancer. 2011 , 6, 195-216	2
1137	BMP-2 inhibits the tumorigenicity of cancer stem cells in human osteosarcoma OS99-1 cell line. 2011 , 11, 457-63	72
1136	Novel approaches to the treatment of acute myeloid leukemia. 2011 , 2011, 43-50	67
1135	microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. 2012 , 40, 747-56	63
1134	Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. 2011 , 286, 32843-53	170
1133	Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response. 2011 , 10, 1430-9	25
1132	Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy. 2011 , 25, 1687-96	14
1131	Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. 2011 , 10, 1378-84	367
1130	Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. 2011 , 11, 621-30	63
1129	RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. 2011 , 10, 1563-70	75
1128	A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. 2011 , 108, 1591-6	94
1127	The Colorectal Cancer Initiating Cell: Markers and Their Role in Liver Metastasis. 2011 , 89-127	2
1126	Direct reprogramming of stem cell properties in colon cancer cells by CD44. 2011 , 30, 3186-99	127
1125	Brain cancer stem cells: current status on glioblastoma multiforme. 2011 , 3, 1777-97	53
1124	Colon Cancer Stem Cells: Bench-to-Bedside-New Therapeutical Approaches in Clinical Oncology for Disease Breakdown. 2011 , 3, 1957-74	9
1123	The role of colorectal cancer stem cells in metastatic disease and therapeutic response. 2011 , 3, 319-39	56
1122	From cancer stem cells to tumor maintenance in melanoma. 2011 , 131, 1600-4	32

1121	Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. 2011 , 52, 1066-79	18
1120	Emerging Evidence for MicroRNAs as Regulators of Cancer Stem Cells. 2011 , 3, 3957-71	8
1119	DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. 2012 , 11, 629-38	62
1118	Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. 2012 , 2012, 708036	312
1117	The role of head and neck squamous cell carcinoma cancer stem cells in tumorigenesis, metastasis, and treatment failure. 2012 , 3, 90	31
1116	Sarcoma stem cells: do we know what we are looking for?. 2012 , 2012, 291705	22
1115	Molecular imaging in tracking tumor stem-like cells. 2012 , 2012, 420364	17
1114	The vascular niche: home for normal and malignant hematopoietic stem cells. 2012 , 26, 54-62	106
1113	Recent advances in acute myeloid leukemia stem cell biology. 2012 , 97, 966-74	99
1112	Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. 2012 , 25, 561-9	36
1111	Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. 2012 , 22, 215-24	45
1110	Human correlates of provocative questions in pancreatic pathology. 2012 , 19, 351-62	23
1109	Targeting Glioblastoma Stem Cells: Cell Surface Markers. 2012 , 19, 6050-6055	16
1108	Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. 2012 , 18, 5374-86	54
1107	Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. 2012 , 26, 1926-44	275
1106	Promises and challenges of exhausting pediatric neural cancer stem cells. 2012 , 71, 523-8	4
1105	Stem-like cells and therapy resistance in squamous cell carcinomas. 2012 , 65, 235-65	26
1104	Neural stem cells: brain building blocks and beyond. 2012 , 117, 132-42	45

1103	Concise review: self-renewal in the central nervous system: neural stem cells from embryo to adult. 2012 , 1, 298-308	32
1102	Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. 2012 , 26, 344-9	102
1101	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. 2012 ,	5
1100	Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. 2012 , 26, 858-60	32
1099	Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. 2012 , 3, e352	93
1098	Absence of IL-12R β in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2R γ -deficient mice. 2012 , 26, 225-35	6
1097	Advances in Cancer Stem Cell Biology. 2012 ,	2
1096	CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model. 2012 , 3, e396	47
1095	Elevated calpain activity in acute myelogenous leukemia correlates with decreased calpastatin expression. 2012 , 2, e51	6
1094	25 years of epidermal stem cell research. 2012 , 132, 797-810	44
1093	Head and neck cancer stem cells. 2012 , 91, 334-40	71
1092	Pharmacogenomic considerations of xenograft mouse models of acute leukemia. 2012 , 13, 1759-72	2
1091	Acute myeloid leukemia: focus on novel therapeutic strategies. 2012 , 6, 205-17	23
1090	Roles of p53 in various biological aspects of hematopoietic stem cells. 2012 , 2012, 903435	13
1089	Increased Levels of Circulating and Tissue mRNAs of Oct-4, Sox-2, Bmi-1 and Nanog in ESCC Patients: Potential Tool for Minimally Invasive Cancer Diagnosis. 2012 , 7, 27-37	6
1088	Targeting myelogenous leukemia stem cells: role of the circulation. 2012 , 2, 86	7
1087	Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias. 2012 , 57	
1086	Through the looking glass: visualizing leukemia growth, migration, and engraftment using fluorescent transgenic zebrafish. 2012 , 2012, 478164	9

1085	Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways?. 2012 , 2, 103	34
1084	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. 2012 , 4, 989-1035	25
1083	Skin-derived precursor cells as an in vitro modelling tool for the study of type 1 neurofibromatosis. 2012 , 2012, 646725	2
1082	Cancer Targeting Gene-Viro-Therapy and its Promising Future: A Trend in Both Cancer Gene Therapy and Cancer Virotherapy. 2012 , 33-83	1
1081	Human lung cancer cell line SPC-A1 contains cells with characteristics of cancer stem cells. 2012 , 59, 685-92	10
1080	Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy. 2012 , 13, 1761-7	14
1079	Immuno-targeting of pancreatic cancer stem cells: A new therapeutic strategy against a devastating disease?. 2012 , 1, 560-562	6
1078	Microenvironmental regulation of cancer stem cell phenotypes. 2012 , 7, 197-216	71
1077	Bladder Cancer and Stem Cells. 2012 , 7, 209-219	
1076	Cancer stem cells: relevance to clinical transplantation. 2012 , 24, 170-5	8
1075	Targeting cancer stem cells with natural products. 2012 , 13, 1054-64	24
1074	The Wnt/ β -catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. 2012 , 5, 1191-6	67
1073	Isolation and characterization of proliferative, migratory and multidrug-resistant endometrial carcinoma-initiating cells from human type II endometrial carcinoma cell lines. 2012 , 28, 527-32	9
1072	Stem cells in brain tumour development and therapy- two-sides of the same coin. 2012 , 39, 145-56	1
1071	Acute myeloid leukemia in the elderly. 2012 , 1, 57-69	1
1070	Drug screening study using glioma stem-like cells. 2012 , 6, 1117-20	26
1069	A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. 2012 , 119, 1200-7	31
1068	A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. 2012 , 119, 3571-7	174

1067	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. 2012 , 119, 217-26	42
1066	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. 2012 , 119, 6198-208	217
1065	Posttranslational regulation of self-renewal capacity: insights from proteome and phosphoproteome analyses of stem cell leukemia. 2012 , 120, e17-27	18
1064	Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells. 2012 , 41, 855-61	55
1063	Erythroid lineage-restricted expression of Jak2V617F is sufficient to induce a myeloproliferative disease in mice. 2012 , 97, 1389-93	4
1062	Parallel induction of cell proliferation and inhibition of cell differentiation in hepatic progenitor cells by hepatitis B virus X gene. 2012 , 30, 842-8	10
1061	c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells. 2012 , 31, 4655-66	81
1060	Regulation of self-renewal in normal and cancer stem cells. 2012 , 279, 3559-3572	38
1059	TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. 2012 , 1266, 118-23	23
1058	Zebrafish xenografts as a tool for in vivo studies on human cancer. 2012 , 1266, 124-37	161
1057	Characteristic features of stem cells in glioblastomas: from cellular biology to genetics. 2012 , 22, 592-606	9
1056	Cancer in light of experimental evolution. 2012 , 22, R762-71	89
1055	Involvement of histone demethylase LSD1 in short-time-scale gene expression changes during cell cycle progression in embryonic stem cells. 2012 , 32, 4861-76	29
1054	Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. 2012 , 151, 344-55	243
1053	A role for GPx3 in activity of normal and leukemia stem cells. 2012 , 209, 895-901	70
1052	Reactive oxygen species in cancer stem cells. 2012 , 16, 1215-28	221
1051	Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice. 2012 , 96, 638-48	6
1050	From oncogene to tumor suppressor: the dual role of Myc in leukemia. 2012 , 11, 1757-64	35

1049	Metformin and cancer stem cells: old drug, new targets. 2012 , 5, 351-4	43
1048	Stem Cells and Cancer Stem Cells: New Insights. 2012 , 17-31	
1047	Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers. 2012 , 14, R18	51
1046	Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. 2012 , 19, 600-5	23
1045	A novel concept of identifying precancerous cells to enhance anti-cancer therapies. 2012 , 19, 621-5	7
1044	Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. 2012 , 15, 440-50	73
1043	Will identification of a prostate cancer stem cell lead to its cure?. 2012 , 30, 351-2	2
1042	Glioblastoma heterogeneity and more accurate representation in research models. 2012 , 78, 594-6	4
1041	Applications of Microfluidics in Stem Cell Biology. 2012 , 2, 277-286	51
1040	Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. 2012 , 33, 1983-96	39
1039	Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles. 2012 , 9, 2302-13	96
1038	Stem cells in gliomas. 2012 , 104, 63-73	9
1037	Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia. 2012 , 5, 117-9	14
1036	Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. 2012 , 19 Suppl 3, S539-48	115
1035	Can breast cancer stem cells evade the immune system?. 2012 , 19, 6036-49	3
1034	Stem cell and benzene-induced malignancy and hematotoxicity. 2012 , 25, 1303-15	51
1033	Cancer stem cells: current status and evolving complexities. 2012 , 10, 717-728	943
1032	Heterogeneity and targeting of pancreatic cancer stem cells. 2012 , 18, 4277-84	61

1031	Disruption of SIRP β signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts. 2012 , 209, 1883-99	97
1030	Antiproliferative activity of trans-avicennol from <i>Zanthoxylum chiloperone</i> var. <i>angustifolium</i> against human cancer stem cells. 2012 , 75, 257-61	9
1029	Use of rHuG-CSF for the Treatment of Myeloid Leukemia and in Targeting Leukemia Stem Cells. 2012 , 169-182	
1028	Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. 2012 , 122, 1849-68	349
1027	Molecular mechanisms of temozolomide resistance in glioblastoma multiforme. 2012 , 12, 635-42	88
1026	The evolving concept of cancer and metastasis stem cells. 2012 , 198, 281-93	299
1025	Cancer stem cell definitions and terminology: the devil is in the details. 2012 , 12, 767-75	489
1024	Cancer Stem Cells: Novel Target Using Dietary Components for Prevention and Treatment. 2012 , 11-38	
1023	Novel approaches to target cancer initiating cells-eliminating the root of the cancer. 2012 , 52, 249-64	13
1022	CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the α -integrin signaling. 2012 , 175, 278-88	27
1021	How do tumor stem cells actively escape from host immunosurveillance?. 2012 , 420, 699-703	19
1020	Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells. 2012 , 94, 1382-9	53
1019	Cancer stem cells and tumor angiogenesis. 2012 , 321, 13-7	47
1018	Sphere formation reverses the metastatic and cancer stem cell phenotype of the murine mammary tumour 4T1, independently of the putative cancer stem cell marker Sca-1. 2012 , 323, 20-28	11
1017	Minimal residual disease in solid neoplasia: New frontier or red-herring?. 2012 , 38, 101-10	15
1016	Role of the microenvironment in hepatocellular carcinoma development and progression. 2012 , 38, 218-25	93
1015	Cancer stem cells hypothesis and stem cells in head and neck cancers. 2012 , 38, 515-39	49
1014	Drug resistance: still a daunting challenge to the successful treatment of AML. 2012 , 15, 62-9	183

1013	Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. 2012 , 55, 8757-69	129
1012	Controlling the stem cell compartment and regeneration in vivo: the role of pluripotency pathways. 2012 , 92, 75-99	27
1011	Signaling in colon cancer stem cells. 2012 , 7, 11	57
1010	MicroRNAs in breast cancer initiation and progression. 2012 , 69, 3587-99	61
1009	Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. 2012 , 11, 3219-26	23
1008	The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. 2012 , 26, 1313-20	78
1007	Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. 2012 , 4,	182
1006	Breast cancer intratumor genetic heterogeneity: causes and implications. 2012 , 12, 1021-32	57
1005	Targeting acute myeloid leukemia cells with cytokines. 2012 , 92, 567-75	9
1004	Processing of primary brain tumor tissue for stem cell assays and flow sorting. 2012 ,	12
1003	Study of chemoresistant CD133+ cancer stem cells from human glioblastoma cell line U138MG using multiple assays. 2012 , 36, 1137-43	23
1002	Cancer stem cells. 2012 , 44, 2144-51	349
1001	Role of cancer stem cells in brain tumors. 2012 , 2, 84-91	7
1000	Review of miR-200b and cancer chemosensitivity. 2012 , 66, 397-402	62
999	A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells. 2012 , 324, 221-30	23
998	Can lung cancer stem cells be targeted for therapies?. 2012 , 38, 580-8	42
997	FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. 2012 , 11, 346-58	69
996	Stem cells in human normal endometrium and endometrial cancer cells: characterization of side population cells. 2012 , 28, 63-71	22

995	Epigenetic alterations involved in cancer stem cell reprogramming. 2012 , 6, 620-36	142
994	Differentiation of Somatic Cells, Stem Cells and Stem Cell Variants: In Vitro Models. 2012 ,	
993	LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. 2012 , 30, 2631-44	119
992	Glioblastoma cell line-derived spheres in serum-containing medium versus serum-free medium: a comparison of cancer stem cell properties. 2012 , 41, 1693-700	65
991	Organic electronics: Organic thin-film magnetometers. 2012 , 11, 663-4	2
990	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. 2012 , 2, 362	200
989	Clinical implications of cancer stem cell biology in hepatocellular carcinoma. 2012 , 39, 461-72	155
988	The Notch pathway in hematopoietic stem cells. 2012 , 360, 1-18	27
987	Targeting pancreatic cancer stem cells for cancer therapy. 2012 , 1826, 385-99	14
986	Cancer Stem Cells in Glioblastoma. 2012 , 113-120	2
985	Genetic variations in stem cell-related genes and colorectal cancer prognosis. 2012 , 43, 584-93	5
984	Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. 2012 , 29, 2849-57	21
983	Identification of cancer stem cells-associated side population by flow cytometry with a violet laser. 2012 , 6, 211-217	
982	Adult and Embryonic Stem Cells. 2012 ,	1
981	[Cancer stem cells and high-throughput screening methods]. 2012 , 188 Suppl 3, 316-9	
980	Myeloma and Leukemia. 2012 , 509-529	
979	Human Cell Transformation. 2012 ,	2
978	Somatic Stem Cells. 2012 ,	6

977	Leukemia and Related Disorders. 2012,	3
976	Targeting Notch signaling for cancer therapeutic intervention. 2012, 65, 191-234	39
975	Cancer Stem Cells and the Bone Marrow Microenvironment. 2012, 2012,	8
974	Stem Cells and Cancer Stem Cells, Volume 1. 2012,	2
973	Stem Cells and Cancer Stem Cells, Volume 4. 2012,	
972	Targeting the cancer initiating cell: the ultimate target for cancer therapy. 2012, 18, 1784-95	36
971	Regulatory RNAs. 2012,	3
970	Cell culture: Soft gels select tumorigenic cells. 2012, 11, 662-3	10
969	Primary Liver Cancer. 2012,	3
968	Notch signaling in cancer stem cells. 2012, 727, 174-85	78
967	Evolutionary Systems Biology. 2012,	24
966	Cancer Stem Cell. 2012, 173-196	1
965	Label-free quantitative proteomics of CD133-positive liver cancer stem cells. 2012, 10, 69	7
964	NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. 2012, 7, e39725	26
963	Ionizing radiation induces stemness in cancer cells. 2012, 7, e43628	124
962	The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. 2012, 7, e47825	50
961	Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling. 2012, 7, e50690	31
960	Cancer stem cells and resistance to chemo and radio therapy. 2012, 4, 2142-9	33

959	On the nature of the tumor-initiating cell. 2012 , 7, 26-35	15
958	Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. 2012 , 2012, 928127	82
957	The role of cancer stem cells in relapse of solid tumors. 2012 , 4, 1528-41	63
956	Telomere and telomerase in stem cells: relevance in ageing and disease. 2012 , 4, 16-30	12
955	Dynamic modeling of genes controlling cancer stem cell proliferation. 2012 , 3, 84	4
954	miRNAs regulate stem cell self-renewal and differentiation. 2012 , 3, 191	46
953	Cancer stem-like cells persist in established cell lines through autocrine activation of EGFR signaling. 2012 , 3, 607-612	19
952	Targeting Tumor Microenvironments for Cancer Prevention and Therapy. 2012 ,	1
951	The role of cancer stem cells in relapse of solid tumors. 2012 , E4, 1528-1541	96
950	Cancer stem cells and resistance to chemo and radio therapy. 2012 , E4, 2142-2149	44
949	Cancer stem cells in the mechanism of metal carcinogenesis. 2012 , 31, 245-63	6
948	The potential origin of glioblastoma initiating cells. 2012 , 4, 190-205	13
947	Cancer stem cell gene expression programmes predict AML patient survival. 2012 , 18, 253-256	
946	MicroRNAs as regulators in normal hematopoietic and leukemia stem cells: current concepts and clinical implications. 2012 , 12, 536-46	5
945	Heterogeneity of cancer-initiating cells within glioblastoma. 2012 , 4, 1235-48	16
944	Apoptosis as a Therapeutic Target in Cancer and Cancer Stem Cells: Novel Strategies and Futures Perspectives. 2012 ,	1
943	Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis. 2012 , 45, 297-305	26
942	Role of microRNAs in leukemia stem cells. 2012 , 4, 799-809	

941	Cultivation and identification of colon cancer stem cell-derived spheres from the Colo205 cell line. 2012 , 45, 197-204	18
940	The dynamics of cancer stem cells. 2012 , 59, 700-7	24
939	Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. 2012 , 30, 372-8	253
938	Concise review: Cancer stem cells and minimal residual disease. 2012 , 30, 89-93	56
937	Self-renewal of leukemia stem cells in Friend virus-induced erythroleukemia requires proviral insertional activation of Spi1 and hedgehog signaling but not mutation of p53. 2012 , 30, 121-30	13
936	Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. 2012 , 12, 2045-59	44
935	Long-term recovery of irradiated prostate cancer increases cancer stem cells. 2012 , 72, 1746-56	21
934	Tumor-initiating label-retaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. 2012 , 30, 591-8	48
933	Understanding cancer stem cell heterogeneity and plasticity. 2012 , 22, 457-72	367
932	Methods for cancer stem cell detection and isolation. 2012 , 879, 513-29	47
931	Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. 2012 , 149, 1284-97	353
930	Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. 2012 , 22, 396-403	672
929	Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. 2012 , 119, 4224-7	19
928	Human Stem Cell Therapy. 2012 , 187-207	
927	Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. 2012 , 21, 430-46	469
926	Cancer stem cells, microRNAs, and therapeutic strategies including natural products. 2012 , 31, 733-51	50
925	EPHA3 as a novel therapeutic target in the hematological malignancies. 2012 , 5, 325-40	23
924	Cancer stem cells and their potential implications for the treatment of solid tumors. 2012 , 106, 209-15	31

923	Diverging fates of cells of origin in acute and chronic leukaemia. 2012 , 4, 283-97	19
922	Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. 2012 , 4, 675-84	164
921	Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. 2012 , 131, 987-96	53
920	Interaction between regulatory T cells and cancer stem cells. 2012 , 131, 1491-8	18
919	Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells. 2012 , 13, 11-9	10
918	Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. 2012 , 119, 5492-501	51
917	Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. 2012 , 14, 575-85	9
916	Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance. 2012 , 7, 779-88	14
915	Heterogeneity of breast cancer stem cells as evidenced with Notch-dependent and Notch-independent populations. 2012 , 1, 105-13	22
914	Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. 2012 , 118, 3899-910	23
913	Flow cytometry in cancer stem cell analysis and separation. 2012 , 81, 284-93	107
912	The expanding frontier of hematopoietic cell transplantation. 2012 , 82, 271-9	13
911	Cancer Stem Cells: Paradigm Shifting or Perishing Concept?. 2012 , 149-174	
910	Notch signaling pathway and cancer metastasis. 2012 , 727, 186-98	96
909	Glioma Stem Cells and their Therapy Resistance. 2012 , 01,	2
908	Isolation and characterization of cancer stem cells from cervical cancer HeLa cells. 2012 , 64, 477-84	20
907	Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. 2012 , 107, 487-501	58
906	Cancer-initiating enriched cell lines from human glioblastoma: preparing for drug discovery assays. 2012 , 8, 288-98	9

905	Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. 2012 , 29, 633-9	50
904	Screening of peptides bound to breast cancer stem cell specific surface marker CD44 by phage display. 2012 , 51, 212-20	37
903	The roles of TGF- β signaling in carcinogenesis and breast cancer metastasis. 2012 , 19, 118-24	116
902	Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes. 2012 , 460, 545-53	22
901	Nestin and other putative cancer stem cell markers in pancreatic cancer. 2012 , 45, 59-65	55
900	T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors. 2012 , 134, 61-70	4
899	Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. 2012 , 271, 111-21	147
898	Cancer stem cells: an evolving concept. 2012 , 12, 133-43	877
897	Tumorigenic cells are common in mouse MPNSTs but their frequency depends upon tumor genotype and assay conditions. 2012 , 21, 240-52	25
896	Cancer stem cells: impact, heterogeneity, and uncertainty. 2012 , 21, 283-96	862
895	From stem cells to cancer stem cells: HIF takes the stage. 2012 , 24, 232-5	47
894	Bortezomib-resistant nuclear factor κ B expression in stem-like cells in mantle cell lymphoma. 2012 , 40, 107-18.e2	16
893	Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. 2012 , 40, 155-65.e1	32
892	Stem cells in squamous head and neck cancer. 2012 , 81, 224-40	45
891	Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?. 2012 , 17, 435-42	30
890	Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: A case of lipophilic functional bioisosterism with bis-acetamides. 2012 , 50, 75-80	2
889	Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutic drugs in side population cells and ABCB1-overexpressing leukemia cells. 2012 , 83, 586-97	95
888	The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy. 2012 , 33, 2961-70	160

887	p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. 2012 , 39, 97-108	42
886	Progress against cancer (1971-2011): how far have we come?. 2012 , 271, 392-9	13
885	MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. 2012 , 279, 2047-59	187
884	Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. 2012 , 22, 159-74	59
883	Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. 2012 , 16, 988-94	6
882	Human skin cancer stem cells: a tale of mice and men. 2012 , 21, 576-80	19
881	Versatility and nuances of the architecture of haematopoiesis - Implications for the nature of leukaemia. 2012 , 36, 14-22	5
880	Gene expression profiling to dissect the complexity of cancer biology: pitfalls and promise. 2012 , 22, 250-60	24
879	Multispecies model of cell lineages and feedback control in solid tumors. 2012 , 304, 39-59	47
878	Prostate cancer stem cells: are they androgen-responsive?. 2012 , 360, 14-24	35
877	The biology of head and neck cancer stem cells. 2012 , 48, 1-9	112
876	About a generalized model of lymphoma. 2012 , 386, 813-829	4
875	Glioma stem cells: their role in chemoresistance. 2012 , 77, 237-40	22
874	Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. 2012 , 27 Suppl 2, 15-8	41
873	Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. 2012 , 12, 48	149
872	Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells. 2012 , 19, 1357-64	42
871	Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. 2012 , 34, 42-9	125
870	Stem cells in liver diseases and cancer: recent advances on the path to new therapies. 2012 , 55, 298-306	78

869	Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 89-99	118
868	Isolation and characterization of stem-like cells from a human ovarian cancer cell line. 2012 , 363, 257-68	66
867	Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. 2013 , 32, 209-21	149
866	Stem cell microRNAs in senescence and immortalization: novel players in cancer therapy. 2013 , 33, 112-38	13
865	Targeting self-renewal pathways in myeloid malignancies. 2013 , 11, 33	23
864	The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. 2013 , 15, R39	72
863	Cancer stem cells and therapeutic targets: an emerging field for cancer treatment. 2013 , 3, 113-20	17
862	Formaldehyde exposure and leukemia: critical review and reevaluation of the results from a study that is the focus for evidence of biological plausibility. 2013 , 43, 661-70	27
861	Endometrial Cancer Stem Cells: Are They a Possible Therapeutic Target?. 2013 , 2, 1-10	7
860	Chromosomal translocations among the healthy human population: implications in oncogenesis. 2013 , 70, 1381-92	21
859	Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. 2013 , 11, 820-33	42
858	Stem cells: bad seeds. <i>Nature</i> , 2013 , 498, S12-3	50.4 6
857	Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. 2013 ,	5
856	Lung cancer stem cells: a biological and clinical perspective. 2013 , 36, 265-75	35
855	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. 2013 , 5, 859-68	8
854	Applications of Electrochemistry in Medicine. 2013 ,	4
853	CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. 2013 , 171, 280-7	132
852	Essentials of circulating tumor cells for clinical research and practice. 2013 , 88, 338-56	61

851	Stem cell function and maintenance - ends that matter: role of telomeres and telomerase. 2013 , 38, 641-9	13
850	Perspectives on cancer stem cells in osteosarcoma. 2013 , 338, 158-67	75
849	Induction of tumor stem cell differentiation--novel strategy to overcome therapy resistance in gastric cancer. 2013 , 398, 603-8	17
848	Stem Cells and Prostate Cancer. 2013 ,	1
847	Impact of cell dissociation on identification of breast cancer stem cells. 2012 , 12, 125-33	16
846	Stem cell plasticity in development and cancer: epigenetic origin of cancer stem cells. 2013 , 61, 545-65	22
845	Modelling acute leukemias in mice: clonal evolution and the emergence of leukemic stem cells. 2013 , 7 Suppl 2, K1	
844	Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame?. 2013 , 341, 97-104	92
843	Modern Clinical Trial Analysis. 2013 ,	3
842	Blastic leukaemias (AML): a biologist's view. 2013 , 66, 13-22	19
841	microRNA in the control of stem-like phenotype of cancer cells. 2013 , 8, 931-942	3
840	Cancer stem cell hypothesis: a brief summary and two proposals. 2013 , 65, 505-12	19
839	In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines. 2013 , 2, 16	8
838	Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells. 2013 , 15, 143-50	49
837	Stem Cells and Cancer Stem Cells, Volume 9. 2013 ,	
836	Stem Cell Niche. 2013 ,	0
835	Lung cancer-initiating cells: a novel target for cancer therapy. 2013 , 8, 159-172	21
834	Cancer Stem Cells: Prospective Isolation and Progress Toward Functional Biomarker Identification. 2013 , 1, 81-90	

833	Animal Models of Cancer Stem Cells: What are They Really Telling Us?. 2013 , 1, 91-99	6
832	Cancer Stem Cells: A Moving Target. 2013 , 1, 111-118	26
831	Mechanisms of chemoresistance in cancer stem cells. 2013 , 2, 3	504
830	Breast Cancer Metastasis and Drug Resistance. 2013 ,	5
829	Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. 2013 , 93, 970-82	153
828	Discovery of the cancer stem cell related determinants of radioresistance. 2013 , 108, 378-87	135
827	Regulation of apoptosis pathways in cancer stem cells. 2013 , 338, 168-73	42
826	Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. 2013 , 51, 177-84	16
825	Nuclear receptors as regulators of stem cell and cancer stem cell metabolism. 2013 , 24, 716-23	7
824	Molecular pharmacology of ABCG2 and its role in chemoresistance. 2013 , 84, 655-69	152
823	Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia. 2013 , 1035, 217-30	8
822	Animal models of leukemia: any closer to the real thing?. 2013 , 32, 63-76	33
821	PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. 2013 , 185, 225-30	26
820	Intratumor heterogeneity: nature and biological significance. 2013 , 78, 1201-15	49
819	Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. 2013 , 9, 840-848	96
818	Cancer Stem Cells in Resistance to Cytotoxic Drugs: Implications in Chemotherapy. 2013 , 151-161	1
817	Concise review: the yin and yang of intestinal (cancer) stem cells and their progenitors. 2013 , 31, 2287-95	26
816	Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition. 2013 , 341, 16-23	23

815	Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications. 2013 , 63, Unit 14.28.	18
814	Regulation of stem cell populations by microRNAs. 2013 , 786, 329-51	96
813	Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. 2013 , 44, 1973-81	60
812	Life history trade-offs in cancer evolution. 2013 , 13, 883-92	154
811	The cancer stem cell hypothesis applied to oral carcinoma. 2013 , 49, 738-46	38
810	Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome. 2013 , 319, 2230-43	74
809	The fruits of Maclura pomifera extracts inhibits glioma stem-like cell growth and invasion. 2013 , 38, 2105-13	17
808	Effect of HDAC9 inhibition on epithelial-mesenchymal transition in CD133+ prostate cancer cell lines. 2021 , 1-10	
807	Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression. 2021 , 28, 1397-1410.e4	6
806	Recent progress on targeting leukemia stem cells. 2021 , 26, 1904-1913	0
805	Insight of nanomedicine strategies for a targeted delivery of nanotherapeutic cues to cope with the resistant types of cancer stem cells. 2021 , 64, 102681	5
804	Stem Cells in Myelodysplastic Syndromes and Acute Myeloid Leukemia: First Cousins or Unrelated Entities?. 2021 , 11, 730899	1
803	Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant. 2021 , 336, 396-409	2
802	Integrative Analysis of Gene Expression Through One-Class Logistic Regression Machine Learning Identifies Stemness Features in Multiple Myeloma. 2021 , 12, 666561	0
801	Lipid droplets as metabolic determinants for stemness and chemoresistance in cancer. 2021 , 13, 1307-1317	1
800	SIRPB1D123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. 2021 , 14, 155	3
799	The role of microRNA-21 in the onset and progression of cancer. 2021 , 13, 1885-1906	7
798	MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia. 2021 , 81, 5733-5744	0

797	Strategic Development of an Immunotoxin for the Treatment of Glioblastoma and Other Tumours Expressing the Calcitonin Receptor. 2021 , 10,	1
796	Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. 2021 ,	7
795	Beyond the Double-Strand Breaks: The Role of DNA Repair Proteins in Cancer Stem-Cell Regulation. 2021 , 13,	3
794	Tumor stem-like cells isolated from MMQ cells resist to dopamine agonist treatment. 2021 , 535, 111396	
793	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. 2021 , 10,	6
792	Targeting IFN- γ -Inducible lysosomal thiol reductase overcomes chemoresistance in AML through regulating the ROS-mediated mitochondrial damage. 2021 , 14, 101159	0
791	Extracellular Vesicles and Cancer Stem Cells in Tumor Progression: New Therapeutic Perspectives. 2021 , 22,	4
790	Cancer Stem Cell for Tumor Therapy. 2021 , 13,	3
789	Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer. 2021 , 7,	
788	Caveolin1: its roles in normal and cancer stem cells. 2021 , 147, 3459-3475	
787	Anatomical phenotyping and staging of brain tumours. 2021 ,	0
786	Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine. 2021 , 37, 2107-2111	
785	Macrophages and cancer stem cells: a malevolent alliance. 2021 , 27, 121	2
784	Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis. 2021 , 12,	0
783	Engineering strategies to capture the biological and biophysical tumor microenvironment in vitro. 2021 , 176, 113852	2
782	NK Cells Lose Their Cytotoxicity Function against Cancer Stem Cell-Rich Radiotherapy-Resistant Breast Cancer Cell Populations. 2021 , 22,	2
781	Preferential interaction of platelets with prostate cancer cells with stem cell markers. 2021 , 206, 42-51	2
780	Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. 2021 ,	2

779	Identification of biomarkers for acute leukemia via machine learning-based stemness index. 2021 , 804, 145903	1
778	A perspective on the role of autophagy in cancer. 2021 , 1867, 166262	10
777	Mitosis Inhibitors and Medicinal Plants: Neurotoxicity and Neuroprotection. 2021 , 1-35	
776	The role of vasculature in cancer stem cell niches. 2021 , 63-84	
775	Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma. 2021 ,	0
774	EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. 2021 , 11, 6632-6643	4
773	Targeting metastatic cancer. 2021 , 27, 34-44	102
772	Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. 2021 , 11, 3489-3501	13
771	Stem Cell Based Modelling of Glioblastoma. 2021 , 237-246	
770	Role of Syndecan-1 in Cancer Stem Cells. 2021 , 279-308	1
769	Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1. 2021 , 21, 195	
768	YY1 regulation of the cancer stem cell phenotype. 2021 , 39-57	
767	Analysis of a Preliminary microRNA Expression Signature in a Human Telangiectatic Osteogenic Sarcoma Cancer Cell Line. 2021 , 22,	
766	Hematological Humanization of Immune-Deficient Mice. 2021 , 2224, 195-202	
765	The Strange Case of Jekyll and Hyde: Parallels Between Neural Stem Cells and Glioblastoma-Initiating Cells. 2020 , 10, 603738	1
764	How to win the ovarian cancer stem cell battle: destroying the roots.. 2020 , 3, 1021-1033	4
763	Ultimate Precision: Targeting Cancer But Not Normal Self-Replication. 2021 , 237-259	
762	Cancer Stem Cells [Basic Concepts.	1

761	In vivo evaluation of leukemic stem cells through the xenotransplantation model. 2008 , Chapter 3, Unit 3.2	2
760	In search of the elusive epidermal stem cell. 2005 , 45-62	5
759	Stem Cells and Cancer: An Introduction. 2009 , 1-31	2
758	Characterization of Arsenic-Induced Cancer Stem-Like Cells. 2020 , 2117, 293-303	6
757	Mathematical Modeling of Plasticity and Heterogeneity in EMT. 2021 , 2179, 385-413	7
756	Hallmarks of Metastasis. 2009 , 29-46	4
755	Stem cell origin of brain tumors. 2010 , 671, 58-66	3
754	Hypoxia, Gene Expression, and Metastasis. 2010 , 43-58	7
753	Cancer Stem Cell and ATP-Binding Cassette: Which Role in Chemoresistance?. 2012 , 267-288	1
752	The Hedgehog Signaling Pathway in Cancer Pathogenesis and Therapy. 2012 , 55-79	1
751	The robustness continuum. 2012 , 751, 431-52	20
750	Deciphering Fate Decision in Normal and Cancer Stem Cells: Mathematical Models and Their Experimental Verification. 2013 , 203-232	1
749	Resistance to Anthracyclines and Taxanes in Breast Cancer. 2013 , 227-247	3
748	Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer. 2013 , 51-75	1
747	Molecular Evolution of Leukemia Stem Cells. 2013 , 449-458	1
746	Hypoxia, Metastasis, and Antiangiogenic Therapies. 2014 , 205-227	2
745	Flow cytometry for hematopoietic cells. 2014 , 1109, 23-46	6
744	The impact of biology on the treatment of secondary AML. 2001 , 108, 231-55	9

743	The Role of MicroRNAs in Hematopoietic Stem Cells and Leukemia Development. 2014 , 139-157	0
742	Ex vivo assays to study self-renewal, long-term expansion, and leukemic transformation of genetically modified human hematopoietic and patient-derived leukemic stem cells. 2014 , 1185, 195-210	7
741	New Heterogeneity of the Leukemic Stem Cells. 2015 , 559-572	1
740	Engineered cell-based therapies: a vanguard of design-driven medicine. 2014 , 844, 369-91	2
739	Breast Cancer Stem Cells: Role in Tumor Initiation, Progression, and Targeted Therapy. 2015 , 63-77	1
738	Characterization of Cancer Stem Cells. 2016 , 1464, 49-62	12
737	Introduction to Brain Tumor Stem Cells. 2019 , 1869, 1-9	6
736	Identification of human pancreatic cancer stem cells. 2009 , 568, 161-73	175
735	The contribution of niche-derived factors to the regulation of cancer cells. 2009 , 568, 217-32	5
734	Identification of murine and human acute myeloid leukemia stem cells. 2009 , 568, 21-35	3
733	Ex vivo assays to study self-renewal and long-term expansion of genetically modified primary human acute myeloid leukemia stem cells. 2009 , 538, 287-300	25
732	Solid Tumor Stem Cells [Implications for Cancer Therapy. 2009 , 527-543	1
731	Tumor Dormancy, Metastasis, and Cancer Stem Cells. 2009 , 141-153	3
730	Implications of Cancer Stem Cells for Cancer Therapy. 2009 , 255-262	3
729	Plasticity Underlying Multipotent Tumor Stem Cells. 2009 , 99-112	1
728	Cancer Stem Cells: Current Concepts and Therapeutic Implications. 2012 , 227-235	1
727	Technical and ethical limitations in making human monoclonal antibodies (an overview). 2014 , 1060, 9-36	7
726	Targeting DNA Hypomethylation in Malignancy by Epigenetic Therapies. 2019 , 1164, 179-196	19

725	HSP90: A Key Player in Metal-Induced Carcinogenesis?. 2019 , 217-247	2
724	Early Hematopoietic Differentiation in Acute Lymphoblastic Leukemia: The Interplay Between Leukemia-Initiating Cells and Abnormal Bone Marrow Microenvironment. 2016 , 291-318	2
723	Implications of CXCR4/CXCL12 Interaction for Cancer Stem Cell Maintenance and Cancer Progression. 2015 , 89-130	2
722	Glioblastoma Stem Cells and Their Microenvironment. 2017 , 1041, 119-140	36
721	The role of bone microenvironment, vitamin D and calcium. 2012 , 192, 33-64	9
720	Application of T cell immunotherapy for human viral and malignant diseases. 2000 , 53-73	2
719	Human Hematopoiesis in SCID Mice. 1995 , 197-212	1
718	TIM-3 Is a Novel Therapeutic Target for Eradicating Acute Myelogenous Leukemia Stem Cells. 2015 , 307-315	5
717	Elimination of Cancer Stem Cells. 2009 , 357-384	1
716	Cancer Stem Cells. 2011 , 351-376	1
715	Oncolytic Virotherapy of Cancer. 2011 , 295-316	3
714	MicroRNAs and Cancer Stem Cells. 2011 , 373-388	1
713	Common Denominators of Self-renewal and Malignancy in Neural Stem Cells and Glioma. 2012 , 387-418	1
712	Breast Cancer Stem Cell: Translating to the Clinic. 2012 , 249-257	1
711	Markers of Cancer Stem Cells and Their Functions. 2013 , 533-558	1
710	Overcoming Radioresistance of Lung Cancer Stem Cells. 2014 , 117-127	2
709	Leukemia Stem Cells in the Pathogenesis, Progression, and Treatment of Acute Myeloid Leukemia. 2019 , 1143, 95-128	1
708	Tissue "Hypoxia" and the Maintenance of Leukemia Stem Cells. 2019 , 1143, 129-145	3

707	Targeting Therapies for Cancer Stem Cells. 2020 , 273-312	6
706	Cancer Stem Cell Case and Evolutionary Paradigm. 2016 , 287-305	3
705	Acute Myeloid Leukemia in Adults. 2008 , 2215-2234	1
704	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. 2009 , 331-402	1
703	Stem Cells, Cell Differentiation, and Cancer. 2014 , 98-107.e3	1
702	Cancer cell lines involving cancer stem cell populations respond to oxidative stress. 2018 , 17, 24-30	16
701	Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions. 2020 , 152, 102993	6
700	Life style factors, tumor cell plasticity and cancer stem cells. 2020 , 784, 108308	5
699	ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia. 2020 , 10, 8349	2
698	Cancer stem cells, becoming common.	7
697	Identification of a subpopulation of long-term tumor-initiating cells in colon cancer. 2020 , 40,	3
696	Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. 2010 , 134, 1740-9	11
695	Making radiation therapy more effective in the era of precision medicine. 2020 , 3, 272-283	1
694	Single-cell analysis uncovers mechanisms of plasticity in leukemia initiating cells.	3
693	ITGA2 is a target of miR-206 promoting cancer stemness and lung metastasis through enhanced ACLY and CCND1 expression in triple negative breast cancer.	1
692	A Mechanism for Epithelial-Mesenchymal Heterogeneity in a Population of Cancer Cells.	11
691	Quantitative Single-Cell Proteomics as a Tool to Characterize Cellular Hierarchies.	12
690	Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. 1995 , 69, 1328-33	46

689	Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s. 2019 , 4,	7
688	New molecularly targeted therapies for lung cancer. 2007 , 117, 2740-50	154
687	Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice. 2007 , 117, 2929-40	127
686	Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis. 2009 , 119, 2528-31	22
685	Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R β -deficient mice. 2011 , 121, 384-95	277
684	CD13 is a therapeutic target in human liver cancer stem cells. 2010 , 120, 3326-39	453
683	Heterogeneity in breast cancer. 2011 , 121, 3786-8	559
682	Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors. 2013 , 123, 315-28	91
681	Cancer stem cells in the development of liver cancer. 2013 , 123, 1911-8	355
680	Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. 2014 , 124, 3847-62	44
679	Positive feedback between NF- κ B and TNF- α promotes leukemia-initiating cell capacity. 2014 , 124, 528-42	134
678	ZIC2-dependent OCT4 activation drives self-renewal of human liver cancer stem cells. 2015 , 125, 3795-808	97
677	Mouse models for cancer stem cell research. 2010 , 38, 62-71	27
676	Engraftment and Development of Human CD34+-Enriched Cells From Umbilical Cord Blood in NOD/LtSz-scid/scid Mice. 1997 , 90, 85-96	6
675	Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Dissemination and Induces Remission of Juvenile Myelomonocytic Leukemia in Engrafted Immunodeficient Mice. 1997 , 90, 4910-4917	41
674	Inhibition of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Dissemination and Induces Remission of Juvenile Myelomonocytic Leukemia in Engrafted Immunodeficient Mice. 1997 , 90, 4910-4917	5
673	Detection and Characterization of Primitive Malignant and Normal Progenitors in Patients With Acute Myelogenous Leukemia Using Long-Term Coculture With Supportive Feeder Layers and Cytokines. 1997 , 90, 2555-2564	3
672	Establishment of a Reproducible Model of Chronic-Phase Chronic Myeloid Leukemia in NOD/SCID Mice Using Blood-Derived Mononuclear or CD34+ Cells. 1998 , 91, 630-640	7

671	Cytotoxic T-Lymphocyte Defined Human Minor Histocompatibility Antigens With a Restricted Tissue Distribution. 1998 , 91, 2197-2207	10
670	Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow. 1998 , 92, 3780-3792	48
669	Most Acute Myeloid Leukemia Progenitor Cells With Long-Term Proliferative Ability In Vitro and In Vivo Have the Phenotype CD34+/CD71 ^{hi} HLA-DR ^{lo} 1998 , 92, 4325-4335	7
668	Autologous Stem Cell Transplantation in Acute Myelocytic Leukemia. 1998 , 92, 1073-1090	1
667	Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice. 1999 , 94, 1761-1772	52
666	Donor stromal cells from human blood engraft in NOD/SCID mice. 2000 , 96, 3971-3978	25
665	Canada. 2010 , 43-57	1
664	Cancer Stem Cells of Sarcoma. 2013 , 23-78	2
663	Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas. 2017 , 23, 1827-1833	8
662	Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- Leukemia Stem Cells Derived from KG1 ⁺ Acute Myeloid Leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (TSC2) Signaling Pathway. 2020 , 26, e918207	9
661	Differential Localization and Invasion of Tumor Cells in Mouse Models of Human and Murine Leukemias. 2020 , 53, 43-53	1
660	Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology. 2006 , 73, 300-7	10
659	Expansion of Primary Human AML by Aryl Hydrocarbon Receptor Antagonism Minimally Affects Leukemic Transcriptional Profiles but Alters Cellular Metabolism. 2016 , 2, 9-16	1
658	A mechanism for epithelial-mesenchymal heterogeneity in a population of cancer cells. 2020 , 16, e1007619	52
657	Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. 2010 , 5, e10277	322
656	Determination of somatic and cancer stem cell self-renewing symmetric division rate using sphere assays. 2011 , 6, e15844	47
655	Rac1 targeting suppresses human non-small cell lung adenocarcinoma cancer stem cell activity. 2011 , 6, e16951	49
654	Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. 2011 , 6, e21369	45

653	Small molecule antagonists of the Wnt/ β -catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. 2012 , 7, e33976	73
652	Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. 2012 , 7, e35830	12
651	In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas. 2012 , 7, e43110	31
650	Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential. 2012 , 7, e46391	103
649	Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells. 2012 , 7, e49752	38
648	FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells. 2013 , 8, e51671	39
647	Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. 2013 , 8, e57641	17
646	Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population. 2013 , 8, e68187	56
645	Targeting the biophysical properties of the myeloma initiating cell niches: a pharmaceutical synergism analysis using multi-scale agent-based modeling. 2014 , 9, e85059	18
644	Cobblestone-area forming cells derived from patients with mantle cell lymphoma are enriched for CD133+ tumor-initiating cells. 2014 , 9, e91042	13
643	Decreased camptothecin sensitivity of the stem-cell-like fraction of Caco2 cells correlates with an altered phosphorylation pattern of topoisomerase I. 2014 , 9, e99628	19
642	All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. 2015 , 10, e0127790	46
641	Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2. 2015 , 10, e0128585	14
640	Identification and Characterization of CXCR4-Positive Gastric Cancer Stem Cells. 2015 , 10, e0130808	32
639	Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells. 2015 , 10, e0134026	6
638	Identification and Validation of Housekeeping Genes for Gene Expression Analysis of Cancer Stem Cells. 2016 , 11, e0149481	37
637	Establishment and Analysis of Cancer Stem-Like and Non-Cancer Stem-Like Clone Cells from the Human Colon Cancer Cell Line SW480. 2016 , 11, e0158903	7
636	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. 2016 , 11, e0164811	13

635	Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy. 2017 , 12, e0171460	12
634	Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. 2017 , 12, e0177227	40
633	Modeling Physiologic Microenvironments in Three-Dimensional Microtumors Maintains Brain Tumor Initiating Cells. 2017 , 5,	3
632	Novel therapies in AML: reason for hope or just hype?. 2014 , e341-51	7
631	Cell softness regulates tumorigenicity and stemness of cancer cells. 2021 , 40, e106123	24
630	Cancer stem cells in tumor pathogenesis after cryoablation. 2015 , 25, 205-218	2
629	p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy. 2018 , 23, 173-187	5
628	Targeting CD44 as a novel therapeutic approach for treating pancreatic cancer recurrence. 2015 , 2, 572-5	16
627	In quest for leukemia initiating cells in AML. 2018 , 5, 9-10	6
626	Molecular identification and targeting of colorectal cancer stem cells. 2010 , 1, 387-95	68
625	CD44variant exon 9 plays an important role in colon cancer initiating cells. 2013 , 4, 785-91	25
624	Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress. 2016 , 7, 50043-50056	22
623	Serotonin transporter antagonists target tumor-initiating cells in a transgenic mouse model of breast cancer. 2016 , 7, 53137-53152	18
622	Rab27A mediated by NF- κ B promotes the stemness of colon cancer cells via up-regulation of cytokine secretion. 2016 , 7, 63342-63351	17
621	Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. 2016 , 7, 65627-65642	6
620	A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. 2016 , 7, 78499-78515	11
619	Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. 2016 , 7, 72685-72698	16
618	WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3 β /catenin signaling pathway. 2016 , 7, 79544-79556	14

617	Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. 2016 , 7, 78095-78109	22
616	Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cells. 2017 , 8, 9425-9441	10
615	Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. 2017 , 8, 17301-17312	46
614	Differential expression of CD44 and CD24 markers discriminates the epithelioid from the fibroblastoid subset in a sarcomatoid renal carcinoma cell line: evidence suggesting the existence of cancer stem cells in both subsets as studied with sorted cells. 2017 , 8, 15593-15609	6
613	SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress. 2017 , 8, 16712-16727	13
612	Expression and functional regulation of stemness gene Lgr5 in esophageal squamous cell carcinoma. 2017 , 8, 26492-26504	11
611	Phosphorylation of HSF1 at serine 326 residue is related to the maintenance of gynecologic cancer stem cells through expression of HSP27. 2017 , 8, 31540-31553	26
610	USP22 maintains gastric cancer stem cell stemness and promotes gastric cancer progression by stabilizing BMI1 protein. 2017 , 8, 33329-33342	22
609	Molecular identification and targeting of colorectal cancer stem cells. 2010 , 1, 387-395	99
608	Tumor status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. 2017 , 8, 83354-83369	6
607	Tumacrophage: macrophages transformed into tumor stem-like cells by virulent genetic material from tumor cells. 2017 , 8, 82326-82343	14
606	CD271 is an imperfect marker for melanoma initiating cells. 2014 , 5, 5272-83	46
605	Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. 2011 , 2, 245-50	36
604	expression in acute myeloid leukemia. 2018 , 9, 7442-7452	4
603	TOP2A ^{high} is the phenotype of recurrence and metastasis whereas TOP2A ^{neg} cells represent cancer stem cells in prostate cancer. 2014 , 5, 9498-513	26
602	The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. 2011 , 2, 313-20	22
601	Photodynamic therapy of cervical cancer by eradication of cervical cancer cells and cervical cancer stem cells. 2019 , 10, 4380-4396	20
600	Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy. 2011 , 2, 713-27	61

599	Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. 2015 , 6, 8663-75	10
598	TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia. 2015 , 6, 20977-92	27
597	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 2012 , 3, 371-94	98
596	Sphere-derived tumor cells exhibit impaired metastasis by a host-mediated quiescent phenotype. 2015 , 6, 27288-303	7
595	Differentiation and transdifferentiation potentials of cancer stem cells. 2015 , 6, 39550-63	51
594	Cancer stem cell targeted therapy: progress amid controversies. 2015 , 6, 44191-206	109
593	Invasive oral cancer stem cells display resistance to ionising radiation. 2015 , 6, 43964-77	30
592	Targeting Notch to overcome radiation resistance. 2016 , 7, 7610-28	36
591	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. 2012 , 3, 1588-99	126
590	Drug resistance in cancer: molecular evolution and compensatory proliferation. 2016 , 7, 11746-55	46
589	Anti-cancer drug 3,3'-diindolylmethane activates Wnt4 signaling to enhance gastric cancer cell stemness and tumorigenesis. 2016 , 7, 16311-24	17
588	Emetine induces chemosensitivity and reduces clonogenicity of acute myeloid leukemia cells. 2016 , 7, 23239-50	9
587	EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/ β -catenin signaling. 2016 , 7, 41540-41558	39
586	The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. 2016 , 7, 41217-41232	48
585	Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.. 2019 , 2, 82-106	6
584	Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets.. 2019 , 2, 457-470	6
583	Cancer-on-a-chip for Drug Screening. 2018 , 24, 5407-5418	7
582	Drug Delivery Systems Using Surface Markers for Targeting Cancer Stem Cells. 2020 , 26, 2057-2071	3

581	Cancer Stem Cell Niche in Colorectal Cancer and Targeted Therapies. 2020 , 26, 1979-1993	3
580	A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties. 2019 , 19, 2-11	5
579	Integrin β (CD49f), The Microenvironment and Cancer Stem Cells. 2019 , 14, 428-436	13
578	Cancer Stem Cells and their Management in Cancer Therapy. 2020 , 15, 212-227	3
577	Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. 2010 , 10, 116-20	32
576	FAK and Nanog cross talk with p53 in cancer stem cells. 2013 , 13, 576-80	22
575	Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. 2020 , 20, 145-151	3
574	Human papillomavirus infections and cancer stem cells of tumors from the uterine cervix. 2012 , 6, 232-40	35
573	Melanoma Stem Cell Sphere Formation Assay. 2017 , 7, e2233	2
572	The potential of nanomedicine to alter cancer stem cell dynamics: the impact of extracellular vesicles. 2020 , 15, 2785-2800	4
571	Stem Cells of Adult Organisms in Biology and Medicine. 2010 , 2, 155-166	1
570	The Role of Cancer Stem Cells in Radiation Resistance. 2020 , 10, 164	57
569	Mitochondria's Role in the Maintenance of Cancer Stem Cells in Glioblastoma. 2021 , 11, 582694	9
568	Cancer, stem cells and cancer stem cells: old ideas, new developments. 2011 , 3, 23	18
567	Isolation and biological analysis of tumor stem cells from pancreatic adenocarcinoma. 2008 , 14, 3903-7	49
566	Stem cells, a two-edged sword: risks and potentials of regenerative medicine. 2008 , 14, 4273-9	18
565	Cellular reprogramming and hepatocellular carcinoma development. 2013 , 19, 8850-60	24
564	Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. 2014 , 20, 2098-106	69

563	Contactin 1: A potential therapeutic target and biomarker in gastric cancer. 2015 , 21, 9707-16	14
562	Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis. 2015 , 21, 2605-13	18
561	Biliary tract cancer stem cells - translational options and challenges. 2017 , 23, 2470-2482	10
560	Targeting cancer stem cells in cholangiocarcinoma (Review). 2020 , 57, 397-408	6
559	Cell division symmetry control and cancer stem cells. 2020 , 7, 82-98	5
558	The top cited articles on glioma stem cells in Web of Science. 2013 , 8, 1431-8	10
557	Circulating cancer stem cells: the importance to select. 2015 , 27, 437-49	45
556	Cancer stem cells in glioma: challenges and opportunities. 2013 , 2, 429-441	24
555	Mechanisms determining the fate of hematopoietic stem cells. 2015 , 2, 10	4
554	Research on human glioma stem cells in China. 2017 , 12, 1918-1926	4
553	Culturing in serum-free culture medium on collagen type-I-coated plate increases expression of CD133 and retains original phenotype of HT-29 cancer stem cell. 2016 , 5, 59	7
552	Alterations of Mitochondria and Related Metabolic Pathways in Leukemia: A Narrative Review. 2020 , 8, 3-11	4
551	Cancer stem cell hypothesis and gastric carcinogenesis: Experimental evidence and unsolved questions. 2012 , 4, 54-9	26
550	Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia. 2009 , 1, 49-54	4
549	Tumor initiating cells in pancreatic cancer: A critical view. 2009 , 1, 8-10	10
548	Cancer stem cell impact on clinical oncology. 2018 , 10, 183-195	29
547	Targeting cancer stem cells in drug discovery: Current state and future perspectives. 2019 , 11, 398-420	40
546	Bone marrow microenvironment: The guardian of leukemia stem cells. 2019 , 11, 476-490	17

545	Advance in metabolism and target therapy in breast cancer stem cells. 2020 , 12, 1295-1306	5
544	Molecular modulation of autophagy: New venture to target resistant cancer stem cells. 2020 , 12, 303-322	13
543	Defining lung cancer stem cells exosomal payload of miRNAs in clinical perspective. 2020 , 12, 406-421	9
542	Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy. 2012 , 4, 44-52	4
541	Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia. 2013 , 5, 196-204	5
540	Emerging role of microRNAs in cancer stem cells: Implications in cancer therapy. 2015 , 7, 1078-89	37
539	Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. 2016 , 8, 316-331	14
538	Role of nuclear receptors in breast cancer stem cells. 2016 , 8, 62-72	10
537	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. 2010 , 2, 114-26	34
536	Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. 2011 , 44, 158-64	46
535	Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. 2014 , 33, 529-38	18
534	Molecular Pathogenesis of Sporadic Melanoma and Melanoma-Initiating Cells. 2010 , 134, 1740-1749	25
533	Cancer Stem Cells: A Review of the Literature and the Implications in Head and Neck Cancer.	2
532	Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer. 2013 , 68, 592-8	9
531	Expression and functional role of ALDH1 in cervical carcinoma cells. 2012 , 13, 1325-31	32
530	How to establish acute myeloid leukemia xenograft models using immunodeficient mice. 2013 , 14, 7057-63	8
529	Growth, clonability, and radiation resistance of esophageal carcinoma-derived stem-like cells. 2013 , 14, 4891-6	6
528	Cancer stem cells and stemness markers in oral squamous cell carcinomas. 2014 , 15, 8549-56	36

527	Emerging roles of Krüppel-like factor 4 in cancer and cancer stem cells. 2015 , 16, 3629-33	15
526	Isolation of cancer stem cells by selection for miR-302 expressing cells. 2019 , 7, e6635	6
525	Alignment of single-cell trajectories by tuMap enables high-resolution quantitative comparison of cancer samples. 2021 ,	0
524	Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?. 2021 , 13,	2
523	Label-Free Cancer Stem-like Cell Assay Conducted at a Single Cell Level Using Microfluidic Mechanotyping Devices. 2021 , 93, 14409-14416	2
522	A New Stemness-Related Prognostic Model for Predicting the Prognosis in Pancreatic Ductal Adenocarcinoma. 2021 , 2021, 6669570	1
521	A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia. 2021 , 10,	3
520	Epigenetic Signaling of Cancer Stem Cells During Inflammation. 2021 , 9, 772211	4
519	Mitochondrial dynamics regulators: implications for therapeutic intervention in cancer. 2021 , 1	2
518	Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities. 2021 , 12, 775128	4
517	Seeding metastases: The role and clinical utility of circulating tumour cells. 2021 , 43, 285-306	0
516	Normal and Leukemic Human Stem Cells. 2000 , 25-36	
515	Donor stromal cells from human blood engraft in NOD/SCID mice. 2000 , 96, 3971-3978	
514	Leukemia Stem Cells with Efficient Drug Efflux in Acute Myeloid Leukemia. 2003 , 128-135	
513	Myelodysplastische Syndrome. 2003 , 268-311	
512	Acute myeloid leukemia in adults. 2004 , 633-656	
511	Hematopoietic Stem Cells, Aging, and Cancer. 2005 , 105-123	
510	Neural Stem Cells: On Where They Hide, in Which Disguise, and How We May Lure Them Out. 2006 , 319-360	2

- 509 The needle in the haystack. **2006**, 6, S10-S10 1
- 508 Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents. **2007**, 345-372
- 507 Cellular and genetic events in retinoblastoma tumorigenesis. **2007**, 405-409
- 506 Differentiation Therapy in AML. **2007**, 293-312
- 505 Future perspectives and unanswered questions on cancer metastasis and the lymphovascular system. **2007**, 135, 293-6
- 504 Molecular Basis of Radiation Therapy. **2008**, 593-604 1
- 503 Stem Cells, Cell Differentiation, and Cancer. **2008**, 95-104
- 502 Cancer Stem Cells and Radiation. **2008**, 285-293
- 501 Conceptual Evolution in Cancer Biology. **2008**, 185-208
- 500 Lung Cancer Stem Cells. **2008**, 213-218
- 499 Modeling Human Leukemia Using Immune-Compromised Mice. **2008**, 121-132 1
- 498 Stem Cell Fates: Control by Small Molecules. 1
- 497 Therapeutic Targeting of the Melanoma Stem Cell Population. **2008**, 83-98
- 496 Cancer stem cells:current status. **2008**, 28, 439-442
- 495 Cellule souche cancéreuse : réflexions histologiques. **2009**, 105, 45
- 494 Pten-Deficient Mouse Models for High-Grade Astrocytomas. **2009**, 77-92 1
- 493 Immune Responses to Stem Cells and Cancer Stem Cells. **2009**, 505-518
- 492 Diagnostic Value II: Hematopoietic Malignancies. **2009**, 211-224

491 Prostate Cancer Stem Cells. **2009**, 137-165

490 Stem Cells and Lung Cancer. **2009**, 193-222

489 Leukemia Stem Cells. **2009**, 281-294

488 The leukemia stem cell. **2010**, 145, 1-17

4

487 Leukemic Stem Cells: New Therapeutic Targets?. **2009**, 519-526

486 The Endometrium: A Novel Source of Adult Stem/Progenitor Cells. **2009**, 391-404

2

485 Breast Cancer Stem Cells. **2009**, 167-192

484 Prostate Cancer Stem/Progenitor Cells. **2009**, 217-230

483 Mouse Model: Telomeres and Telomerase in Stem Cell and Cancer. **2009**, 149-167

1

482 The Stem State in Cancer. **2009**, 217-244

481 Cancer Stem Cells in Metastatic Melanoma. **2009**, 435-441

480 Brain Cancer Stem Cells as Targets of Novel Therapies. **2009**, 1057-1075

479 Implications of Cancer Stem Cells for Tumor Metastasis. **2009**, 443-453

478 Cancer Stem Cells and Skin Cancer. **2009**, 251-267

477 Role of Bone Marrow-Derived Cells in Gastric Adenocarcinoma. **2009**, 561-586

476 The Role of the Tumor Suppressor Fhit in Cancer-Initiating Cells. **2009**, 489-493

475 Telomere and Telomerase for the Regulation of Stem Cells. **2009**, 123-134

474 Cancer Stem Cells in Colorectal Cancer. **2009**, 223-250

473 Detection and Clinical Implications of Occult Systemic Micrometastatic Breast Cancer. **2009**, 1203-1210

472 Cancer Stem Cells: Potential Mediators of Therapeutic Resistance and Novel Targets of Anti-cancer Treatments. **2009**, 559-579

471 p75NTR in isolation and identification of cancer stem cells from human esophageal carcinoma. **2009**, 29, 481-486

470 Cancer Stem Cells: An Overview. **2010**, 173-181

469 Cancer stem cells of multiple myeloma: recent progress. **2009**, 29, 953-955

468 The Future of Lung Cancer. **2010**, 503-514

467 Cancer Stem Cell Biology and Its Role in Radiotherapy. **2010**, 1532-1543

466 Molecular targeting therapy: Cancer stem cell and invasion/metastasis. **2010**, 36, 442-446

465 Future Treatments of Ependymoma. **2010**, 291-304

464 Diagnosis and Prognosis. **2010**, 103-114

463 Cancer Stem Cells: Potential Targets for Molecular Medicine. **2010**, 73-80

462 Regulation of Self-Renewing Divisions in Normal and Leukaemia Stem Cells. **2010**, 109-125

461 Update on the Molecular Pathology of Precursor Lymphoid Leukemias. **2011**, 103-126

460 Tumor Stem Cells: Therapeutic Implications of a Paradigm Shift in Multiple Myeloma. **2011**, 349-362

459 Stem Cells and Liver Cancer. **2011**, 815-829

458 WNT/ECatenin Signaling in Leukemia. **2011**, 129-142

457 Melanoma Stem Cells. **2011**, 255-279

456 The Cancer Stem Cell Paradigm. **2011**, 225-248

455 Future Directions: Cancer Stem Cells as Therapeutic Targets. **2011**, 403-429

454 Cancer Stem Cells in Brain Cancer. **2011**, 37-56

1

453 Cancer Stem Cells in Melanoma. **2011**, 117-138

452 Very Small Embryonic-like Stem Cells and Their Potential Relevance for Kidney Homeostasis. **2011**, 189-201

451 Stem-cell Biology in Normal and Malignant Hematopoiesis. 1-16

450 Stem Cells and Alcohol-Related Cancers. **2011**, 211-223

449 Cancer Stem Cells and Disease Prognosis. **2011**, 329-343

448 Cellular Immortality in Brain Tumors: An Overview. **2011**, 21-32

447 Molecular targeting of cancer stem cells. **2011**, 202-216

446 Stem Cells and Cancer Stem Cells: Biological and Clinical Interrelationships. **2012**, 289-300

445 Leukemia Stem Cells. **2012**, 85-103

444 Cancer Stem Cells and Glioblastoma Multiforme: Pathophysiological and Clinical Aspects. **2012**, 123-140

443 Cancer Stem Cells and the Microenvironment. **2012**, 69-84

442 Immunomodulatory Functions of Cancer Stem Cells. **2012**, 301-332

441 Acute Myeloid Leukemia (AML). **2012**, 1-36

440 Melanoma Cell Propagation: Cancer Stem Cell, Clonal Evolution and Interconversion Models of Tumorigenicity. **2012**, 227-241

439 Stem Cells and Leukemia. **2012**, 267-306

438 Global OMICs Profiling and Functional Analysis of CD44+/CD24^{low} Stem-Like Cells in Normal Human Breast Tissue and Breast Cancer. **2012**, 607-626

- 437 Cross Talks Among Notch, Wnt, and Hedgehog Signaling Pathways Regulate Stem Cell Characteristics. **2012**, 593-606
- 436 Enrichment and tumorigenicity identification of cells with side population phenotype from hepatocellular carcinoma in NOD-SCID mice. **2011**, 31, 1126-1130
- 435 The Biology of Lung Cancer Stem Cells. **2012**, 509-532
- 434 Breast Cancer Stem Cells. **2012**, 451-465
- 433 Maintenance of Hematopoiesis: Role of Early B Cell Factor 2. **2012**, 41-50
- 432 Changing Paradigms in Cancer Clinical Trials. **2012**, 227-246
- 431 Concepts, Challenges and Perspectives in Cancer Research. **2012**, 1-17
- 430 Introduction to Cancer Stem Cells. **2013**, 1-18
- 429 MicroRNAs in Cancer Stem Cells. **2013**, 29-41
- 428 Breast Cancer Stem Cells. 251-270
- 427 Cancer Stem Cells: A Matter of Perspective. **2013**, 3-10
- 426 Non-Hierarchically Organized Operations in Malignancies: Stromal Dysfunction Induces and Maintains Hematopoietic Malignancies. **2013**, 69-90
- 425 Cancer Stem Cells: The Gist of the Matter. **2013**, 199-224
- 424 Microenvironmental Influence on Breast Cancer Dormancy and Metastasis. **2013**, 23-33
- 423 Prostate Cancer Stem Cells: A Brief Review. **2013**, 37-49
- 422 The Immune System in Breast Cancer Initiation and Progression: Role of Epithelial to Mesenchymal Transition. **2013**, 43-64
- 421 [Identification of "side population" associated with cancer stem cells by flow cytometry with violet laser]. **2013**, 59, 339-48
- 420 MDS Stem Cell Biology. **2013**, 73-84

419 TGF- β in Cancer Stem Cells. **2013**, 93-112

418 Proliferation and Regeneration. **2013**, 31-52

417 Breast Cancer Stem Cells: From Theory to Therapy. **2013**, 477-489

1

416 Adult Ovary Stem Cells. **2014**, 239-264

415 Tumour Stem Cell Enrichment by Anticancer Drugs: A Potential Mechanism of Tumour Recurrence. **2014**, 9-19

414 LGR5 as a Marker in Brain Cancer. **2014**, 1-14

413 Stem Cells of the Reproductive System: At a Glance. **2014**, 235-257

412 Cancer Stem Cells in Gastric Cancer. **2014**, 191-202

411 SCID-hu Mice as a Model for the Study of Human Malignancies. **1995**, 157-170

410 Functional Assays for Human AML Cells by Transplantation into SCID Mice. **1996**, 453-455

409 Responses of Leukemia Cells to Hematopoietic Growth Factors. **1996**, 303-319

408 Characterization of Normal and Leukemic Lymphohematopoietic Precursor Cells by Three-Color Flow Cytometry and Detection of Clone-Specific Leukemia-Associated T-Cell Receptor γ Rearrangements. **1997**, 224-231

407 Functional Expression of Fas (CD95) in Acute Myeloid Leukemia Cells in the Context of CD34 and CD38 Expression: Possible Correlation With Sensitivity to Chemotherapy. **1997**, 90, 4901-4909

2

406 Functional Characterization of Leukemic Stem Cells in Acute Myeloid Leukemia. **1998**, 13-18

405 Clonal Chromosomal Abnormalities in the Stem Cell Compartment of a Patient with Acute Myeloid Leukemia in Hematological Complete Remission. **1998**, 1007-1011

404 THE SCID MOUSE MUTANT: DEFINITION AND POTENTIAL USE AS A MODEL FOR IMMUNE DISORDERS. **1998**, 603-618

403 Flow Cytometric Analysis of Immature Cell Populations in B-Cell Precursor ALL. **1998**, 78-81

402 Evaluation Of NOD-SCID-Mice for a Human B-Cell Precursor ALL Xenograft Model. **1998**, 73-77

- 401 Involvement of CD34+ Stem Cells in Malignant Transformation in AML and MDS [Genetic Analysis of Sorted Subpopulations by Classical and Molecular Cytogenetics. **1998**, 19-28 1
- 400 Distinct phases of human prostate cancer initiation and progression can be driven by different cell-types. **2014**, 1, 2
- 399 The Role of Centrosomes in Cancer Stem Cell Functions. 259-279
- 398 Retinoblastoma Tumorigenesis. **2015**, 61-68
- 397 Accounting for randomness in measurement and sampling in studying cancer cell population dynamics. **2014**, 8, 230-41
- 396 Cancer Stem Cell: The Mastermind of Carcinogenesis. **2014**, 11, 1-18
- 395 Insight into Cancer Stem Cell Niche; Lessons from Cancer Stem Cell Models Generated In Vitro. **2015**, 211-226
- 394 LGR5 as Marker in Brain Cancer. **2015**, 361-378
- 393 Epithelial to Mesenchymal Transition (EMT) and Intestinal Tumorigenesis. **2015**, 309-364
- 392 Non-coding RNAs in Cancer and Cancer Stem Cells. **2015**, 131-153
- 391 Leukemic and Lymphoid Stem Cells. **2015**, 307-332
- 390 Head and Neck Cancer Stem Cells. **2015**, 297-305
- 389 Glioma Stem Cells. **2015**, 24, 358-365
- 388 Epigenetic of Retinoic Acid Receptor β Gene in Breast Cancer. **2015**, 311-362
- 387 MicroRNA Signatures as Biomarkers in Cancer. 1-20 0
- 386 Humanized (SCID) Mice as a Model to Study human Leukemia. **2015**, 21, 51-59 2
- 385 Stem Cell Targeting and Alteration by Arsenic. 397-420
- 384 Translational Research Methods: Renal Stem Cells. **2016**, 525-569

383 Neoplasia of the Gastrointestinal Tract. 587-616

382 Cancer stem cells - a brief overview. **2016**, 5, 61-68

381 Chapter 4:The Role of Catecholamines in Stem Cell Mobilisation. **2016**, 64-93

380 Pathogenic Features of Liver Metastasis: Growth, Regrowth, Stem Cells, and Circulating Tumor Cells. **2016**, 1-7

379 Stem Cell Antigens in Cancer. **2016**, 420-425

378 Pathogenic Features of Liver Metastasis: Growth, Regrowth, Stem Cells, and Circulating Tumor Cells. **2017**, 1989-1995

377 Role of Cancer Stem Cells in Oral Cancer. **2017**, 487-529

376 Targeting Cancer Stem Cells-A Renewed Therapeutic Paradigm. **2017**, 13, 45-55

1

375 Melanoma Stem Cells. **2017**, 311-337

374 Cancer Stem Cell: From Conjecture to Reality. **2017**, 757-787

373 Cell Proliferation and Differentiation. **2017**, 11-35

372 Cancer Stem CellsBiopathology with Reference to Head and Neck Cancers. **2017**, 37-57

1

371 Hematopoietic Stem Cells: The Basis of Normal and Malignant Hematopoiesis. **2017**, 3-29

370 Leukemia Stem Cells in Blood Cells; Focused on Acute Myeloid Leukemia. **2017**, 23, 1-7

369 Improving leukemic CD34+/CD38Blasts characterization with single-cell transcriptome sequencing.

368 NOTCH1 Activation Depletes the Pool of Side Population Stem Cells in ATL. **2017**, 4,

367 Lung Cancer Stem Cells. **2018**, 45-56

366 Gene expression profiling and construction of a putative gene regulatory network of bladder cancer tumor-initiating cells. **2017**, 8, 111271-111280

- 365 Cancer Stem Cells and Their Therapeutic Applications. **2018**, 3-12
- 364 Automation In High Throughput/Content Screening For Cancer Stem Cell Drug Discovery. **2018**,
- 363 Significant antitumour effect of an antibody against TMEM180, a new cancer-specific molecule.
- 362 Isolation of cancer stem cells by selection for miR-302 expressing cells.
- 361 Prelude and premise to the special issue: disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm Epistemology of the origin of cancer **2019**, 2, 6
- 360 Genomics, Proteomics, and Metabolomics of Cancer Stem Cells (CSCs). **2019**, 159-179 1
- 359 Preface. **2019**, 141, xi-xiii
- 358 CAST Therapy. **2019**, 269-288
- 357 Cancer Stem Cell Biology.
- 356 PI3K/AKT inhibition in tumor propagating cells of DLBCL reverses R-CHOP resistance by destabilizing SOX2.
- 355 Exponential Growth of Glioblastoma In Vivo Driven by Rapidly Dividing and Outwardly Migrating Cancer Stem Cells.
- 354 Tumorigenicity of Esophageal Cancer Stem Cells (ECSCs) in nude mouse xenograft model. **2019**, 7, 4-10 0
- 353 Acquisition of temozolomide resistance by the rat C6 glioma cell line increases cell migration and side population phenotype. **2019**, 42, 2355-2362 3
- 352 Cancer Stem Cells and Oral Carcinogenesis; a Review Article. **2019**, 12,
- 351 Immunopathology and Immunotherapy of Myeloid Leukemia. **2020**, 103-117
- 350 The miR-567/RPL15/TGF- β /Smad axis inhibits the stem-like properties and chemo-resistance of gastric cancer cells.. **2020**, 9, 3539-3549 0
- 349 High type I collagen density fails to increase breast cancer stem cell phenotype. **2020**, 8, e9153
- 348 Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies. **2021**, 22, 2

- 347 Fructose Metabolism and Acute Myeloid Leukemia. **2021**, 000, 000-000 2
- 346 Cancer Stem Cells in Oral Carcinoma. **2020**, 427-437
- 345 Metabolic Changes and Their Characterization. **2020**, 35-70
- 344 OMIP 072: A 15-color panel for immunophenotypic identification, quantification, and characterization of leukemic stem cells in children with acute myeloid leukemia. **2021**, 99, 382-387 0
- 343 SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells. **2020**, 31, e46 2
- 342 MDS Stem Cell Biology. **2020**, 55-72
- 341 Isolation and Characterization of Cancer Stem Cells (CSCs). **2020**, 51-67
- 340 Cancer Stem Cells and the Development of Cancer. **2020**, 151-192
- 339 Controversies in Isolation and Characterization of Cancer Stem Cells. **2020**, 257-272
- 338 Generation of induced secretome from adipose-derived stem cells specialized for disease-specific treatment: An experimental mouse model. **2020**, 12, 70-86 0
- 337 Vitamin D Compounds and Cancer Stem Cells in Cancer Prevention. **2020**, 143-159
- 336 Technological Advancement in Cancer Stem Cell Research. **2020**, 241-256 2
- 335 Lgr5-mediated restraint of Eatenin is essential for B-lymphopoiesis and leukemia-initiation. 0
- 334 Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells. **2021**, 13, 1 1
- 333 How the Hedgehog Outfoxed the Crab. **2006**, 1-22 1
- 332 Leukemic Stem Cells: New Therapeutic Targets?. **2009**, 215-230
- 331 Cancer originating from bone marrow stem cells: can we extrapolate from gastritis to colitis?. 170-178
- 330 Targeting Signaling Pathways In the Search of Melanoma's Achilles' Heel. **2008**, 27-42

- 329 Acute Myeloid Leukemias. **2006**, 767-775
- 328 The Role of RNA Interference in Targeting the Cancer Stem Cell and Clinical Trials for Cancer. **2012**, 387-408 0
- 327 Evaluation of diagnostic accuracy of serum calcium channel α_1 subunit in hepatocellular carcinoma-related cirrhosis. **2020**, 10,
- 326 Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7. **2020**, 4, e469 0
- 325 Disruption of a GATA2, TAL1, ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
- 324 Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice. **2020**, 15, e0241375 2
- 323 Leukemia Stem Cells: Concept and Implications. **2021**, 2185, 25-37 0
- 322 Analysis and Isolation of Mouse Leukemic Stem Cells. **2021**, 2185, 51-63
- 321 Oncolytic virus as a cancer stem cell killer: progress and challenges. **2014**, 1, 22 5
- 320 The scientific challenge of Langerhans cell histiocytosis. **1994**, 23, S61-3 1
- 319 Human embryonic and neuronal stem cell markers in retinoblastoma. **2007**, 13, 823-32 107
- 318 Pancreatic cancer stem cells and EMT in drug resistance and metastasis. **2009**, 64, 489-500 122
- 317 Advances in ovarian cancer screening: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns. **2011**, 84, 47-9 1
- 316 Prostate cancer stem cell biology. **2012**, 64, 19-33 26
- 315 Targeting cancer stem cells: a new therapy to cure cancer patients. **2012**, 2, 340-56 81
- 314 Targeting prostate cancer stem cells for cancer therapy. **2012**, 13, 135-42 19
- 313 Characterization and retinal neuron differentiation of WERI-Rb1 cancer stem cells. **2012**, 18, 2388-97 16
- 312 What is the clinical value of cancer stem cell markers in gliomas?. **2013**, 6, 334-48 57

311	Molecular characteristics of cancer stem-like cells derived from human breast cancer cells. 2013 , 33, 763-77	6
310	Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies. 2013 , 2, 52-61	28
309	Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer. 2012 , 1, 59-74	28
308	Mouse models for colorectal cancer. 2013 , 3, 240-50	32
307	Potential clinical role of telomere length in human glioblastoma. 2011 , 1, 243-70	6
306	Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples. 2014 , 7, 184-93	15
305	Clinical value of CD133 and nestin in patients with glioma: a population-based study. 2014 , 7, 3739-51	39
304	Similarity on neural stem cells and brain tumor stem cells in transgenic brain tumor mouse models. 2013 , 8, 2360-9	
303	Metastatic cancer stem cells: from the concept to therapeutics. 2014 , 3, 46-62	53
302	New insights in hepatocellular carcinoma: from bench to bedside. 2013 , 1, 15	10
301	In vivo molecular imaging of cancer stem cells. 2015 , 5, 14-26	17
300	Pancreatic cancer stem cells. 2015 , 5, 894-906	10
299	CANCER STEM CELLS IN OSTEOSARCOMA. 2013 , 10, 38-42	4
298	Study on like-stem characteristics of tumor sphere cells in human gastric cancer line HGC-27. 2015 , 8, 19717-24	1
297	Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion and sphere formation. 2016 , 6, 1078-88	32
296	Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/ β -catenin pathways. 2014 , 34, 1709-13	48
295	[Culture and identification of tumor stem cells from surgically resected colorectal cancer tissues]. 2019 , 39, 415-421	
294	Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. 2018 , 11, 2092-2099	4

293	[Clinical significance of CD44 and CD133 expression in oral potentially malignant disorder and oral squamous cell carcinoma]. 2017 , 35, 311-316	
292	[Characteristic and prognostic significance of leukemia stem cells associated antigens expressions in t (8;21) acute myeloid leukemia]. 2019 , 40, 831-836	
291	Molecular imaging in tracking cancer stem cells: A review. 2020 , 34, 90	1
290	SOX13 regulates cancer stem-like properties and tumorigenicity in hepatocellular carcinoma cells. 2021 , 11, 760-772	1
289	Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia. 2021 , 39, 723-736	2
288	Cancer stem cells in head and neck cancer. 2021 , 10, 28-35	1
287	Role of ROS in Cancer Stem Cells. 2021 , 1-29	
286	Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia. 2021 , 39, 723-736	3
285	A reciprocal feedback loop between HIF-1α and HPIP controls phenotypic plasticity in breast cancer cells. 2021 , 526, 12-28	1
284	A preview of select articles. 2021 , 39, 669-672	
283	Emerging role of G9a in cancer stemness and promises as a therapeutic target. 2021 , 10, 76	1
282	Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. 2021 , 13,	0
281	The IVF-generated human embryonic microenvironment reverses progesterin resistance in endometrial cancer cells by inducing cancer stem cell differentiation. 2021 , 526, 311-311	0
280	Upregulation of miR-216a-5p by Lentinan Targeted Inhibition of JAK2/STAT3 Signaling Pathway to Reduce Lung Adenocarcinoma Cell Stemness, Promote Apoptosis, and Slow Down the Lung Adenocarcinoma Mechanisms.. 2021 , 11, 778096	0
279	Understanding the Role of Autophagy in Cancer Formation and Progression Is a Real Opportunity to Treat and Cure Human Cancers. 2021 , 13,	4
278	Wnt/ECatenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. 2021 , 8, 1415-1444	9
277	An autoimmune stem-like CD8 T cell population drives type 1 diabetes. <i>Nature</i> , 2021 ,	50.4 5
276	Colorectal Cancer Stem Cells: An Overview of Evolving Methods and Concepts. 2021 , 13,	0

275	Adhesion Molecules Involved in Stem Cell Niche Retention During Normal Haematopoiesis and in Acute Myeloid Leukaemia. 2021 , 12, 756231	0
274	GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. 2021 , 21, 1241	0
273	PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in Acute Myeloid Leukemia. 2021 ,	1
272	Side population analysis in clear cell renal cell carcinoma. 2021 , 585, 196-202	
271	Promotion of tumor progression by exosome transmission of circular RNA circSKA3.. 2022 , 27, 276-292	1
270	Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow. 2021 , 23, 1252-1260	0
269	Dormant Cancer Cells: Molecular Features, in vitro Models, and Identification Methods. 2021 , 37, 5-13	
268	Multifaceted role of chemokines in solid tumors: From biology to therapy.. 2022 ,	5
267	CD34+ CD38- subpopulation without CD123 and CD44 is responsible for LSC and correlated with imbalance of immune cell subsets in AML. 2022 , 46, 159-169	
266	Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development.. 2022 , 147, 112616	4
265	Extract Reduces Stemness of Gastric Cancer Stem Cells by Targeting PDCD4 and EIF3H. 2021 , 20, 15347354211058168	
264	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML.	
263	Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.. 2022 , 1-10	
262	Breast Cancer Classification Based on Tumor Budding and Stem Cell-Related Signatures Facilitate Prognosis Evaluation.. 2021 , 11, 818869	1
261	Advances in the Research of Osteosarcoma Stem Cells and its Related Genes.. 2021 ,	1
260	The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.. 2021 , 11, 791696	1
259	Cancer stem cells. 2022 , 187-204	
258	Integrated Machine Learning and Bioinformatic Analyses Constructed a Novel Stemness-Related Classifier to Predict Prognosis and Immunotherapy Responses for Hepatocellular Carcinoma Patients.. 2022 , 18, 360-373	2

257	ROS activated prodrug for ALDH overexpressed cancer stem cells. 2021 ,	1
256	The Influence of Cancer Stem Cells on the Risk of Relapse in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Prospective Cohort Study.. 2022 , 11, 239-247	3
255	ROS Signaling in Brain Tumor. 2022 , 1-20	
254	Slow-cycling cells in glioblastoma: a specific population in the cellular mosaic of cancer stem cells.	
253	DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells.. 2022 , 18, 1211-1219	1
252	Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications.. 2022 , 1	2
251	Introduction to cancer biology. 2022 , 1-17	
250	Childhood Medulloblastoma: An Overview.. 2022 , 2423, 1-12	
249	Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?. 2022 , 28, 37-42	1
248	Molecular mechanism of therapeutic approaches for human gastric cancer stem cells.. 2022 , 14, 76-91	2
247	Loss of miR-31-5p drives hematopoietic stem cell malignant transformation and restoration eliminates leukemia stem cells in mice.. 2022 , 14, eabh2548	0
246	Role of ROS in Cancer Stem Cells. 2022 , 1855-1883	
245	Understanding the function and regulation of Sox2 for its therapeutic potential in breast cancer.. 2022 , 188692	1
244	Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment.. 2022 , 120, 105596	1
243	A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells and .. 2022 ,	1
242	ZNF32 promotes the self-renewal of colorectal cancer cells by regulating the LEPR-STAT3 signaling pathway.. 2022 , 13, 108	1
241	Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.. 2022 , 12, 807266	1
240	Deciphering functional tumor states at single-cell resolution.. 2021 , e109221	2

239 Leukemic Stem Cell Research and Its Impact on Therapy Development. **2021**, 110, 53a-58a

238 Cancer Stem Cell Oxidative Phosphorylation: Target for Cancer Therapy. **2022**, 1-17

237 : A Potential New Treatment Option for Human Breast Cancer and Its Validation in a Clinical Setting.. **2022**, 16, 11782234211059931 0

236 Targeting Signaling Pathways in Cancer Stem Cells for Therapy of Cancer. **2022**, 1-18

235 The Historical Relationship Between Meis1 and Leukemia.. **2022**, 1

234 Protein Degradation by E3 Ubiquitin Ligases in Cancer Stem Cells.. **2022**, 14, 0

233 Slow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem Cells.. **2022**, 14, 0

232 Glycosphingolipids in human embryonic stem cells and breast cancer stem cells, and potential cancer therapy strategies based on their structures and functions.. **2022**, 39, 177 0

231 The Role of Tumor Stem Cell Exosomes in Cancer Invasion and Metastasis.. **2022**, 12, 836548 1

230 The Coming of Age of Preclinical Models of MDS.. **2022**, 12, 815037

229 Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.. **2022**, 0

228 Roles of lncRNAs Mediating Wnt/ β Catenin Signaling in HCC.. **2022**, 12, 831366 1

227 SIRP β -expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling.. **2022**, 132, 1

226 A comprehensive single-cell expression atlas of human AML leukemia-initiating cells unravels the contribution of HIF pathway and its therapeutic potential.

225 Forces in stem cells and cancer stem cells.. **2022**, 203776 0

224 CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.. **2022**, e14990 2

223 Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.. **2022**, 13, 200 1

222 In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.. **2022**, 0

221	Breast Cancer Stem Cell Membrane Biomarkers: Therapy Targeting and Clinical Implications.. 2022 , 11,	1
220	Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.. 2022 , 1	0
219	Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells.. 2022 , 14,	0
218	Deciphering cancer stem cells in liver cancers: new tools with improved resolution.. 2022 ,	
217	Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis.. 2022 , 198, 114955	0
216	Cancer stem cells: The adventurous journey from hematopoietic to leukemic stem cells.. 2022 ,	2
215	Malignant peripheral nerve sheath tumor: models, biology, and translation.. 2022 ,	1
214	The CD133CXCR4 Colorectal Tumor Cells Promote Colorectal Cancer Progression by PI3K/AKT Signaling.. 2022 ,	1
213	Celebrating scientific excellence and global health impact: The 2022 Canada Gairdner Awards.. 2022 ,	
212	High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion.. 2022 ,	1
211	Animal Models of Acute lymphoblastic leukemia: recapitulating the human disease to evaluate drug efficacy and discover therapeutic targets.. 2022 , 114970	1
210	Glioblastoma microenvironment: The stromal interactions.. 2022 , 232, 153813	1
209	The characteristics, tumorigenicities and therapeutics of cancer stem cells based on circRNAs.. 2022 , 233, 153822	0
208	Identification of HCC Subtypes With Different Prognosis and Metabolic Patterns Based on Mitophagy.. 2021 , 9, 799507	0
207	Bioinformatics analysis of miRNAs identifies enrichment of axon guidance pathway genes in ovarian cancer stem cells. 2021 ,	
206	The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy.. 2021 , 13,	
205	Reduced Osteogenic Differentiation Potential in Acute Myeloid Leukaemia Patients Correlates with Decreased Expression in Mesenchymal Stromal Cells.. 2021 ,	
204	NF- κ B signaling in inflammation and cancer.. 2021 , 2, 618-653	8

203 New Approaches in Cancer Research: Stem Cell Research, Translational Research, Immunotherapy, and Others. **2022**, 377-405

202 Genome-wide RNA interference screen in cancer stem cells. **2022**,

201 Cancer stem-like cells evade CD8CD103 tumor-resident memory T (T) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model.. **2022**, 10, ○

200 Generation of Cancer Stem/Initiating Cells by Cell-Cell Fusion.. **2022**, 23, ○

199 Data_Sheet_1.docx. **2019**,

198 Data_Sheet_1.PDF. **2019**,

197 Image_1.TIF. **2019**,

196 Presentation_1.pptx. **2020**,

195 Image_1.JPEG. **2020**,

194 Image_1.TIF. **2018**,

193 Image_2.TIF. **2018**,

192 Table_1.DOCX. **2018**,

191 Video_1.MP4. **2018**,

190 Presentation_1.pdf. **2020**,

189 Table_1.XLSX. **2020**,

188 Table_2.XLSX. **2020**,

187 Table_3.XLSX. **2020**,

186 Table_4.XLSX. **2020**,

185	Table_1.doc. 2018 ,	
184	Cancer Stem Cells in the Head and Neck Cancers. 2022 , 17-30	1
183	Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells.. 2022 , 39, 110752	1
182	Targeting Mitochondrial Oxidative Phosphorylation Eradicates Acute Myeloid Leukemic Stem Cells.. 2022 , 12, 899502	1
181	Human acute myeloid leukemia stem cells: evolution of concept.. 2022 , 57, 67-74	1
180	Nanomedicines Targeting Glioma Stem Cells.. 2022 ,	0
179	The multifaceted role of autophagy in cancer.. 2022 , e110031	5
178	The Role of Cancer Stem Cell-Derived Exosomes in Cancer Progression.. 2022 , 2022, 9133658	0
177	Drug resistance in cancer therapy: the Pandora's Box of cancer stem cells.. 2022 , 13, 181	3
176	Therapeutic Role of Carotenoids in Blood Cancer: Mechanistic Insights and Therapeutic Potential.. 2022 , 14,	1
175	Quiescence regulation by normal hematopoietic stem cells and leukemia stem cells.. 2022 ,	1
174	Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives.. 2022 , 14,	0
173	Current aspects of systematics, diagnosis and treatment of breast cancer. 2022 , 18, 25-39	
172	The application of cancer stem cell model in malignant mesothelioma.. 2022 , 103698	1
171	Leukemic Stem Cells as a Target for Eliminating Acute Myeloid Leukemia: Gaps in Translational Research.. 2022 , 103710	0
170	identified as a stemness-related gene by screening DNA methylation sites based on machine learning-accessed stemness in pancreatic cancer.. 2022 ,	
169	Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.	2
168	The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.	0

167	Redox Metabolism Maintains the Leukemogenic Capacity and Drug Resistance of AML Cells.	
166	Cancer Stem Cells: The Greatest Menace in Conquering Cancer Management.	
165	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.	2
164	Lung Cancer Stem Cell Markers as Therapeutic Targets: An Update on Signaling Pathways and Therapies. 12,	1
163	Neoadjuvant chemotherapy endows CD9 with prognostic value that differs between tumor and stromal areas in patients with pancreatic cancer.	0
162	Nestin Regulates Keap1-Nrf2-HO-1-Mediated Antioxidant Responses during Stress and Malignant Hematopoiesis. 2022, 2022, 1-5	
161	Melatonin and andrographolide synergize to inhibit the colospheroid phenotype by targeting Wnt/beta-catenin signaling.	0
160	Characteristics of the cancer stem cell niche and therapeutic strategies. 2022, 13,	1
159	Acute myeloid leukemia: therapeutic targeting of stem cells. 1-10	0
158	One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia. 13,	
157	Hypoxia-inducible factors: cancer progression and clinical translation. 2022, 132,	10
156	Effects of Lovastatin on Brain Cancer Cells. 2022, 31, 096368972211029	1
155	Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells. 2022, 12, 850	0
154	The Landscape of Exosome-Derived Non-Coding RNA in Leukemia. 13,	1
153	Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens. 2022, 23, 6813	2
152	Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity.	1
151	Fluorescence Detection of Cancer Stem Cell Markers Using a Sensitive Nano-Aptamer Sensor. 10,	0
150	CRISPR screening in cancer stem cells.	1

149	Leukemic Stem Cell: A Mini-Review on Clinical Perspectives. 12,	1
148	Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.	0
147	The overall process of metastasis: From initiation to a new tumor. 2022 , 1877, 188750	1
146	Murine Models of Acute Myeloid Leukemia. 12,	
145	VEGF-B targeting by aryl hydrocarbon receptor mediates the migration and invasion of choriocarcinoma stem-like cells. 2022 , 22,	
144	Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting. 2022 , 2022, 1-28	4
143	The splicing factor RBM17 drives leukemic stem cell maintenance by evading nonsense-mediated decay of pro-leukemic factors. 2022 , 13,	2
142	Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.	0
141	Effects of immune response and time delays in models of acute myeloid leukemia.	
140	Potential to Eradicate Cancer Stemness by Targeting Cell Surface GRP78. 2022 , 12, 941	
139	Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. 12,	0
138	Development of a bispecific Antibody Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia.	
137	Gel-Free Single-Cell Culture Arrays on a Microfluidic Chip for Highly Efficient Expansion and Recovery of Colon Cancer Stem Cells.	
136	Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. 2022 , 15,	0
135	PI3K/Akt/mTOR signaling pathway in cancer stem cells. 2022 , 237, 154010	1
134	Prevalence of CD44+/CD24 ^{low} Cells in Breast Cancer May Not Be Associated with Clinical Outcome but May Favor Distant Metastasis. 2005 , 11, 1154-1159	126
133	Myeloma and Leukemia. 2023 , 503-528	
132	Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. 2022 , 40, 111115	

- 131 Cancer stem cells and tumor heterogeneity: Deciphering the role in tumor progression and metastasis. **2022**, 157, 155968 0
- 130 Properties of Leukemic Stem Cells in Regulating Drug Resistance in Acute and Chronic Myeloid Leukemias. **2022**, 10, 1841
- 129 Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14. **2022**, 98, 325-335
- 128 Functional interplay between long non-coding RNAs and Breast CSCs. **2022**, 22, 0
- 127 Mesenchymal/stromal stem cells: necessary factors in tumour progression. **2022**, 8, 0
- 126 Regulation of the Cancer Stem Phenotype by Long Non-Coding RNAs. **2022**, 11, 2352 0
- 125 Evaluation of CD44+/CD24- and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer. **2022**,
- 124 An Epigenetic Role of Mitochondria in Cancer. **2022**, 11, 2518 5
- 123 Metabolic determinants of stemness in medulloblastoma. **2022**, 14, 587-598
- 122 Growth dynamics of breast cancer stem cells: effects of self-feedback and EMT mechanisms.
- 121 Cancer: Immunology and Immunotherapy. **2022**, 159-164
- 120 The inhibitory effect and mechanism of Yi-qi-hua-yu-jie-du decoction on the drug resistance of gastric cancer stem cells based on ABC transporters. **2022**, 17, 0
- 119 Single cell genomics in AML: extending the frontiers of AML research. 1
- 118 Panoramic view of microRNAs in regulating cancer stem cells. 1
- 117 NRF2 and Mitochondrial Function in Cancer and Cancer Stem Cells. **2022**, 11, 2401 1
- 116 Chasing leukemia differentiation through induction therapy, relapse and transplantation. **2022**, 101000
- 115 Concise review: Cancer cell reprogramming and therapeutic implications. **2022**, 24, 101503 0
- 114 Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs. **2022**, 111, 109116 0

113	Resetting the epigenome: Methylation dynamics in cancer stem cells. 10,	0
112	CD93 promotes acute myeloid leukemia development and is a potential therapeutic target. 2022 , 420, 113361	0
111	The role of fatty acids metabolism on cancer progression and therapeutics development. 2023 , 101-132	0
110	Cancer Stem Cell Oxidative Phosphorylation: Target for Cancer Therapy. 2022 , 2003-2019	0
109	Targeting Signaling Pathways in Cancer Stem Cells for Therapy of Cancer. 2022 , 1985-2001	0
108	Stem Cells and Kidney Regeneration. 2022 , 115-141	0
107	Stem Cell-Derived Exosomes: A Promising Therapeutic Role in Animal Models with Colorectal Cancer. 2022 , 1-19	0
106	Use of Stem Cells on Animal Model of Cancer Research. 2022 , 1-22	0
105	ROS Signaling in Brain Tumor. 2022 , 2565-2584	0
104	Endometrial stem/progenitor cells: Properties, origins, and functions. 2022 ,	0
103	The lipid rafts in cancer stem cell: a target to eradicate cancer. 2022 , 13,	1
102	Glyoxalase 1 as a Therapeutic Target in Cancer and Cancer Stem Cells. 2022 ,	0
101	A Gold Nanoparticle Bioconjugate Delivery System for Active Targeted Photodynamic Therapy of Cancer and Cancer Stem Cells. 2022 , 14, 4558	2
100	Comparison of Predator-Prey Model and Hawk-Dove Game for Modelling Leukemia. 2022 , 2022, 1-11	0
99	Epigenetic mechanisms controlling human leukemia stem cells and therapy resistance.	0
98	Targeting Gastric Cancer Stem Cells to Enhance Treatment Response. 2022 , 11, 2828	0
97	Hypothesis: can transfer of primary neoplasm-derived extracellular vesicles and mitochondria contribute to the development of donor cell-derived hematologic neoplasms after allogeneic hematopoietic cell transplantation?. 2022 ,	0
96	A distinct subpopulation of leukemia initiating cells in acute precursor B lymphoblastic leukemia: quiescent phenotype and unique transcriptomic profile. 12,	0

95	Signaling pathways in the regulation of cancer stem cells and associated targeted therapy. 2022 , 3,	1
94	Leukemic Stem Cell Research and Its Impact on Therapy Development. 2021 , 110, 1735-1742	0
93	The Wnt/ β -catenin signalling pathway in Haematological Neoplasms. 2022 , 10,	1
92	Metabolic Plasticity of Cancer Stem Cells in Response to Microenvironmental Cues. 2022 , 14, 5345	1
91	Fatty acid metabolism predicts prognosis and NK cell immunosurveillance of acute myeloid leukemia patients. 12,	0
90	The Tumor Invasion Paradox in Cancer Stem Cell-Driven Solid Tumors. 2022 , 84,	0
89	MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. 2022 , 13, 1217-1236	0
88	Regulation of the aryl hydrocarbon receptor in cancer and cancer stem cells of gynecological malignancies: An update on signaling pathways. 2022 , 86, 1186-1202	1
87	Microfluidic chip with reversible interface for noninvasive remission status monitoring and prognosis prediction of acute myeloid leukemia. 2023 , 219, 114803	1
86	ANALYSIS OF THE NUMBER OF CELLS WITH CD34+CD38- AND CD34+CD38-CD19+ PHENOTYPES AS POTENTIAL LEUKEMIC STEM CELLS IN ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN. 2011 , 66-69	0
85	The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance. 2022 , 23, 13577	0
84	Cytoskeletal and Cytoskeleton-Associated Proteins: Key Regulators of Cancer Stem Cell Properties. 2022 , 15, 1369	0
83	Influence of Long Non-Coding RNA in the Regulation of Cancer Stem Cell Signaling Pathways. 2022 , 11, 3492	0
82	Potential Role of the Circadian Clock in the Regulation of Cancer Stem Cells and Cancer Therapy. 2022 , 23, 14181	0
81	Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?. 2022 , 14, 5655	1
80	Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. 2022 , 23, 14224	0
79	Updates and Controversies in the Management of Head and Neck Malignancy. 2022 , 455-483	0
78	Splice Variants of G Protein-Coupled Receptors Expressed in Cancers: Effective Targeting with Monoclonal Antibodies and Antibody-Like Scaffolds As Ligands Irrespective of the Pharmacological Status of Isoforms. 2022 , 1-45	0

- 77 Targeting emerging cancer hallmarks by transition metal complexes: Cancer stem cells and tumor microbiome. Part I. **2023**, 477, 214923 ○
- 76 The roles of Linc-ROR in the regulation of cancer stem cells. **2023**, 28, 101602 ○
- 75 Cancer Stem Cells—the Insight into Non-Coding RNAs. **2022**, 11, 3699 ○
- 74 Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment. **2022**, 10, 2988 ○
- 73 CD44-targeted chimeric antigen receptor-T eradicates acute myeloid leukaemic stem cells. **2022**, 2, ○
- 72 Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia. ○
- 71 Learning cell identity in immunology, neuroscience, and cancer. ○
- 70 Notch signaling sculpts the stem cell niche. 10, ○
- 69 Expression of ALDH1 plays the important role during generation and progression in human cervical cancer. 1-11 ○
- 68 Cancer Stem Cells (CSCs): key player of radiotherapy resistance and its clinical significance. 1-28 ○
- 67 The Role of Tumor Microenvironment in Regulating the Plasticity of Osteosarcoma Cells. **2022**, 23, 16155 ○
- 66 Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis. **2022**, 21, ○
- 65 Cancer Stem Cells: Biology and Therapeutic Implications. **2022**, 53, 770-784 1
- 64 Humanized mouse models for immuno-oncology research. ○
- 63 PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia. 2
- 62 Biological effects of cancer stem cells irradiated by charged particle: a systematic review of in vitro studies. ○
- 61 GPD2: The relationship with cancer and neural stemness. **2023**, 173, 203824 ○
- 60 CANCER STEM CELLS: THE GREATEST MENACE IN CONQUERING CANCER MANAGEMENT. 954-975 ○

- 59 Present and Future Role of Immune Targets in Acute Myeloid Leukemia. **2023**, 15, 253 ○
- 58 Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. **2023**, 15, 211 ○
- 57 ERRα confers oncogenesis and cisplatin resistance via transcriptionally activating CCNE2 in breast cancer. ○
- 56 Cancer Stem Cells: Roles in Cancer Etiology. **2023**, 1-19 ○
- 55 Therapeutic Approaches Targeting Cancer Stem Cells. ○
- 54 Insights into the Cancer Stem Cell Model of Glioma Tumorigenesis. **2007**, 36, 352-357 2
- 53 Functional and Molecular Characters of Cancer Stem Cells Through Development to Establishment. **2022**, 83-101 ○
- 52 The role of hypoxia-inducible factors in breast cancer stem cell specification. **2023**, 154349 ○
- 51 Sulforaphane: An emergent anti-cancer stem cell agent. 13, ○
- 50 Molecular Mechanisms in Murine Syngeneic Leukemia Stem Cells. **2023**, 15, 720 ○
- 49 Bone Marrow Mesenchymal Stem Cell-Derived miR-29b Promotes the Progression of Acute Myeloid Leukemia. **2023**, 13, 52-58 ○
- 48 Use of Stem Cells on Animal Model of Cancer Research. **2023**, 111-132 ○
- 47 The Significance of Cancer Stem Cells and Epithelial-Mesenchymal Transition in Metastasis and Anti-Cancer Therapy. **2023**, 24, 2555 ○
- 46 Oct-4 induces cisplatin resistance and tumor stem cell-like properties in endometrial carcinoma cells. **2023**, 62, 16-21 ○
- 45 Signaling pathways governing the behaviors of leukemia stem cells. **2023**, ○
- 44 Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells. **2023**, 161, 1-36 ○
- 43 Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. **2023**, 62, 102692 ○
- 42 The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia. **2023**, 212, 115539 ○

- 41 Cancer stem cell-derived exosome-induced metastatic cancer: An orchestra within the tumor microenvironment. **2023**, 212, 1-11 ○
- 40 A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer. **2023**, 90, 15-28 1
- 39 Properties of cancer stem cells. **2022**, 57, 213-224 ○
- 38 The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy. 12, ○
- 37 Stem Cell-Derived Exosomes: A Promising Therapeutic Role in Animal Models with Colorectal Cancer. **2023**, 757-775 ○
- 36 Leukemic stem cells and therapy resistance in acute myeloid leukemia. **2023**, 108, 353-366 ○
- 35 Slow TCA flux and ATP production in primary solid tumours but not metastases. **2023**, 614, 349-357 1
- 34 MiR-7-5p/KLF4 signaling inhibits stemness and radioresistance in colorectal cancer. **2023**, 9, ○
- 33 Identity matters: cancer stem cells and tumour plasticity in head and neck squamous cell carcinoma. **2023**, 25, ○
- 32 A mysterious triangle of blood, bones, and nerves. ○
- 31 Targeting leukemic stem cell subpopulation in AML using phytochemicals: An in-silico and in-vitro approach. **2023**, 155, 106644 ○
- 30 Pharmacological ascorbate potentiates combination nanomedicines and reduces cancer cell stemness to prevent post-surgery recurrence and systemic metastasis. **2023**, 295, 122037 ○
- 29 N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells Properties and Lenvatinib Resistance Through WNT/ECatenin and Hippo Signaling Pathways. **2023**, 164, 990-1005 ○
- 28 Association of NRF2 with HIF-2 β -induced cancer stem cell phenotypes in chronic hypoxic condition. **2023**, 60, 102632 ○
- 27 Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. 14, ○
- 26 An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4. **2023**, 15, 1275 ○
- 25 Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. **2023**, 22, ○
- 24 CD99 Promotes Self-renewal in Hematopoietic Stem Cells and Leukemia Stem Cells by Regulating Protein Synthesis. ○

- 23 Phenotypic characterization of disease-initiating stem cells in JAK2 - or CALR -mutated myeloproliferative neoplasms. **2023**, 98, 770-783 ○
- 22 Cancer Initiation and Inflammation. **2023**, 1-15 ○
- 21 Microbiota-Derived Natural Products Targeting Cancer Stem Cells: Inside the Gut Pharma Factory. **2023**, 24, 4997 ○
- 20 Immunotargeting of Cancer Stem Cells. **2023**, 15, 1608 ○
- 19 LSD1 inhibition modulates transcription factor networks in myeloid malignancies. 13, ○
- 18 Leukemic stem cells hijack lineage inappropriate signalling pathways to promote their growth. ○
- 17 Stemming Tumoral Growth: A Matter of Grotesque Organogenesis. **2023**, 12, 872 ○
- 16 The Renin-Angiotensin System and Cancer. **2023**, 277-339 ○
- 15 High trophinin-associated protein expression predicts good survival in acute myeloid leukemia with normal cytogenetics. **2023**, 36, 221-230 ○
- 14 Epigenetic misactivation of a distal developmental enhancer cluster drives SOX2 overexpression in breast and lung cancer. ○
- 13 Epitranscriptomics in the development, functions, and disorders of cancer stem cells. 13, ○
- 12 DNA Repair and Therapeutic Strategies in Cancer Stem Cells. **2023**, 15, 1897 ○
- 11 Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. **2023**, 14, ○
- 10 Insights into radiation carcinogenesis based on dose-rate effects in tissue stem cells. 1-19 ○
- 9 Eradicating the tumor seeds: nanomedicines-based therapies against cancer stem cells. ○
- 8 Emerging Role of NRF2 Signaling in Cancer Stem Cell Phenotype. **2023**, 46, 153-164 ○
- 7 Preleukemic Fusion Genes Induced via Ionizing Radiation. **2023**, 24, 6580 ○
- 6 Can Immunoexpression of Cancer Stem Cell Markers Prognosticate Tongue Squamous Cell Carcinoma? A Systematic Review and Meta-Analysis. **2023**, 12, 2753 ○

- 5 Upregulation of ROBO3 promotes proliferation, migration and adhesion of AML cells and affects the survival of AML patients. **2023**, 661, 1-9
- 4 Cancer stem cells and nitric oxide. **2023**, 135-150
- 3 Therapeutic vulnerabilities of cancer stem cells and effects of natural products.
- 2 Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies. **2023**, 325, 121771
- 1 BCL7B, an SWI/SNF complex subunit, orchestrates cancer immunity and stemness.